


Depot fluphenazine decanoate and enanthate for schizophrenia (Review)

David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J



**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2006, Issue 1

<http://www.thecochranelibrary.com>



TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	2
OBJECTIVES	2
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW	2
SEARCH METHODS FOR IDENTIFICATION OF STUDIES	3
METHODS OF THE REVIEW	4
DESCRIPTION OF STUDIES	5
METHODOLOGICAL QUALITY	7
RESULTS	7
DISCUSSION	13
AUTHORS' CONCLUSIONS	15
POTENTIAL CONFLICT OF INTEREST	15
ACKNOWLEDGEMENTS	15
SOURCES OF SUPPORT	15
REFERENCES	16
TABLES	29
Characteristics of included studies	29
Characteristics of excluded studies	63
ANALYSES	74
Comparison 01. FLUPHENAZINE DECANOATE vs PLACEBO	74
Comparison 02. FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS	74
Comparison 03. FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS	75
Comparison 04. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD	76
Comparison 05. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD	77
Comparison 06. FLUPHENAZINE ENANTHATE vs PLACEBO	77
Comparison 07. FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS	77
Comparison 08. FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS	77
Comparison 09. FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE	78
Comparison 10. FLUPHENAZINE DECANOATE vs FLUPHENAZINE ENANTHATE	78
INDEX TERMS	79
COVER SHEET	79
GRAPHS AND OTHER TABLES	80
Analysis 01.01. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 01 Death	80
Analysis 01.02. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 02 Global state: Relapse	81
Analysis 01.03. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 03 Behaviour: Leaving the study early	82
Analysis 01.04. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 04 Mental state: Depression (medium term - 6 months to 1 year)	82
Analysis 01.05. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 05 Adverse effects: 1. Movement disorders - tardive dyskinesia (longer term - more than 1 year)	83
Analysis 01.06. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 06 Adverse effects: 2. Toxicity	83
Analysis 02.01. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 01 Global state: 1. No clinically important global change	84
Analysis 02.02. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 02 Global state: 2. Relapse	85
Analysis 02.03. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 03 Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score=worse)	85

Analysis 02.04. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 04	86
Behaviour: 1. Leaving the study early	
Analysis 02.05. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 05	87
Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)	
Analysis 02.06. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 06	87
Behaviour: 3. skewed data (endpoint scores)	
Analysis 02.07. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 07 Mental	88
state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score=poor)	
Analysis 02.08. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 08 Mental	88
state: 2. Depression	
Analysis 02.09. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 09 Adverse	89
effects: 1a. Movement disorders - general	
Analysis 02.10. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 10 Adverse	89
effects: 1b. Movement disorders - akathisia	
Analysis 02.11. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 11 Adverse	90
effects: 1c. Movement disorders - needing anticholinergic drugs	
Analysis 02.12. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 12 Adverse	91
effects: 1d. Movement disorders - tardive dyskinesia	
Analysis 02.13. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 13 Adverse	91
effects: 1e. Movement disorders - tremor (longer term - more than 1 year)	
Analysis 02.14. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 14 Adverse	92
effects: 1f. Movement disorders - average score (Simpson & Angus, 0 to 5 weeks, high = poor)	
Analysis 02.15. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 15 Adverse	92
effects: 2. Blurred vision - medium term (6 months to 1 year)	
Analysis 02.16. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 16 Adverse	93
effects: 3. Toxicity - medium term (6 months to 1 year)	
Analysis 02.17. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 17 Adverse	93
effects: 4. General adverse effects	
Analysis 03.01. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	94
01 Death	
Analysis 03.02. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	94
02 Global state: 1. No clinically important global change (medium term - 6 months to 1 year)	
Analysis 03.03. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	95
03 Global state: 2. Relapse	
Analysis 03.04. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	96
04 Global state: 3. Severely ill (medium term 6 months to 1 year)	
Analysis 03.05. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	96
05 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year)	
Analysis 03.06. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	96
06 Global state: 5. Clinical Global Impression. (short term - 6 weeks to 5 months) (skewed data)	
Analysis 03.07. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	97
07 Global state: 6. Clinical Global Impression. (medium term - 6 months to 1 year)	
Analysis 03.08. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	98
08 Global state: 7. Clinical Global Impression - not improved (high score=poor)	
Analysis 03.09. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	99
09 Behaviour: 1. Leaving the study early	
Analysis 03.10. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	101
10 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)	
Analysis 03.11. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	102
11 Mental state: 1. BPRS (endpoint scores - high score=poor)	
Analysis 03.12. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome	103
12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data)	

Analysis 03.13. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 13 Mental state: 3. Depression (6 months to 1 year)	104
Analysis 03.14. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 14 Adverse effects: 1a. Movement disorders - general	105
Analysis 03.15. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 15 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs	106
Analysis 03.16. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 16 Adverse effects: 1c. Movement disorders - parkinsonism	107
Analysis 03.17. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 17 Adverse effects: 1d. Movement disorders - tardive dyskinesia: longer term (more than 1 year)	108
Analysis 03.18. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 18 Adverse effects: 1e. Movement disorders - tremor	109
Analysis 03.19. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 19 Adverse effects: 2. Blurred vision	110
Analysis 03.20. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 20 Adverse effects: 3. Dry mouth: longer term (more than 1 year)	111
Analysis 03.21. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 21 Adverse effects: 4. General adverse effects	112
Analysis 04.01. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 01 Global state: 1. Relapse (medium term - 6 months to 1 year)	113
Analysis 04.02. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 02 Global state: 2. Needing additional antipsychotic treatment (medium term - 6 months to 1 year)	114
Analysis 04.03. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 03 Global state: 3. Not improved (medium term - 6 months to 1 year)	115
Analysis 04.04. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 04 Behaviour: Leaving the study early (medium term - 6 months to 1 year)	116
Analysis 04.05. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 05 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score=poor)	117
Analysis 04.06. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 06 Adverse effects: Movement disorders - needing anticholinergic drugs (medium term - 6 months to 1 year)	118
Analysis 05.01. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 01 Global state: Relapse	119
Analysis 05.02. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 02 Behaviour: Leaving the study early	120
Analysis 05.03. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 03 Adverse effects: 1. Movement disorders (medium term - 6 months to 1 year)	121
Analysis 05.04. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 04 Adverse effects: 2. Continuous data - skewed data (endpoint scores, high = poor)	121
Analysis 06.01. Comparison 06 FLUPHENAZINE ENANTHATE vs PLACEBO, Outcome 01 Adverse effects: Movement disorders - general	122
Analysis 07.01. Comparison 07 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 01 Global state: No clinically important global change (immediate - 0 to 5 weeks)	122
Analysis 07.02. Comparison 07 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 02 Adverse effects: Movement disorders - general	123
Analysis 08.01. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 01 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year)	123
Analysis 08.02. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 02 Global state: 2. Relapse	124
Analysis 08.03. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 03 Behaviour: Leaving the study early	124

Analysis 08.04. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 04 Mental state: 1. BPRS - endpoint scores (medium term - 6 months to 1 year) (high score =poor)	125
Analysis 08.05. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 05 Mental state: 2. Depression (medium term - 6 months to 1 year)	126
Analysis 08.06. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 06 Adverse effects: 1a. Movement disorders - general (medium term - 6 months to 1 year)	126
Analysis 08.07. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 07 Adverse effects: 1b. Movement disorders - needing additional anticholinergic drugs	127
Analysis 08.08. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 08 Adverse effects: 1c. Movement disorders - tardive dyskinesia: medium term (6 months to 1 year)	127
Analysis 08.09. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 09 Adverse effects: 1d. Movement disorders - tremor (medium term - 6 months to 1 year)	128
Analysis 08.10. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Adverse effects: 2. Blurred vision (medium term - 6 months to 1 year)	128
Analysis 08.11. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Adverse effects: 3. Dry mouth (medium term - 6 months to 1 year)	129
Analysis 09.01. Comparison 09 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 01 Global state: Relapse (short term - 6 weeks to 5 months)	129
Analysis 09.02. Comparison 09 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 02 Behavior: Leaving the study early (short term - 6 weeks to 5 months)	130
Analysis 10.01. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 01 Global state: 1. Needing additional antipsychotic treatment	130
Analysis 10.02. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 02 Global state: 2. Relapse	131
Analysis 10.03. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 03 Behavior: Leaving the study early	132
Analysis 10.04. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 04 Mental State: BPRS medium term (6 months to 1 year - high score=poor)	132
Analysis 10.05. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 05 Adverse effects: 1a. Movement disorders - general	133
Analysis 10.06. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 06 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs	133
Analysis 10.07. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 07 Adverse effects: 1c. Movement disorders - parkinsonism (short term - 6 weeks to 5 months)	134
Analysis 10.08. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 08 Adverse effects: 2. General adverse effects (immediate - 0 to 5 weeks)	134

Depot fluphenazine decanoate and enanthate for schizophrenia (Review)

David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J

This record should be cited as:

David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. *The Cochrane Database of Systematic Reviews* 2004, Issue 2. Art. No.: CD000307. DOI: 10.1002/14651858.CD000307.

This version first published online: 19 April 2004 in Issue 2, 2004.

Date of most recent substantive amendment: 22 January 2004

ABSTRACT

Background

Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance. The benefits gained by long acting preparations, however, may be offset by a higher incidence of adverse effects.

Objectives

To investigate the clinical effects of fluphenazine decanoate and enanthate.

Search strategy

For this update we searched the Cochrane Schizophrenia Group's Register (May 2002).

Selection criteria

We considered all relevant randomised clinical controlled trials focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations.

Data collection and analysis

We reliably selected, quality rated and data extracted studies. For dichotomous data we estimated relative risk (RR) with 95% confidence intervals (CI), and, where possible, the number needed to treat/harm (NNT/H). Analysis was by intention-to-treat. We used the weighted mean difference (WMD) for normal continuous data. Tests of heterogeneity and for publication bias were undertaken.

Main results

This review now includes 70 randomised studies. Compared with placebo, fluphenazine decanoate did not reduce relapse over 6 months to 1 year, but one longer term study found that relapse was significantly reduced in the fluphenazine arm (n=54, RR 0.35, CI 0.2 to 0.6, NNT 2 CI 2 to 4). Fluphenazine decanoate does not reduce relapse more than oral neuroleptics (n=419, 6 RCTs, RR relapse 26-52 weeks 1.46 CI 0.8 to 2.8) or other depot antipsychotics (n=581, 11 RCTs, RR relapse 26-52 weeks 0.82 CI 0.6 to 1.2). Relapse rates over 6 months to 1 year were not significantly different between standard dosage of fluphenazine decanoate over a low dose group (n=523, 4 RCTs, RR 2.09 CI 0.6 to 7.1). Movement disorders were significantly less for people receiving fluphenazine decanoate compared with oral neuroleptics (n=259, 3 RCTs, RR 0.47 CI 0.2 to 0.9, NNT 14 CI 10 to 82).

For fluphenazine enanthate there were limited data but no clear difference in global change (0 to 5 weeks) when compared with oral neuroleptics (n=31, 1 RCTs, RR 0.67 CI 0.3 to 1.7), and in relapse rates over 6-26 weeks between fluphenazine enanthate and other depots. Compared with placebo, giving the enanthate caused no more people to need anticholinergic drugs (n=25, 1 RCT, RR 9.69 CI 0.6 to 163.0) and movement disorders, tardive dyskinesia, tremor, blurred vision and dry mouth were equally prevalent when enanthate was compared with other depot neuroleptics.

Authors' conclusions

There are more data for fluphenazine decanoate than for the enanthate ester. Both are effective antipsychotic preparations. In the context of trials, there is little advantage of these depots over oral medications in terms of compliance but this is unlikely to be applicable to everyday clinical practice.

PLAIN LANGUAGE SUMMARY

For the November 2004 update we extended the scope of the review to include any comparison relevant to these common depot treatments. We subsequently looked for randomised controlled trials to determine the effects of depot fluphenazine decanoate and enanthate for schizophrenia when compared with placebo, other oral antipsychotics, other depot antipsychotics and studies comparing the depot fluphenazine esters. We included results of 70 trials. Fluphenazine decanoate reduces the rate of relapse when compared to placebo. Outcomes for fluphenazine decanoate and enanthate are similar to those of other oral and depot neuroleptics.

BACKGROUND

One in every 10,000 people per year are diagnosed with schizophrenia, with a lifetime prevalence of about 1% (Jablensky 1992). It often runs a chronic course with acute exacerbations and often partial remissions. The neuroleptic group of drugs is the mainstay treatment for this illness (Dencker 1980). These are generally regarded as highly effective, especially in controlling such symptoms as hallucinations and fixed false beliefs (delusions) (Kane 1986). They seem to reduce the risk of acute relapse. A systematic review undertaken over a decade ago suggested that, for those with serious mental illness, stopping anti-psychotics resulted in 58% of people relapsing, whereas only 16% of those who were still on the drugs became acutely ill within a one year period (Davis 1986). Evidence also points to the fact that experiencing a relapse of schizophrenia lowers a person's level of social functioning and quality of life (Curson 1985). Relapse prevention has also enormous financial implications. For example, within the UK, a Department of Health burden of disease analysis in 1996 indicated that schizophrenia accounted for 5.4% of all National Health Service inpatient expenditure, placing it behind only learning disability and stroke in magnitude (DoH 1996).

Anti-psychotic drugs are usually given orally (Aaes-Jorgenson 1985) but compliance with medication given by this route may be difficult to quantify. Problems with treatment adherence are common throughout medicine (Haynes 1979). Those who suffer from long-term illness such as schizophrenia are less likely to take medication regularly if experiencing adverse effects (Kane 1998), or if they experience cognitive impairments (David 1994) and erosion of insight. The development of depot injections in the 1960s and initial clinical trials (Hirsch 1973b) gave rise to extensive use of depots as a means of long-term maintenance treatment. Depots mainly consist of an ester of the active drug held in an oily suspension. This is injected intramuscularly and is slowly released. Depots may be given every 1 to 6 weeks. Individuals may be maintained in the community with regular injections administered by community psychiatric nurses, sometimes in clinics set up for this purpose (Barnes 1994). The use of depots eradicates covert non-compliance.

Fluphenazine was one of the first oral antipsychotics to be produced in a depot form. Two forms of the depot, a decanoate (Modectate) and an enanthate (Moditen) are available. The decanoate

is more commonly prescribed (Marder 1990) and lasts about 4-6 weeks in the body while a single dose of the enanthate is shorter acting (1-3 weeks). Evidence also suggests that the decanoate may produce slightly less adverse effects than its enanthate counterpart (Kurland 1970). However in comparison with newer depot formulations fluphenazine decanoate has been reported to cause greater extrapyramidal adverse effects (Knights 1979) and to significantly lower mood (De Alarcon 1969a).

OBJECTIVES

To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes.

CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

Types of studies

All relevant randomised controlled trials. We included trials described as 'double-blind' if it was implied that the study was randomised and the demographic details regarding participants in each group were similar. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.

Types of participants

People with schizophrenia or other similar psychotic disorders, irrespective of mode of diagnosis, age, ethnicity and sex. We did include studies describing participants as suffering from "serious mental illnesses" and did not giving a particular diagnostic grouping. The exception to this rule was when the majority of those randomised clearly did not have a functional non-affective psychotic illness.

Types of intervention

1. Fluphenazine decanoate: any dose.
2. Fluphenazine enanthate: any dose.
3. Oral anti-psychotics (with the exception of fluphenazine hydrochloride): any dose.
4. Other depot preparations: any dose.

We tested the sensitivity of the primary outcomes as to whether high (250mg) or low (25mg) dose of fluphenazine decanoate was used or whether the trials used an intermediate/high (0.5) or low (0.25mg) dose of fluphenazine enanthate.

Types of outcome measures

Outcomes of interest:

1. Death and all causes of mortality*
2. Clinical global response
 - 2.1 Relapse*
 - 2.2 Clinically significant change in global state - as defined by each of the studies*
 - 2.3 Mean score/change in global state
 - 2.4 Leaving the study early
3. Mental state
 - 3.1 Clinically significant change in psychotic symptoms - as defined by each of the studies
 - 3.2 Mean score/change in psychotic symptoms
 - 3.3 Clinically significant change in positive symptoms - as defined by each of the studies
 - 3.4 Mean score/change in positive symptoms
 - 3.5 Clinically significant response in negative symptoms - as defined by each of the studies
 - 3.6 Mean score/change in negative symptoms
4. Extrapyramidal adverse effects
 - 4.1 Incidence of use of antiparkinson drugs
 - 4.2 Clinically significant extrapyramidal adverse effects - as defined by each of the studies
 - 4.3 Mean score/change in extrapyramidal adverse effects
5. Other adverse effects, general and specific
6. Service utilisation outcomes
 - 6.1 Hospital admission*
 - 6.2 Days in hospital
7. Economic outcomes
8. Quality of life/satisfaction with care for either recipients of care or carers
 - 8.1 Significant change in quality of life/satisfaction - as defined by each of the studies
 - 8.2 Mean score/change in quality of life/satisfaction.

Outcomes were grouped into immediate (0-5 weeks), short term (6 weeks-5 months), medium term (6 months-1 year) and longer term (over 12 months)

* Primary outcomes

SEARCH METHODS FOR IDENTIFICATION OF STUDIES

See: Schizophrenia Group methods used in reviews.

1. Electronic searching.

1.1 We updated previous searches in May 2002 using The Cochrane Schizophrenia Group's Register. The search phrase used was:

```
{
[ fluphen* or *fluphen* or *modec* or *moditen* or *eutimox*
or *flufen* or *prolixin* or *siqualone* or *anaten* or *dapo-
tum* or *decazate* or *lyoridin* in title, abstract, index terms of
[REFERENCE] or [(fluphenaz* AND depot*) in interventions of
STUDY]]
```

2. Details of previous electronic search.

2.1 Electronic searching

Relevant randomised trials were identified by searching several electronic databases (the Cochrane Schizophrenia Group's Register of Trials, the Cochrane Library, Biological Abstracts, EMBASE, MEDLINE, PsycLIT and SCISEARCH).

2.2 Cochrane Schizophrenia Group's Register: we searched this register using the phrase:

```
(FLUPHEN* and DECANOATE or ENANTHATE ) or ((DE-
POT* or (LONG and ACTING) or (DELAY* and ACTION))
and (FLUPHEN* or MODEC* or MODITEN* or EUTIMOX*
or FLUFEN* or PROLIXIN* or SIQUALONE* or ANATEN*
or DAPOTUM* or DECAZATE* or LYORIDIN*) or (#44=2
and #44=230) or #44=549)
```

2.3 COCHRANE LIBRARY (Issue 2, 1998): we searched this Library using the Cochrane Schizophrenia Group's phrase for schizophrenia (see Group search strategy) combined with the phrase:

```
(FLUPHEN* and DECANOATE or ENANTHATE) or ((DE-
POT* or (LONG and ACTING) or (DELAY* and ACTION))
and (FLUPHEN* or MODEC* or MODITEN* or EUTI-
MOX* or FLUFEN* or PROLIXIN* or SIQUALONE* or
ANATEN* or DAPOTUM* or DECAZATE* or LYORIDIN*))
or (FLUPHEN* ME and DELAYED-ACTION-PREPARA-
TIONS* ME))
```

2.4 BIOLOGICAL ABSTRACTS (January 1982 to June 1998 - current disc issue): we searched this database using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:

```
[and (FLUPHENAZINE near1 DECANOATE or ENAN-
THATE) or ((DEPOT* or (LONG near4 ACTING) or (DE-
LAY* near2 ACTION)) near (FLUPHENAZINE or MODEC*
or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or
SIQUALONE* or ANATEN* or DAPOTUM* or DECAZOTE*
or LYONRIDIN*))]
```

2.5 EMBASE (January 1980 to June 1998 - current disc issue): we searched this database using the Cochrane Schizophrenia Group's

phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:

(FLUPHEN* near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (FLUPHEN* or MODITEN* or MODEC* or FLUFEN* or EUTIMOX* or PROLIXIN* or SQUALONE* or ANATEN* or DAPOTUM* or DECAZATE* or LYORIDIN*) or "FLUPHENAZINE-DECANOATE"/ all subheadings]

2.6 MEDLINE (January 1966 to June 1998 - current disc issue): we searched this database using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:

(FLUPHEN* near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (FLUPHEN* or MODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SEQUALONE* or ANATEN* or DAPOTUM* or DECAZATE* or LYORIDIN*) or ("FLUPHENAZINE"/ all subheadings and explode "DELAYED-ACTION-PREPARATIONS"/ all subheadings))]

2.7 PsycLIT (January 1974 to June 1998 - current disc issue): we searched this database using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:

(FLUPHEN* near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION)) near (FLUPHEN* or MODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SQUALONE* or ANATEN* or DAPOTUM* or DECAZATE* or LYORIDIN*))

3. Reference searching

We also inspected the references of all identified trials for more studies. We sought each of the included studies as a citation on the SCISEARCH database. Then we inspected reports of articles that had cited these studies in order to identify further trials.

4. Personal contact

We tried to contact the first author of each included study for information regarding unpublished trials. We contacted companies producing depots and made requests for reports of published and unpublished trials.

METHODS OF THE REVIEW

1. Study selection

In the original review, all the studies we identified were inspected by the principal reviewer (SQ). A randomly selected sample of 10% of all reports was re-inspected by AD in order to ensure selection was reliable. Where disagreement occurred, we resolved this by discussion, where there was still doubt, we acquired the full article for further inspection. Once we had obtained the full

articles, SQ and AD independently decided whether they met the review criteria. We resolved disagreement by discussion and when this was not possible sought further information. We added these trials to the list of those awaiting assessment pending acquisition of further information. For the updated version of this review, JR inspected and data extracted all studies.

2. Assessment of methodological quality

We allocated trials to three quality categories, as described in the Cochrane Collaboration Handbook (Alderson 2004). Again we resolved disputes by discussion. When this was not possible and further information was necessary to clarify which category to allocate a trial to, we did not enter data and allocated the trial to the list of those awaiting assessment. We included only trials in Category A or B in the review.

3. Data collection

In the first version of this review SQ and AD independently extracted data from selected trials. JR did this for the updated version. Again we resolved disputes by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added this outcome of the trial to the list of those awaiting assessment.

4. Data synthesis

4.1 Incomplete data.

Where more than 30% of those randomised were lost to follow-up by 6 months, or 50% by beyond that time, we felt data to be too prone to bias and did not use these outcomes.

4.2 Dichotomous - yes/no - data.

4.2.1 Statistics: For binary outcomes, for example 'admitted' or 'not admitted', we estimated a Relative Risk with 95% confidence interval. Where possible, we calculated the number needed to treat statistic (NNT) taking into account the event rate in the control group.

4.2.2 Intention to treat: We present data on a 'once-randomised-always-analyse' basis. Those who were lost to follow up are all assumed to have the negative outcome, with the exception of death, which was coded separately. For example, for the outcome of relapse, we considered those who were lost to follow up all to have relapsed.

4.2.3 Data reporting

4.3 Continuous - scale - data

4.3.1 Normal data: Mental health continuous data are often not 'normally' distributed. To avoid the pitfall of applying parametric tests to non-parametric data we applied the following standards to all data before inclusion: i. standard deviations and means had to be reported in the paper or had to be obtainable from the authors; ii. when a continuous outcome started from a finite number (such as 0), the standard deviation, when multiplied by 2, had to be less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - Altman

1996). We did not enter data not meeting the second standard into the RevMan calculator (which assumes a normal distribution). However, data not meeting these standards can be reported in the 'Other data types' of the results section if they have been analysed with appropriate non-parametric tests. If continuous data were recording change, where the finite parameters of the measure were unclear, the reviewers decided whether the data were usable or not.

4.3.2 Rating scales: A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or are ad hoc. For outcome instruments some minimum standards have to be set. They could be that: i. the psychometric properties of the instrument should have been described in a peer-reviewed journal; ii. not written or modified by one of the trialists; iii. the instrument should either be: (a) a self report, or (b) completed by an independent rater or relative (not the therapist); and iv. the instrument should be a global assessment of an area of functioning (Marshall 1998).

4.3.3 Endpoint versus change data: where possible we presented endpoint data and if both endpoint and change data were available for the same outcomes then we only reported the former in this review.

4.3.4 Cluster trials

Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997, Gulliford 1999).

Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999). If clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but would have adjusted for the clustering effect.

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = $1+(m-1)*ICC$] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999).

5. Heterogeneity

Firstly, we considered all the included studies within any comparison to judge clinical heterogeneity. We then used visual inspection of graphs to investigate the possibility of statistical heterogeneity.

This was supplemented using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (Higgins 2003). If inconsistency was high, we did not summate these data, but presented them separately and investigated reasons for heterogeneity. Data were presented using a fixed effect model for homogeneous data and a random effects model for heterogeneous data.

6. Tables and figures

Where possible we entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for the fluphenazine esters.

DESCRIPTION OF STUDIES

See Excluded and Included studies table.

1. Excluded studies

We excluded one hundred and eighty one studies, mainly because they were not randomised controlled trials (RCTs), or controlled clinical trials (CCTs), or because neither fluphenazine decanoate nor fluphenazine enanthate were included in the interventions or because trialists did not report any usable data. In the latter case we contacted authors requesting raw data but we have, in most cases, received no reply. Other reasons for exclusion were that the two drugs were not analysed (Crawford 1974, Wistedt 1983a) or clinical outcomes were not measured (Landmark 1994, Leff 1973, Marder 1990, Marder 1991a, Stevens 1973).

2. Awaiting assessment

Five studies await assessment. Del Giudice 1970, Jue 1996, Kabes 1984, Ravanic 1996 are reports for which we have citations but no papers. These are currently being sought. One paper awaits translation (Engstrand 1969).

3. Ongoing studies

We have identified no ongoing studies.

4. Included studies

We included 70 randomised controlled trials with a total of 89 reports.

4.1 Length of trials

The duration for all the studies ranged between 2-3 weeks (Altamura 1985) to 3 years (Dencker 1973).

4.2 Participants

The diagnoses of all participants were schizophrenia or some other similar psychotic disorder. Most of the studies included people of both sexes, although seven studies (Albert 1980, Asarnow 1988, Kurland 1966, Marder 1984, Marder 1987, McCreadie 1980, McCreadie 1982) included only men and fourteen trials failed to mention the sex of participants. Ages ranged between 13 and 81 years.

4.3 Setting

The trials were both community and hospital based. People in two studies (Schooler 1980, Wistedt 1984) were given the first two injections whilst in hospital and after which medication continued to be administered in the community. Both Dencker 1973 and Wistedt 1984 studied people initially in a hospital setting followed by a continuation in the community. Several studies involved people from both hospital and community settings (Dencker 1973, Donlon 1976, Kaneno 1991, Magnus 1979, Marder 1987, McCreddie 1980, Rifkin 1977, Schooler 1997, Simon 1978). A surprisingly large number (12) of studies did not mention the setting used (Albert 1980, Javed 1991, Kissling 1985, Marder 1984, McKane 1987, Odejide 1982, Quitkin 1978, Russell 1982, Schneider 1981, Schlosberg 1978, Sharma 1991, Wistedt 1983).

4.4 Study size

The largest study was by Schooler 1997 who randomised 313 people, whereas Altamura 1985 only included 11. The majority randomised between 30 and 60 people.

4.5 Interventions

Five of the included trials compared fluphenazine decanoate with placebo (Dotti 1979, Hirsch 1975, Jolley 1990, Odejide 1982, Rifkin 1977) and one study compared fluphenazine enanthate with placebo (Van Praag 1970). Eight studies compared fluphenazine decanoate with enanthate (Altamura 1985, Asarnow 1988, Chouinard 1982, Donlon 1976, Keskiner 1971, Kurland 1966, MacCrimmon 1978, Van Praag 1973). Fourteen studies compared fluphenazine esters with oral antipsychotics. Thirty-four trials compared fluphenazine decanoate or enanthate with other depot formulations. There were eight dosage studies - eight comparing fluphenazine decanoate and one comparing fluphenazine enanthate (Goldstein 1978).

Seven studies (Altamura 1985, Chouinard 1978, Chouinard 1982, Donlon 1976, Kurland 1966, MacCrimmon 1978, Van Praag 1973) compared the fluphenazine esters, decanoate and enanthate and a further eight studies compared different doses of the decanoate ester (Asarnow 1988, Hogarty 1988, Kane 1983, Kelly 1977, Marder 1984, Marder 1987, McClelland 1976) or enanthate (Goldstein 1978). The rest of the trials compared fluphenazine decanoate or enanthate with other depot formulations. Of the 70 included trials, 63 of the studies used fluphenazine decanoate as an intervention.

4.6 Outcome reporting

Many of the trials presented their findings in graphs or using p-values alone. Graphical presentation made it impossible to acquire raw data for synthesis. Requests for raw data from authors have so far failed with the exception of Pinto 1979 and Quitkin 1978. It was also common to use p-values as a measure of association between intervention and outcomes instead of showing the strength of the association.

4.6.1 Outcome scales

Scales that provided usable data are listed below. We listed data that were not usable in the 'included studies table' under outcomes, 'unable to use'.

4.6.1.1 Global functioning

4.6.1.1.1 Clinical Global Impression - CGI (Guy 1976)

This is a three item rating instrument commonly used in schizophrenia studies. It enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery.

4.6.1.2 Mental state

4.6.1.2.1 Brief Psychiatric Rating Scale - BPRS (Overall 1962)

The BPRS is an 18 item scale measuring positive symptoms, general psychopathology and affective symptoms. The original scale has 16 items, but a revised 18 item scale is commonly used. Scores can range from 0-126. Each item is rated on a seven-point scale, with high scores indicating more severe symptoms.

4.6.1.2.2 Comprehensive Psychopathological Rating Scale - CPRS (Asberg 1978)

The scale is designed to measure psychopathology over time via a clinical interview. It contains 67 items, including one global rating and one item documenting the reliability of the interview. The majority of the items (40) are based upon reported symptoms. Assumed reliability of the rating is scored as zero (very poor), one (fair), two (good) or three (very good).

4.6.1.2.3 Krawiecka Scale (Krawiecka 1977)

This mental state scale encompasses both positive and negative symptoms of schizophrenia. It is used to evaluate the mental state and behaviour in chronic psychotic people with higher scores indicating greater severity. It is also known as the Manchester Scale.

4.6.1.3 Behaviour

4.6.1.3.1 Nurses Observational Scale of Inpatients Evaluation - NOSIE (Honigfeld 1962).

This is an 80 item scale with items rated on a five-point scale from zero (not present) to four (always present). Ratings are based on behaviour over the previous three days. The seven headings are social competence, social interest, personal neatness, cooperation, irritability, manifest psychosis and psychotic depression. The total score ranges from 0-320 with high scores indicating a poor outcome.

4.6.1.4 Adverse effects

4.6.1.4.1 Abnormal Involuntary Movement Side Effects Scale - AIMS (Guy 1976)

This is a twelve-item scale designed to record the occurrence of dyskinesic movements. Ten items of this scale have been used to assess tardive dyskinesia, a long-term drug-induced movement disorder. A five-point scoring system (from 0 - none to 4 - severe) has been used to rate each of the ten items. Using this scale in short-term treatment may be helpful in assessing some short-term

abnormal movement disorders. A low score indicates low levels of dyskinesic movements.

4.6.1.4.2 Dosage Record and Treatment Emergent Symptoms Scale - DOTES (Guy 1976a)

This adverse effect tool seems less of a scale, where the degree and severity of a symptom is recorded, and more of a checklist. The DOTES seems to record the presence or absence of a list of adverse effects.

4.6.1.4.3 Extrapyramidal Symptom Rating Scale - ESRS (Chouinard 1980)

This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinesic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder.

4.6.1.4.4 Simpson and Angus Scale (Simpson 1970b)

This SAS is a ten item scale, used to evaluate the presence and severity of drug-induced parkinsonian symptomatology. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0-4 scale, with a scoring system of 0-4 for each item. A low score indicates low levels of parkinsonism

4.6.1.4.5 UKU Side Effects Rating Scale - UKU-SERS (Lingjaerde 1987).

The UKU rates four major topics: psychological adverse effects (10 items), neurological adverse effects (eight items), autonomic adverse effects (11 items) and other adverse effects (19 items). Each item is defined by means of a four-point scale where zero means not present or doubtfully present. Scoring range 0-144.

4.6.1.4.6 Treatment Emergent Symptom Scale -TESS (Guy 1976a)

This checklist assesses a variety of characteristics for each adverse event, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator.

4.6.1.4.7 Symptom Checklist 90 - SCL-90 (Derogatis 1977)

This is a self-report scale of physical symptoms.

METHODOLOGICAL QUALITY

1. Randomisation

Trialists described all included studies as randomised. Frangos 1978, Kissling 1985, Magnus 1979 and Wistedt 1984 were the only included studies that specified the process by which they undertook the allocation (code, coin throwing, pre-arranged pre-scribing list and randomisation list).

2. Blindness

Sixty six studies reported using double blind methodology, although the technique used was not described in any of them. Chien 1973, Hranov 1998. Goldstein 1978 used a single blind method and Leong 1989 described using a 'partially-blinded' method, although they gave no further details. No studies indicated that blind evaluation had been tested at outcome.

3. Loss to follow up

Sixty three studies accounted for all participants at completion of the study. Drop out rates were less than 25% on average for the four largest outcomes, i.e., fluphenazine decanoate versus placebo (17%), fluphenazine decanoate versus oral antipsychotics, (18%), fluphenazine decanoate versus other depot antipsychotics (23%), and fluphenazine enanthate versus other depot antipsychotics (21%).

Falloon 1978, Leong 1989 and Cookson 1986 reported no people on fluphenazine decanoate leaving the study early when compared with either oral or depot neuroleptics. In the latter study, last observations were carried forward and entered into the analysis. Kane 1979 and Pinto 1979 reported that no people left the control group (the former study compared fluphenazine decanoate with placebo and the latter study compared fluphenazine decanoate with another depot, flupenthixol decanoate). DeWolfe 1971 also reported no people having left the control group; in this case fluphenazine enanthate was compared to a thiorazine-stelazine regimen (given orally). Kissling 1985 reported a 60% (13/22) drop out rate in the fluphenazine decanoate group and a 30% (10/32) drop out rate in the comparison haloperidol decanoate group after six months. This made all other results reported in the study unusable and these were not included in the analysis. DeWolfe 1971 reported a high drop out rate in the fluphenazine enanthate group (6/10) in a period of six weeks and therefore according to the protocol, all further results reported were not usable. Another two studies had high drop out rates, the first compared (Dencker 1978) fluphenazine decanoate with pipothiazine palmitate with a drop out rate of 63% in the control group and the other (Jain 1975) reported a 73% drop out rate in the control group. In both cases data are not usable and we did not enter them into the analysis.

4. Unbalanced groups

Several studies had very unbalanced groups. Dencker 1973 reported a drop out rate of 10 in the fluphenazine decanoate group compared to 21 in the other depot group. Reasons for withdrawal were adverse effects, shifts to other medications, two patients moved to another place and another refused to continue medication while on fluphenazine decanoate. Asarnow 1988 also used fluphenazine decanoate as an intervention and reported unbalanced groups in the fluphenazine decanoate dosage study which observed low (n=22) and standard doses (n=14).

RESULTS

1. The search

The original search yielded 982 citations using the search strategy. Two hundred and forty eight citations were related to fluphenazine decanoate or enanthate but only 62 referred to controlled clinical trials (all published in journals). We updated the review in May 2002. A further electronic search yielded 247 citations from which we obtained 124 articles for further inspection. We found 12 studies new to this review so there now are 70 randomised controlled trials in the included studies table and 180 in the excluded studies table. Six studies await assessment, five have so far been unobtainable and one awaits translation.

2. COMPARISON 1: FLUPHENAZINE DECANOATE versus PLACEBO

2.1 Death

The only instance of mortality came from Jolley 1990 where two deaths were reported in the treatment group (fluphenazine decanoate) compared to none occurring in the placebo group (n=54, RR 5.0 CI 0.3 to 99.5). Nevertheless the result was not statistically significant.

2.2 Global state

Heterogeneous data from three studies (Hirsch 1975, Odejide 1982, Rifkin 1977) found relapse rates to be equivocal over 6 months to 1 year for the fluphenazine decanoate group compared with people receiving placebo (n=196, 3 RCTs, RR 0.62 CI 0.2 to 1.6). Relapse rates for longer-term studies (Jolley 1990) at two years significantly favoured fluphenazine decanoate (n=54, RR 0.35, CI 0.2 to 0.6, NNT 2 CI 2 to 4) to placebo.

2.3 Behaviour

Four trials in which 216 people had been randomised to fluphenazine decanoate or placebo had, in total, 21% attrition. No significant difference was found in people leaving the study early between groups (RR 1.30 CI 0.8 to 2.2). Jolley 1990 reported longer-term data at two years for leaving the study early that significantly favoured depot fluphenazine to placebo (n=54, RR 0.47, CI 0.2 to 1.0, NNT 4 CI 3 to 46).

2.4 Mental state

The single study by Odejide 1982 reporting on depression showed equivocal results between fluphenazine decanoate and placebo.

2.5 Adverse effects

Limited data were available. Jolley 1990 reported equivocal data for incidence of tardive dyskinesia. Rifkin 1977 reported on toxicity (no further details reported) which was significantly higher in the depot fluphenazine group (n=45 RR, 7.65 CI 1.04 to 56.26, NNH 4 CI 2 to 551).

3. COMPARISON 2: FLUPHENAZINE DECANOATE versus ORAL NEUROLEPTICS

3.1 Death

There were no reports of death in any of the studies comparing depot fluphenazine versus other oral neuroleptics.

3.2 Global state

Using the negative outcome, 'no clinically important global change' Adamson 1973 and Curry 1972 produced results favouring fluphenazine decanoate at 0 to 5 weeks (n=74, 2 RCTs, RR 0.61 CI 0.5 to 0.8, NNT 3 CI 2 to 6). Song 1993 reported on outcomes at 6 months to one year, with equivocal findings (n=102, RR 0.85, CI 0.6 to 1.3). Using the CGI scale, Shu 1983 also reported equivocal findings (n=34, MD at 6 weeks -0.10 CI -2.8 to 2.6). There was no significant difference between those taking fluphenazine decanoate and people on oral neuroleptics for relapse at 6 months to one year (n=419, 6 RCTs, RR 1.46 CI 0.8 to 2.8). Relapse data recorded at more than one year were also not significant (n=216, 3 RCTs, RR 1.30, CI 0.9 to 2.0).

3.3 Behaviour

Ten trials reported no significant different difference between the number of people who left the study early over 6 month to 1 year in either the fluphenazine decanoate group or the oral antipsychotic group (n=937, RR 0.96 CI 0.7 to 1.3). Studies by Curry 1972 (at 28 days), Shu 1983 (at 6 weeks) and Falloon 1978 and Simon 1978 (at more than 1 year) were also equivocal. This is further supported by Simon 1978, who found no difference in NOSIE scale scores between groups (n=120, MD -0.56 CI -6.9 to 5.8). Barnes 1983, reported on significant difference for change in disturbed behaviour (n=36). These data are skewed.

3.4 Mental state

Only Simon 1978, reported on mental state (BPRS endpoint scores) and found no significant difference between groups (n=120, MD -0.75 CI -5.8 to 4.3). Schooler 1979 and Falloon 1978 reporting on depression found no significant difference between those receiving fluphenazine decanoate and oral neuroleptics (n=214, RR 6 months to 1 year 0.89 CI 0.6 to 1.3; n=44, RR more than 1 year 1.53 CI 0.9 to 2.6).

3.5 Adverse effects

Three studies, McCreadie 1980, McCreadie 1982 and Schooler 1980, report homogenous data for general movement disorders (6 months to 1 year), which significantly favoured fluphenazine decanoate to oral neuroleptics (n=259, RR 0.47 CI 0.2 to 0.9, NNT 14 CI 10 to 82). The single longer-term study by Falloon 1978 found no significant difference for incidence of movement disorders (n=44, RR 0.40 CI 0.1 to 1.3). Rifkin 1977 reported on akathisia at one year. Akathisia was significantly lower in the oral fluphenazine group (n=51, RR 20.54 CI 1.3 to 338). Trials reported limited data for the outcome 'needing anticholinergic drugs' and all findings were equivocal. McCreadie 1982 found tardive dyskinesia to be significantly less common for those allocated fluphenazine decanoate compared with people on pimozide (n=28, RR medium term 0.60 CI 0.4 to 0.9). The other study to report on tardive dyskinesia was Simon 1978. Trialists did not find any difference between fluphenazine decanoate and oral neuroleptic (n=120, RR at 18 months 0.16 CI 0.0 to 3.0). Shu 1983, using the Simpson & Angus Scale reported no significant difference at six weeks between fluphenazine decanoate and penfluridol

(n=32, MD 1.30 CI 0.01 to 2.6). Adamson 1973 (immediate), McCreddie 1982 and Schooler 1980 (medium term) reported general adverse effects. Outcomes are equivocal. Falloon 1978 was the only longer-term study to report on tremor, with equivocal results for depot fluphenazine and pimozide (n=44, RR 0.80 CI 0.3 to 2.5). Schooler 1976 reports equivocal data for the adverse effect of blurred vision. Rifkin 1977 also reported on toxicity (no further details) which was more frequent for the depot fluphenazine group (n=51, RR 4.87 RR 1.1 to 20.7, NNH 4 CI 2 to 101).

4. COMPARISON 3: FLUPHENAZINE DECANOATE versus OTHER DEPOT NEUROLEPTICS

4.1 Death

McKane 1987 reported one death occurring in the treatment group (fluphenazine decanoate) compared to none in the haloperidol decanoate group (n=38, RR 3.0 CI 0.1 to 69.3). Nevertheless the result was not statistically significant.

4.2 Global state

Eleven studies report the outcome of 'relapse' at 6 months to one year. We found no statistically significant difference between the fluphenazine decanoate group and the other depot groups (n=581, RR 0.82 CI 0.6 to 1.2). Longer studies (more than one year) also found no difference between interventions (n=252, RR 1.22 CI 0.8 to 1.9). Wistedt 1984 did report relapse data at 20 weeks but, again, results were equivocal. Outcomes for 'no clinically important global change' at 6 months to 1 year reported by Dencker 1973, Leong 1989 and Schlosberg 1978 were not significant for the fluphenazine decanoate and other depot neuroleptic groups (n=187, RR 1.04 CI 1.0 to 1.1). Leong 1989 supported this result by reporting no significant differences in the number of people who became severely ill in the comparison of fluphenazine decanoate with other depot drugs (n=60, RR 1.07 CI 0.9 to 1.2).

Chouinard 1984 and Schlosberg 1978 report continuous data at 6 months to 1 year on clinical global impression. There is no clear advantage between fluphenazine decanoate and other depot neuroleptics (n=90, WMD -0.10 CI -0.4 to 0.2). These findings were confirmed by Chouinard 1984 and Cookson 1986 who reported no significant difference in needing additional antipsychotics at 6 months to 1 year between the depot groups (n=91, RR 0.53 CI 0.1 to 2). Frangos 1978 also reported the outcome of 'not improved' (n=50, RR at 4 months RR 2.50 CI 0.5 to 11.7) and Leong 1989, at 7 months (n=60, RR 0.75 CI 0.2 to 3.1). Finally Wistedt 1984 reported non-significant data for clinical global impression at zero to 5 weeks. These data are skewed so are not displayed graphically.

4.3 Behaviour

Fifteen included trials found no significant difference in the number of people who left the study early in either the fluphenazine decanoate group or the other depot group (n=775, RR medium term 1.13 CI 0.9 to 1.4). Studies found no differences across any time period from the immediate to those lasting longer than one year. Simon 1978 supported this outcome by reporting no differ-

ence in NOSIE-30 scores between the groups (n=118, MD -0.56 CI -6.92 to 5.8).

4.4 Mental state

We found short and medium term studies assessing mental state (BPRS endpoint scores) to significantly favour 'other depot neuroleptics' for the short term (n=51, 1 RCT MD 1.10 CI 0.9 to 1.4) and medium term (n=162, 3 RCTs, WMD 1.20 CI 1.1 to 1.3). Longer-term studies (McKane 1987, Simon 1978) did not show any differences for mental state in either intervention (n=141, WMD 0.85 CI -2.3 to 4.0). Dichotomised medium term BPRS data reported by Dencker 1973 found no significant difference between depot fluphenazine and pipothiazine palmitate. The only study reporting on the outcome of depression was Dencker 1973 who found no significant difference between fluphenazine decanoate and pipothiazine palmitate (n=67, RR medium term 1.02 CI 0.8 to 1.3).

4.5 Adverse effects

The occurrence of dyskinesic movements in general was the same across short, medium and longer-term studies. Feng 1990 reporting on a small, short-term study found no significant difference between fluphenazine decanoate and haloperidol decanoate (n=30 RR 2.0 CI 0.4 to 9.3). Dencker 1973, Leong 1989 and Schlosberg 1978 (comparing fluphenazine decanoate with pipothiazide palmitate) and McLaren 1992 (comparing with bromperidol decanoate) found no significant difference in the occurrence of dyskinesic movements (n=234, RR at 6 months to 1 year 1.08 CI 0.9 to 1.4). Longer-term studies also found no significant difference with movement disorders between fluphenazine decanoate and other depot neuroleptics. For the outcome of 'needing anticholinergic medication', eight studies, when synthesised, found in favour of other depots by one year (n=448, RR 1.22 CI 1.0 to 1.5 NNT 12 CI 6 to 84). However these data were heterogeneous and using the random effects model (as per protocol) the result was not statistically significant. For the same outcome, three longer-term studies were equivocal but significantly favoured the 'other depot neuroleptics' group when analysed with a fixed effects model (n=220, RR 1.28 CI 1.1 to 1.5, NNT 6 CI 4 to 20). Outcomes such as dry mouth, tardive dyskinesia and parkinsonism were not significantly different between depot fluphenazine and other depot neuroleptics. Tremor (short term, 2 RCTs and medium term, 3 RCTs) was not more common for people given the depot flupenthixol. When reporting blurred vision, the results of one medium term trial were not significant, but one longer-term study, Pinto 1979, did report significant results (p=0.04) favouring flupenthixol decanoate (n=65, RR 17.88 CI 1.1 to 294.8, NNT 4 CI -8.3 to -2.4). General adverse effects (short term data) were reported by Frangos 1978 and Javed 1991 and favoured other depot neuroleptics (n=88, RR 1.36 CI 1.1 to 1.7). However, medium term data (n=249, 6 months to 1 year) were equivocal.

5. COMPARISON 4: FLUPHENAZINE DECANOATE - DOSAGE STUDIES (HIGH DOSE versus STANDARD

DOSE)

5.1 Global state

McClelland 1976 and Kreisman 1988 reported no significant difference in relapse scores (medium term) between either depot group (n=184, RR 2.11, CI 0.3 to 14.9). Also, McClelland 1976 reported no significant difference in needing additional antipsychotics (6 months to 1 year) between fluphenazine decanoate (high dose) group and the standard dosage groups (n=50, 1 RCTs, RR 1.67 CI 0.5 to 6.2). Outcomes for global improvement 'not improved' were reported by Lehmann 1980 (nurse and psychiatrist rated) at 6 months to one year. Results for nurse rated outcomes significantly favoured the standard dosage group (n=40, 1 RCT, RR 1.58 CI 1.1 to 2.3). However, results for psychiatrist rated were not significant for either dosage intervention at 6 months (n=40, 1 RCT, RR 1.15 CI 0.8 to 1.7).

5.2 Behaviour

Lehmann 1980 and McClelland 1976 reported no difference in the number leaving the study (6 months to 1 year) for either intervention (n=90, 2 RCTs, RR 0.60 CI 0.2 to 2.4).

5.3 Mental state

McClelland 1976 further reports no difference in BPRS endpoint score (n=50, 1 RCT, MD -0.03 CI -5.8 to 5.7) for either high or standard dosage group.

5.4 Adverse effects

McClelland 1976 reported no difference between the groups for those needing anticholinergic medication (n=50, RR 1.67 CI 0.5 to 6.2) at six months to one year, suggesting the incidence of adverse effects is comparable between the groups, as the use of anticholinergic drugs is considered to be a direct measure of the severity of adverse effects due to medication.

6. COMPARISON 5: FLUPHENAZINE DECANOATE - DOSAGE STUDIES - (LOW DOSE versus STANDARD DOSE)

6.1 Global state

Relapse data, assessed over six months to one year were equivocal. Longer term studies (more than 1 year) reported by Asarnow 1988, Hogarty 1988 and Marder 1987 were also equivocal.

6.2 Behaviour

Marder 1984 reported no significant difference in those leaving the study early (6 months to 1 year) after receiving either low or standard dose fluphenazine decanoate (n=50, RR 0.31 CI 0.1 to 1.5). Asarnow 1988, Hogarty 1988, and Marder 1987 also report no difference in the number of people who left the study early in each dosage group after more than one year of medication (n=172, RR 0.67 CI 0.3 to 1.4).

6.3 Mental state

The data obtained for mental state (e.g. BPRS score etc.) were skewed and therefore could not be included in the analyses.

6.4 Adverse effects

Marder 1984 reported that there was no significant difference in the number of people requiring additional anticholinergic drugs at six months to one year (n=50, RR 2.55 CI 0.7 to 9.1). Kane 1983 supported this finding by reporting that the number of people with tardive dyskinesia (n=126, RR 0.52 CI 0.1 to 2.7) at six months to one year, was not significantly different between the groups receiving low doses of fluphenazine decanoate and standard dosage fluphenazine. Kane 1983, however, did report a statistically significant (p=0.03) difference at endpoint analysis with the Simpson Dyskinesia Scale (n=126), which favoured low dose fluphenazine decanoate, although data was skewed and therefore not graphically reported.

No study reported on hospital and service outcomes or commented on participants' overall satisfaction during or after the trial. Economic outcomes were not reviewed by any of the included studies.

7. COMPARISON 6: FLUPHENAZINE ENANTHATE versus PLACEBO

7.1 Adverse effects - at 8 weeks

Only Van Praag 1973 reports for this comparison. This small trial reported no significant difference in the number of people needing anticholinergic drugs in the fluphenazine enanthate and placebo groups (n=25, RR 9.69 CI 0.6 to 163.0).

8. COMPARISON 7: FLUPHENAZINE ENANTHATE versus ORAL NEUROLEPTICS

8.1 Global state

Chien 1973 reported no significant difference in global change (immediate term- 0 to 5 weeks) between fluphenazine enanthate and chlorpromazine (n=31, RR 0.67 CI 0.3 to 1.7).

8.2 Adverse effects

Reports of adverse effects, again from the same study and for the immediate term were all not significantly different (n=31, RR movement disorders 2.34 CI 0.5 to 10.3; RR general adverse effects 2.81 CI 0.9 to 8.5; RR parkinsonism 6.56, CI 0.9 to 47.2).

9. COMPARISON 8: FLUPHENAZINE ENANTHATE versus OTHER DEPOT NEUROLEPTICS

9.1 Global state

Albert 1980 and Chouinard 1978 reported no significant difference in needing additional antipsychotics (at 6 months to one year) for fluphenazine enanthate compared with other depot groups (n=65, RR 0.50 CI 0.2 to 1.1). Both Malm 1974, at 6 weeks to 5 months (n=57, RR 2.38 CI 0.7 to 8.6) and Chouinard 1978, at 6 months to 1 year (n=32, RR 0.33 CI 0.0 to 2.9) reported no statistically significant differences in relapse rates between the fluphenazine enanthate group and the other depot (pipothiazine palmitate) groups.

9.2 Behaviour

Only Jain 1975 provided data for numbers leaving the study early (0 to 5 weeks). These data significantly favoured fluphenazine

enanthate compared with the other depot neuroleptics - pipothiazine palmitate (n=30, RR 0.09, CI 0.0 to 0.6). However, this outcome should be interpreted with caution given the limited number of participants. The number of people who left the study early by 6 weeks to 5 months, in the single study by Malm 1974 using fluspirilene as a control, was not significant (n=57, RR 2.38 CI 0.7 to 8.6). Similarly, Chouinard 1978 found no difference between the fluphenazine enanthate group and the other depot neuroleptic group - pipothiazine palmitate at 6 months to 1 year (n=32, RR 0.33 CI 0.0 to 2.9).

9.3 Mental state

Singh 1979 reported general BPRS scores and found a significant difference between the two groups favouring the other depot group (n=30, MD 0.40 CI 0.3 to 0.5). Specific scores on, for example, depression found no difference between the two groups (Singh 1979, n=30, RR 7.00 CI 0.4 to 124.8).

9.4 Adverse effects

Findings were equivocal for outcomes of 'movement disorders' (medium term - n=63, 2 RCTs, RR 1.52 CI 0.8 to 3.1), tardive dyskinesia (medium term- n=32, 1 RCT, RR 0.89 CI 0.5 to 1.7), tremor (medium term- n=95, 3 RCTs, RR 1.24 CI 0.8 to 1.9), blurred vision (medium term- n=30, 1 RCT, RR 3.00 CI 0.1 to 68.3) and dry mouth (medium term- n=62, 2 RCTs, RR 0.80 CI 0.4 to 1.8). Malm 1974 reported that those receiving fluspirilene required significantly less anticholinergic drugs at 6 weeks to 5 months than the fluphenazine enanthate group (n=57, RR 2.86 CI 1.2 to 7.1). The numbers of people needing additional anticholinergic drugs at 6 months to one year were found (Albert 1980 and Chouinard 1978) to be equivocal (n=65, RR 1.02 CI 0.8 to 1.3) for the fluphenazine enanthate and other depot neuroleptic groups.

10. COMPARISON 9: FLUPHENAZINE ENANTHATE - DOSAGE STUDIES (LOW DOSE versus INTERMEDIATE/HIGH DOSE)

10.1 Global state

A single study by Goldstein 1978 reported the global outcome of relapse at six weeks to five months. Trialists found statistically significant differences favouring the high dosage fluphenazine enanthate group compared with low dosage fluphenazine enanthate (n=104, RR 9.35 CI 2.3 to 38.3). For every fourth person administered a low dose of fluphenazine decanoate one would relapse (NNT 4 CI 2 to 21). However this result must be treated with caution as only one study is involved.

10.2 Behaviour

Goldstein 1978 found no significant difference in the number of people who left the study early (6 weeks to 5 months) whilst receiving either high or low dosages of fluphenazine enanthate (n=103, RR 3.12 CI 0.7 to 14.7).

11. COMPARISON 10: FLUPHENAZINE DECANOATE versus FLUPHENAZINE ENANTHATE

11.1 Global state

Van Praag 1973 reported data for 'needing additional antipsychotic treatment' at zero to 5 weeks. This trial found a significant difference between the fluphenazines (decanoate and enanthate) (n=33, RR 0.39 CI 0.2 to 0.9 NNT 3 CI 2 to 10). Chouinard 1982 was the only study to report the numbers of people requiring additional antipsychotic treatment at 6 months to 1 year and found no significant difference.

The number of people who relapsed whilst receiving medication at zero to 5 weeks was not significant for the two studies available (n=44, 2 RCTs, RR 0.66 CI 0.2 to 2.4). Donlon 1976 reported no significant difference in relapse rates at 6 weeks to 5 months between the fluphenazine decanoate group and the fluphenazine enanthate group (n=30, RR 2.29 CI 0.7 to 7.5). MacCrimmon 1978, reporting on relapse over the medium term (6 months to 1 year) found no significant difference (n=39, RR 2.43 CI 0.7 to 8.3).

11.2 Behaviour

The number of people leaving the study early at zero to 5 weeks was not significantly different between the fluphenazine decanoate and enanthate groups (n=44, 2 RCTs, RR 0.66 CI 0.2 to 2.4). Short term outcomes (6 weeks to 5 months) were also not significantly different between the fluphenazine ester groups (n=42, 2 RCTs, RR 2.29 CI 0.7 to 7.5). Medium term data (6 months to 1 year) were consistent with the results of the two shorter study periods, finding no difference in the number of people leaving the study early for the two fluphenazine ester groups (n=49, 1 RCT, RR 2.43 CI 0.7 to 8.3).

11.3 Mental state

Only one study by MacCrimmon 1978 reported on mental state, using BPRS endpoint scores at one year. They found no significant difference between the fluphenazine esters (n=39, MD 0.00 CI -3.9 to 3.9).

11.4 Adverse effects

The number of people in these studies reporting movement disorders for short term (6 weeks to 5 months) was not significantly different between the fluphenazine esters (n=49, 2 RCTs, RR 1.14 CI 0.8 to 1.6). Reports of adverse effects (0 to 5 weeks) and parkinsonism (6 weeks to 5 months) were equivocal for fluphenazine decanoate and enanthate groups.

The number of people needing anticholinergic drugs at zero to 5 weeks was found by Van Praag 1973 to be significantly lower for the fluphenazine decanoate group (n=33, RR 0.29 CI 0.1 to 0.7, NNT 2 CI 2 to 5). For longer term studies (6 weeks to 5 months and 6 months to 1 year) there were no significant differences in the number of people needing anticholinergic drugs.

No study reported on hospital and service outcomes or commented on participants' overall satisfaction during or after the trial. Economic outcomes were not reviewed by trialists in any of the included studies.

DISCUSSION

1. General

Since the review was first published we have identified 1229 citations and included 70 studies. These 70 trials included 4638 people. Most studies were small, involving less than 60 people ($n=49$), although ten randomised over 100 (range 105-290). The age range was wide (between 13 and 81 years) but most people were in the 18 to 65 age range. Most trial participants had long histories of schizophrenia, although many studies ($n=41$) failed to mention the length of time people had been ill. Researchers frequently used operational criteria for diagnoses (DSM III, II, RDC, Schneider's 1st rank symptoms, Hay & Forrest 1972 criteria, PSE, Kraepelinian, ICD -9, DSM-II/III, Bleuler's criteria, Feighner 1972 criteria and Huangshan council schizophrenia standard), although 30 (43%) trials did not specify which diagnostic criteria were used. Trials were based mainly in the community, or combined both hospital and community settings. The dosages of fluphenazine decanoate and enanthate reflected current clinical practice. Outcomes were, however, limited. No trials reported data on quality of life, service utilisation, hospital admission and economic outcomes. This broad mixture of participants, settings, clinical applicability of the interventions should increase generalisability. It is a shame that so few outcomes were included.

2. Quality of reporting

The quality of reporting was poor in the majority of studies, with only eight studies describing how randomisation was conducted. All studies were classified as category B (unclear allocation concealment) with a moderate risk of overestimating the estimate of effect.

3. COMPARISON: ALL INVOLVING FLUPHENAZINE DECANOATE

3.1 Global state

Relapse rates (medium term - 6 months to 1 year) were not significantly lower in the fluphenazine decanoate group compared with placebo. Only longer term data (more than one year) significantly reduced relapse. The benefits of giving antipsychotic drugs as a maintenance treatment in the medium term for schizophrenia are unclear when compared to placebo. The results are only significant when a fixed effects model is used for this heterogeneous group of data. For the outcome of relapse, fluphenazine decanoate did not seem to hold any advantage over the oral preparation or other depots, at least in the context of randomised trials. The impression that depot preparations offer an advantage to oral antipsychotics in terms of fewer demands on resources such as fewer hospitalisations is neither supported nor refuted by these trial-derived data. Equivocal relapse data were also reported for the dosage studies.

3.2 Behaviour

The numbers of people leaving the study early (6 months to 1 year) in the fluphenazine decanoate (24%) and placebo (19%) groups

were very similar. This figure could be higher in clinical practice because rigorous adherence to protocols in these randomised studies may decrease attrition, although the opposite could also be true. Although adherence to protocol improves internal validity, it can potentially decrease the external validity and applicability of results. The single two-year study significantly favoured fluphenazine decanoate compared with placebo (NNT 4) (Jolley 1990).

Similar drop out rates occurred in fluphenazine decanoate (17%) versus oral neuroleptics (18%). Higher proportions of people left the study early when fluphenazine decanoate (24%) was compared with other depot neuroleptics (22%), but again the differences were not statistically significant. The dosage studies (6 months to 1 year) generally had even lower rates of drop out, high dose fluphenazine decanoate (6%) vs standard dose (11%), and low dose (22%) vs standard dose (7%). Again there was no significant difference between groups. Randomised studies imply that fluphenazine decanoate does not seem to offer additional benefits to prevent drop out compared with oral and other depot neuroleptics, or even placebo.

Simon 1978 reported scale derived behavioural data (NOSIE) for the comparisons fluphenazine decanoate versus oral neuroleptics and other depot neuroleptics. Both sets of data were equivocal.

3.3 Mental state

When fluphenazine decanoate was compared with oral neuroleptics, researchers found no differences for BPRS endpoint data (more than one year). Short and medium term BPRS data, however, significantly favoured 'other depot neuroleptics', although these findings were all based on small studies and are not totally convincing.

Depression scores (medium term and more than one year) were equivocal for fluphenazine decanoate when compared to placebo and oral and other depot neuroleptics, suggesting certain mental states may not be improved with antipsychotic medication. As only Odejide 1982 reported this outcome, larger studies, particularly with placebo comparators, are needed to confirm these initial findings.

3.4 Adverse affects

The occurrence of tardive dyskinesia (long term) was not significantly lower for placebo, although data were again from a single small study.

For oral neuroleptic comparisons, general movement disorders were significantly lower for fluphenazine decanoate over the medium term, but this advantage was not found in longer-term studies. The outcome of 'needing additional anticholinergic drug' was equivocal over short, medium and longer-term, suggesting oral neuroleptics and fluphenazine decanoate are similar in their ability to induce movement disorders. Also, tardive dyskinesia was significantly lower for the fluphenazine decanoate group during medium term evaluation, but was not different to oral neuroleptic

tics with longer-term data. For comparisons with other depot neuroleptics, general movement disorders and tardive dyskinesia were found equally commonly to fluphenazine decanoate. Needing anticholinergic drugs was equivocal for short term studies (fixed effects model); heterogeneous data from medium and longer-term studies also did not favour either depot fluphenazine or other depot neuroleptics. McClelland 1976 reported no difference in the requirement for anticholinergic medication between high dose fluphenazine decanoate and standard dose groups. Kane 1983 also reported no difference in the incidence of tardive dyskinesia between low and standard dosage groups. Fluphenazine in the decanoate form is considered by some to have more of a propensity to movement disorders than oral antipsychotics. The results from the randomised trials did not support this.

Studies reporting general adverse effects at 6-26 weeks significantly favoured the other depot group to fluphenazine decanoate. However, those treated with fluphenazine decanoate versus other depot antipsychotics at 6 months to 1 year reported no difference between the depots.

3.5 General

Fluphenazine is one of the older depots on the market and has been less favourably compared to the newer depots. The latter have been said to produce less adverse effects and improve the mental state. However, only six studies are involved and only three other depots have been used (haloperidol decanoate, pipothiazine palmitate and bromperidol). Such claims against fluphenazine decanoate seem more to do with marketing and less associated with evidence.

4. COMPARISON: ALL INVOLVING FLUPHENAZINE ENANTHATE

4.1 Global state

Relapse rates were similar for people given either fluphenazine enanthate or other depot neuroleptics. Data sets were small (Malm 1974, Chouinard 1978) and larger studies would be necessary to determine if fluphenazine enanthate reduces relapse more than other depot antipsychotics. Significantly less people relapsed when they were given intermediate/high dose fluphenazine enanthate compared to those receiving low dose (Goldstein 1978).

Chien 1973 was the only study to report data for 'no clinically important global change' (immediate term) with equivocal results between fluphenazine enanthate and oral neuroleptics. In the comparison with other depot antipsychotics, medium term data for 'needing additional antipsychotic treatment' were equivocal. Both outcomes were derived from small numbers of people and, if this preparation continues to be used, larger studies are needed to determine effects of the enanthate ester.

4.2 Behaviour

Van Praag 1970 compared fluphenazine enanthate with placebo but the authors failed to report how many people left the study early or relapsed during the trial. Jain 1975, however, reported that numbers of people leaving the study early (immediate term) were

significantly higher in those given 'other depot neuroleptics', but numbers were very small (n=30).

4.3 Mental state

Only medium term BPRS data were available from Singh 1979. These significantly favoured the 'other depot neuroleptics' group (pipothiazine palmitate). Although the outcome was highly significant no firm conclusion can be made on such a small sample size (n=30). Singh 1979 also reported depression outcomes. These showed no advantage for either preparation.

4.4 Adverse affects

For fluphenazine enanthate compared with placebo, data on general movement disorders and parkinsonism were equivocal over the immediate term, although, again, these are limited (n=31). General adverse effects may have been lower in the placebo group. In the comparison with other depots, rates of general movement disorders, tardive dyskinesia, tremor, blurred vision and dry mouth were all found to be similar. Again data were all extracted from small studies. One short term outcome, reported by Malm 1974, 'needing additional anticholinergics' was significantly lower for the other depot neuroleptics group, but this was not replicated by Albert 1980 and Chouinard 1978 over the medium term.

5. COMPARISON: ALL INVOLVING FLUPHENAZINE DECANOATE VERSUS FLUPHENAZINE ENANTHATE

5.1 Global state

Relapse data for immediate, short and medium term were all equivocal from these small studies (maximum n=49). Needing additional antipsychotic treatment (immediate term) significantly favoured the decanoate form although this came from a single study randomising just 33 people. Medium term data (n=49) were equivocal.

5.2 Behaviour

In terms of leaving the study early over the immediate, short and medium term, the two preparations were equally acceptable. Unfortunately the numbers randomised for these outcomes were small (maximum n=49).

5.3 Mental state

BPRS data were only available from one small trial (MacCrimmon 1978). This study reported identical scores for both of the fluphenazine depots groups.

5.4 Adverse affects

The two preparations caused roughly equal incidences of general movement disorders, parkinsonism and general adverse effects. The only statistically significant outcome was that fewer people in the decanoate group required additional anticholinergics (immediate term) but this was not replicated in the short and medium term studies.

In clinical practice, many people with schizophrenia are first prescribed an antipsychotic with less potent parkinsonian adverse effects or are adequately treated with occasional antiparkinsonian

medications. The studies we reviewed neither refute nor support the use of these routine therapeutic options.

6. Sensitivity analyses

The mean daily dose of fluphenazine decanoate at endpoint ranged from 0.3mg-300mg and for fluphenazine enanthate ranged from 2.35-387.5mg. Two studies, Cookson 1986 and Curry 1972, did not specify the average dose. The way data were reported did not permit any more sensitivity analyses than those which have already been presented.

AUTHORS' CONCLUSIONS

Implications for practice

1. For people with schizophrenia

Compared with placebo, fluphenazine decanoate does not appear to have a clinically important effect in terms of improving relapse rates based on medium term (6 months to 1 year) data. One longer term study, however, does support the use of fluphenazine decanoate to reduce relapse. Relapse data for fluphenazine enanthate were limited and no data comparing it with placebo or oral neuroleptics were available. Fluphenazine depot preparations, especially the decanoate, seem equivalent to oral medications and may even cause less adverse effects.

2. For clinicians

The data on the effects of fluphenazine decanoate are clearer than for fluphenazine enanthate. Within the highly unusual setting of a randomised trial, the decanoate may have some advantages over the oral antipsychotics. In clinical life there may be greater advantages in terms of compliance. There are no data to support the claim that depots cause more adverse effects than oral preparations. There are also no data to support use of high doses.

3. For managers or policy makers

Studies did not report data relating to service utilisation and care management. Outcomes relating to use of hospitals and services, satisfaction with care and economics were not reported in any study. This deficiency remains and should be addressed in real world randomised studies.

Implications for research

1. General

Trialists involved in future studies should implement the CONSORT statement (Moher 2001) to ensure that outcomes are more relevant. Inclusion of hospital and services outcomes, satisfaction with care and economic outcomes would provide valuable data for people with schizophrenia, clinicians and policy makers.

2. Specific

A recurring failure to report the exact methodology of allocation was evident throughout the included trials. Only four studies stated the randomisation process used; Kissling 1985 used a coin-

throwing method, Frangos 1978 a randomisation code, Magnus 1979 a pre-arranged prescribing list and Wistedt 1984 a randomisation list. Allocation concealment is essential to ensure that selection bias is kept to a minimum. Seven studies failed to implement double blind evaluation of the outcomes (Chien 1973, Goldstein 1978, Hranov 1998, Kane 1978, Kelly 1977, Leong 1989, Simon 1978). This is an important strategy for avoiding performance and detection bias. Odejide 1982 included participants who were unaccounted for after randomisation was undertaken. This study did not specify from which groups this withdrawal had occurred. In sixteen trials the number of people who left the study was not reported. It is important to know how many, and from which groups, people were withdrawn in order to evaluate exclusion bias. Studies included both community-based and hospitalised people but 17 failed to report the setting (Albert 1980, Feng 1990, Hranov 1998, Javed 1991, Kissling 1985, Kreisman 1988, Lehmann 1980, Marder 1984, McKane 1987, Odejide 1982, Quitkin 1978, Rossi 1990, Russell 1982, Schlosberg 1978, Schneider 1981, Sharma 1991, Wistedt 1983). A few studies, all using fluphenazine decanoate as an intervention, involved people in hospital at the beginning of the trial but these people were later discharged into the community (Dencker 1973, Donlon 1976, Magnus 1979, Marder 1987, McCreadie 1980, Rifkin 1977, Schooler 1980, Schooler 1997, Simon 1978, Wistedt 1984). More community based studies would be welcome.

This review highlights the need for good controlled clinical trials to address the effects of fluphenazine decanoate and fluphenazine enanthate and to assess their clinical suitability in certain situations. More studies are required in each category but particularly in the case of fluphenazine enanthate where data were particularly few.

POTENTIAL CONFLICT OF INTEREST

None.

ACKNOWLEDGEMENTS

We would like to thank Leanne Roberts for her help and support as well as Drs Cookson, Merskey, Russell, Quitkin, Pinto and McCreadie for their assistance.

Thank you to Mingming Zhang and Huilin Liu for translation of Chinese papers.

SOURCES OF SUPPORT

External sources of support

- NHS-ROCD Health Technology Assessment Programme. UK

Internal sources of support

- No sources of support supplied

REFERENCES

References to studies included in this review

Adamson 1973 *{published data only}*

Adamson L, Currey SH, Bridges PK, Firestone AF, Lavin NI, Lewis DM, Watson RD, Xavier CM, Anderson JA. Fluphenazine decanoate trial in chronic inpatient schizophrenics failing to absorb oral chlorpromazine. *Diseases of the Nervous System* 1973;**34**(4):181–91.

Albert 1980 *{published data only}*

Albert JM, Elie R, Cooper SF. Long term double-blind evaluation of pipotiazine palmitate and fluphenazine decanoate. *Current Therapeutic Research* 1980;**27**(6):897–907.

Altamura 1985 *{published data only}*

Altamura AC, Curry SH, Montgomery S, Wiles DH. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. *Psychopharmacology* 1985;**87**:30–3.

Asarnow 1988 *{published data only}*

Asarnow RE, Marder SR, Mintz J, Van Putten T, Zimmerman KE. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing skills. *Archives of General Psychiatry* 1988;**45**:822–7.

Barnes 1983 *{published data only}*

Barnes TRE, Milavic G, Curson DA, Platt SD. Use of the social behaviour assessment schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozone versus fluphenazine. *Social Psychiatry* 1983;**18**:193–9.

Chien 1973 *{published data only}*

Chien CP, Cole JO. Depot phenothiazine treatment in acute psychosis: A sequential comparative clinical study. *American Journal of Psychiatry* 1973;**130**(1):13–17.

Chouinard 1978 *{published data only}*

Chouinard G, Annable L, Kropfky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. *The Journal of Clinical Psychopharmacology* 1978;**Feb-Mar**:148–54.

Chouinard 1982 *{published data only}*

Chouinard G, Annable L, Ross-Chouinard A. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. *American Journal of Psychiatry* 1982;**139**(3):312–18.

Chouinard 1984 *{published data only}*

Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. *Journal of Clinical Psychopharmacology* 1989;**9**(4):247–53.

Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J. A double-blind, controlled clinical trial of haloperidol decanoate and

fluphenazine decanoate in the maintenance treatment of schizophrenia. *Psychopharmacology Bulletin* 1984;**20**:108–9.

Cookson 1986 *{published data only}*

Cookson JC, Kennedy NM, Gribbon D. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. *International Clinical Psychopharmacology* 1986;**Suppl1**:41–51.

Crawford 1974 *{published data only}*

Crawford R, Forrest A. Controlled trial of depot fluphenazine in outpatient schizophrenics. *British Journal of Psychiatry* 1974;**124**:385–91.

Curry 1972 *{published data only}*

Curry SH, Adamson L. Double-blind trial of fluphenazine decanoate. *Lancet* 1972;**2**(776):543–4.

Dencker 1973 *{published data only}*

Dencker SJ, Frankenberg K, Lepp M, Lindberg D, Malm U. Three years' maintenance neuroleptic treatment in schizophrenia - before and beyond. *Acta Psychiatrica Scandinavica* 1978;**57**:103–14.

Dencker SJ, Frankenberg K, Lepp M, Lindberg D, Malm U. How schizophrenic patients change during 3 years' treatment with depot neuroleptics. *Acta Psychiatrica Scandinavica* 1978;**57**:115–23.

Dencker SJ, Frankenberg K, Malm U, Zell B. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. *Acta Psychiatrica Scandinavica* 1973;**241** (suppl 241):101–18.

Donlon 1976 *{published data only}*

Donlon PT, Axelrad AD, Tupin JP, Chien C. Comparison of depot fluphenazines: Duration of action and incidence of side effects. *Comprehensive Psychiatry* 1976;**17**(2):369–76.

Dotti 1979 *{published data only}*

Dotti A, Bersani G, Rubino IA, Elliseo C. Double blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics [Studio in doppio cieco della flufenazina decanoato versus placebo nella terapia ambulatoriale di mantenimento di pazienti schizofrenici cronici]. *Rivista di Psichiatria* 1979;**14**(5):374–83. 75003702.

Falloon 1978 *{published data only}*

Falloon I, Watt DC, Shepherd M. The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: pimozone vs fluphenazine. *Psychological Medicine* 1978;**8**:265–74.

Falloon I, Watt D. A comparative controlled trial of pimozone and fluphenazine decanoate in the continuation therapy of schizophrenia. *Psychological Medicine* 1978;**8**:59–70.

Shepherd M. Medical-social evaluation of the long term pharmacotherapy of schizophrenia. *Progress Neuro-Psychopharmacology* 1979;**3**:383–89.

- Feng 1990** {published data only}
Feng L. Double blind controlled trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenia [[data not available]]. *Chinese Journal of Nervous and Mental Disorders* 1990;**16**(5): 299.
- Frangos 1978** {published data only}
Frangos H, Zississ NP, Leontopoulos I, Diamantas N, Tsitouridis S, Gavriil I, Tsolis K. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. *Acta Psychiatrica Scandinavica* 1978;**57**:436–46.
- Goldstein 1978** {published data only}
Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg MR. Drug and family therapy in the aftercare of acute schizophrenics. *Archives of General Psychiatry* 1978;**35**:1169–77.
- Hirsch 1975** {published data only}
Hirsch SR. *On the origin of schizophrenic psychoses*. De Erven Bohn BV, 1975. [MedLine: 76263054.
- Hogarty 1979** {published data only}
Hogarty GE, Schooler NR, Ulrich R, Mussare I, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. *Archives of General Psychiatry* 1979;**36**:1283–94.
- Hogarty 1988** {published data only}
Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RF, Carter M, Madonia MJ. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. *Archives of General Psychiatry* 1988;**45**:797–805.
- Hranov 1998** {published data only}
Hranov LG, Yanakiev N, Stefanov S, Nikolova N, Yakimova R. Haloperidol decanoate and fluphenazine decanoate for schizophrenia: a comparative naturalistic medium term study of efficacy and tolerability. 11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 3 - Nov 4; Paris, France. 1998.
- Jain 1975** {published data only}
Jain RC, Ananth JV, Lehmann HE, Ban TA. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients. *Current Therapeutic Research* 1975;**18**(4):585–9.
- Javed 1991** {published data only}
Javed MA, Chaudhry MR. Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. *The Pakistan Journal of Clinical Psychiatry* 1991;**1**(2): 69–74.
- Jolley 1990** {published data only}
Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. *British Medical Journal* 1990;**301**:837–42.
- Kane 1983** {published data only}
Kane JM, Rifkin A, Woerner M, Reardon G. Low-Dose Neuroleptics in Outpatient Schizophrenics. *Psychopharmacology Bulletin* 1982;**18**(1):20–21.

* Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. *Archives of General Psychiatry* 1983;**40**:893–6.
- Kaneno 1991** {published data only}
Kaneno S, Ohkuma T, Yamashita I, Mori Atsuyoshi, Yagi G, Kudo Y, Kawakita Y, Nakane Y. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients [[data not available]]. *Rinsho Hyoka (Clinical Evaluation)* 1991;**19**(1):15–45. 70166858.
- Kelly 1977** {published data only}
Kelly HB, Freeman HL, Banning B, Schiff AA. Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. *International Pharmacopsychiatry* 1977;**12**:54–64.
- Keskiner 1971** {published data only}
Keskiner A, Itil T, Han H, Hsu W, Ulett G. EEG changes after fluphenazine enanthate and decanoate based on analog power spectra and digital computer period analysis. *Psychopharmacologia* 1971;**20**(3):230–41. 71275801.
- Kissling 1985** {published data only}
Kissling W, Moller HJ, Walter K, Wittman B, Kruegger R, Trenk D. Double-blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. *Pharmacopsychiatry* 1985;**18**:240–5.
- Kreisman 1988** {published data only}
Kreisman D, Blumenthal R, Borenstein M, Woerner M, Kane J, Rifkin A, Reardon G. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view. *Psychiatry* 1988;**51**(1):3–13. 88218101.
- Kurland 1966** {published data only}
Kurland AA, Richardson JH. A comparative study of two long acting phenothiazine preparations, fluphenazine enanthate and fluphenazine decanoate. *Psychopharmacologia (Berl)* 1966;**9**:320–7.
- Lehmann 1980** {published data only}
Lehmann E, Quadbeck H, Tegeler J, Fararuni M, Heinrich K. Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms. *Pharmakopsychiatrie und Neuropsychopharmakologie* 1980;**13**(3):117–29.
- Leong 1989** {published data only}
Leong OK, Wong KE, Tay WK, Gill RC. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. *Singapore Medical Journal* 1989;**30**:536–40.
- Levenson 1976** {published data only}
Levenson AJ, Burnett GB, Nottingham JD, Sermas CE, Thornby JI. Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HCl with thiothixene and haloperidol. *Current Therapeutic Research Clinical and Experimental* 1976;**20**(5):695–700. 77048014.
- Lundin 1990** {published data only}
* Lundin L, Dencker SJ, Malm U. Community-based rehabilitation of schizophrenia. *Nordisk Psykiatrisk Tidsskrift* 1990;**44**:81–7.

Lundin L, Dencker SJ, Malm U. Community-based rehabilitation of schizophrenia: corrected version. *Nordisk Psykiatrisk Tidsskrift* 1992;**46**(2):121–7.

- MacCrimmon 1978** {published data only}
MacCrimmon DJ, Saxena B, Foley P, Grof P. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia. *Neuropsychobiology* 1978;**4**:360–5.
- Magnus 1979** {published data only}
* Magnus RV. A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. *Journal of Pharmacotherapy* 1979;**2**(3):109–14.

Magnus
RV. Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin-Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. *Munchener Medizinische Wochenschrift* 1980;**122**:1758–60.
- Malm 1974** {published data only}
Malm U, Perris C, Rapp W, Wedren G. A Multicentre Trial of Fluspirilene and Fluphenazine Enanthate in Chronic Schizophrenic syndromes. *Acta Psychiatrica Scandinavica Supplementum* 1974;**249**:94–116.
- Marder 1984** {published data only}
Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PRA. Costs and benefits of two doses of fluphenazine. *Archives of General Psychiatry* 1984;**41**:1025–9.
- Marder 1987** {published data only}
Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA. Low and conventional dose maintenance therapy with fluphenazine decanoate. *Archives of General Psychiatry* 1987;**44**:518–21.
- McClelland 1976** {published data only}
McClelland H, Farquharson RG, Leyburn P, Furness JA, Schiff AA. Very high dose fluphenazine decanoate. *Archives of General Psychiatry* 1976;**33**:1435–9.
- McCreadie 1980** {published data only}
McCreadie RG, Dingwall JM, Wiles DH, Heykants JJP. Intermittant pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. *British Journal of Psychiatry* 1980;**137**:510–7.
- McCreadie 1982** {published data only}
McCreadie R, Mackie M, Morrison D, Kidd J. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. *British Journal of Psychiatry* 1982;**140**:280–6.
- McKane 1987** {published data only}
McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS. Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. *British Journal of Psychiatry* 1987;**151**:333–6.
- McLaren 1992** {published data only}
* McLaren S, Cookson J. C, Silverstone T. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromoperidol and fluphenazine decanoates. *International Clinical Psychopharmacology* 1992;**7**:67–72.

McLaren S, Cookson J, Silverstone J. A comparative trial of bromoperidol decanoate and fluphenazine decanoate in chronic. Annual Meeting of the British Association for Psychopharmacology; 1990 July 15, Cambridge, England. 1990.
- Odejide 1982** {published data only}
Odejide OA, Aderonmu AF. Double-blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. *Psychopharmacology* 1982;**43**(5):195–6.
- Pinto 1979** {published data only}
Pinto R, Banerjee A, Ghosh N. A double-blind comparison of fluphenazine decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. *Acta Psychiatrica Scandinavica* 1979;**60**:313–22.

Pinto R, Banerjee A, Ghosh N. A double-blind comparison of fluphenazine decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. *Acta Psychiatrica Scandinavica* 1979;**60**:313–22.
- Quitkin 1978** {published data only}
Quitkin F, Rifkin A, Kane J, Ramos-Lorenzi JR, Klein DF. Long-acting oral vs injectable antipsychotic drugs in schizophrenics. *Archives of General Psychiatry* 1978;**35**:889–92.
- Rifkin 1977** {published data only}
Rifkin A, Quitkin F, Kane J, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. *Psychopharmacology Bulletin* 1977;**13**(2):40–50.

Rifkin A, Quitkin F, Kane J, Klein DF, Ross D. The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. *Biological Psychiatry* 1979;**14**(3):499–508.

Rifkin A, Quitkin F, Klein D. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics - Rating scale data. *Archives of General Psychiatry* 1977;**34**:15–9.

Rifkin A, Quitkin F, Rabiner C, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics - Relapse years after one year. *Archives of General Psychiatry* 1977;**34**:43–7.
- Rossi 1990** {published data only}
Rossi A, Di Michele VD, Volonte MV, Casacchia M. Therapeutic evaluation of bromperidol decanoate in schizophrenia - a double-blind comparison vs. Fluphenazine decanoate [Efficacia terapeutica e tollerabilità del Bromperidolo decanoato VS Flufenazina decanoato nel Disturbo Schizofrenico]. *Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali* 1990;**114**(6):1379–86.
- Russell 1982** {published data only}
Russell N, Landmark J, Merskey H, Turpin T. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. *Canadian Journal of Psychiatry* 1982;**27**:593–6.
- Schlosberg 1978** {published data only}
Schlosberg A, Shadmi M. A comparative controlled study of two long-acting phenothiazines: Pipothiazine palmitate and fluphenazine decanoate. *Current Therapeutic Research* 1978;**23**(5):642–54.
- Schneider 1981** {published data only}
Schneider SJ, Kirby EJ, Itil TM. Clinical blood chemistry values and long acting phenothiazines. *Pharmacopsychiatry* 1981;**14**:107–14.
- Schooler 1976** {published data only}
Schooler NR, Levine J, NIMH-PRB Collaborative Fluphenazine Study Group. The initiation of long-term pharmacotherapy in

- schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. *Pharmakopsychiatria* 1976;**9**(4):159–69.
- Schooler 1979** *{published data only}*
Schooler NR, Levine J, Severe JB. Depot fluphenazine in the prevention of relapse in schizophrenia: Evaluation of a Treatment Regimen. *Psychopharmacology Bulletin* 1979;**15**(2):44–7.
- Schooler 1980** *{published data only}*
Gelenberg AJ, Dollar JC, Schooler NR, Mieske M, Severe J, Mandel MR. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. *American Journal of Psychiatry* 1979;**136**(2):217–9.
- Levine J, Schooler NR, Severe J, Escobar J, Geleberg A, Mandel M, Sovner R, Steinbook R. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: A controlled study. *Advanced Biochemical Psychopharmacology* 1980;**24**:483–93.
- Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. *Archives of General Psychiatry* 1982;**39**:197–203.
- Schooler NR, Levine J, NIMH-PRB Collaborative Fluphenazine Study Group. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparison between oral and depot fluphenazine. *Pharmakopsychiatria* 1976;**9**:159–69.
- Schooler NR, Levine J, Severe JB. Depot fluphenazine in the prevention of relapse in schizophrenia: Evaluation of a Treatment Regimen. *Psychopharmacology Bulletin* 1979;**15**(2):44–7.
- Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB. Prevention of relapse in schizophrenia - An evaluation of fluphenazine decanoate. *Archives of General Psychiatry* 1980;**37**:16–24.
- Schooler 1997** *{published data only}*
Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG. Relapse and rehospitalisation during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. *Archives of General Psychiatry* 1997;**54**(5):453–63.
- Sharma 1991** *{published data only}*
Sharma SK, Jaigirdar SH. A comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophrenia. *British Journal of Clinical Research* 1991;**2**:177–86.
- Shu 1983** *{published data only}*
Shu L. Double-blind study of domestic penfluridol and fluphenazine decanoate [[data not available]]. *Chung Hua Shen Ching Ching Shen Ko Tsa Chih (Chinese Journal of Neurology and Psychiatry)* 1983;**16**(3):141–5. 84083784.
- Simon 1978** *{published data only}*
Simon P, Fermanian J, Ginestet D, Goujet MA, Peron-Magnan P. Standard and long-acting depot neuroleptics in chronic schizophrenics. *Archives of General Psychiatry* 1978;**35**:893–7.
- Singh 1979** *{published data only}*
Singh AN, Saxena B. A comparative study of prolonged action (depot) neuroleptics: pipotiazine palmitate versus fluphenazine enanthate in chronic schizophrenic patients. *Current Therapeutic Research* 1979;**25**(1):121–32.
- Song 1993** *{published data only}*
Song Y. A double-blind control study on the effect of pipotiazine palmitate and fluphenazine decanoate in the treatment of schizophrenia [[data not available]]. *Chinese Journal of Neurology and Psychiatry* 1993;**26**(3):137–40.
- Van Praag 1970** *{published data only}*
Van Praag HM, Breetveld J, Van Mesdag-etty H, Westerhuis R, Pen A, Schut T. A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. *Psychiatria, Neurologia, Neurochirurgia* 1970;**73**:165–75.
- Van Praag 1973** *{published data only}*
Van Praag HM, Dols LCW. Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. *American Journal of Psychiatry* 1973;**130**(7):801–4.
- Walker 1983** *{published data only}*
Walker CA. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients. *Pharmatherapeutica* 1983;**3**(5):289–93.
- Wistedt 1983** *{published data only}*
Wistedt B, Ranta J. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. *Acta Psychiatrica Scandinavica* 1983;**67**:378–88.
- Wistedt 1984** *{published data only}*
Wistedt B. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. *International Clinical Psychopharmacology* 1986;**1**(Suppl 1):15–23.
- Wistedt B, Persson T, Helbom E. A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate. *Current Therapeutic Research* 1984;**35**(5):804–14.
- Woggon 1977** *{published data only}*
Woggon B, Dick P, Fleischhauer HJ, Gmur M, Gruber G, Angst J, Heimann H. International Pharmacopsychiatry. *International Pharmacopsychiatry* 1977;**12**(4):193–209.

References to studies excluded from this review

- Abuzzahab 1976a**
Abuzzahab FS. Fluphenazine in chronic schizophrenia. *Unidentified report* 1976:72–3.
- Abuzzahab 1976b**
Abuzzahab FS Sr, Zimmermann RL. A three-year double-blind investigation of pimozide versus fluphenazine in chronic schizophrenia. *Psychopharmacology Bulletin* 1976;**12**(2):26–7. 76152826.
- Abuzzahab 1977**
Abuzzahab FS Sr. Evaluations of social functioning in a 3-year double-blind investigation of pimozide versus fluphenazine in chronic schizophrenia. *Psychopharmacology Bulletin* 1977;**13**:71–3. 77103340.
- Abuzzahab 1980**
Abuzzahab FS, Zimmermann RL. Factors determining patient tenure on a 3-year double-blind investigation of pimozide ver-

- sus fluphenazine HCl. *Advances in Biochemical Psychopharmacology* 1980;**24**:547–50. 80262450.
- Ahlfors 1971**
Ahlfors UG. A double-blind trial with long-acting neuroleptics. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971. [MedLine: 80262450.]
- Ahlfors 1973**
Ahlfors UG. Controlled clinical evaluation of depot neuroleptics. A double-blind trial with pipotiazine undecylenate and fluphenazine decanoate. *Acta Psychiatria Scandinavica* 1973;**241**:95–9.
- Altamura 1987**
Altamura AC, Mauri MC, Guercetti G, Cazullo CL. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia. *Progressive Neuro-Psychopharmacological and Biological Psychiatry* 1987;**11**:613–23.
- Angst 1975**
Angst VJ, Woggon B. Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, fluspirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate [Klinische prufung von funf depotneuroleptika]. *Arzneimittel Forschung* 1975;**25**(2):267–70.
- Arato 1979**
Arato M, Erdos A. Experience with depot neuroleptics [Tapasztalataink depo neuroleptikumokkal]. *Orvosi Hetilap* 1979;**not known** (17):1015–21. 79157578.
- Astrup 1974**
Astrup G, Grimsgard A, Hebnes K, Kruse-Jensen A, Lid M. A study of flupenthixol decanoate and pipothiazine undecylenate in schizophrenics. *Acta Psychiatria Scandinavica* 1974;**50**:481–91.
- Balon 1982**
Balon R, Kabes J, Parezova G. A comparison of the efficacy of fluphenazine decanoate and hydroxyprotepine decanoate in the treatment of schizophrenia (a double-blind crossover study). 1982;**82**:116–8. *Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova* 1982;**82**(1):116–8.
- Bankier 1968**
Bankier RG, Pettit DE, Bergen B. A comparative study of fluphenazine enanthate, trifluoperazine in chronic schizophrenic patients. A comparative study of fluphenazine enanthate and trifluoperazine in chronic schizophrenic patients. *Diseases of the Nervous System* 1968;**29**(1):56–60.
- Bao 1991**
Bao GW. Efficacy and safety of flupenthixol decanoate in chronic schizophrenia [[data not available]]. *Chinese Journal of Nervous and Mental Disorders* 1991;**17**(1):49–50.
- Barsa 1965**
Barsa JA, Saunders JC. A double blind study of fluphenazine enanthate. *Diseases of the Nervous System* 1965;**26**:496–8. 77103340.
- Bastie 1974**
Bastie Y. Outcome in 64 chronic psychotics treated with delayed action Moditen or Modecate [Devenir de 64 psychotiques chroniques sous Moditen retard ou Modecate]. *Annales Medico Psychologiques* 1974;**1**(4):531–6. 75003702.
- Benassi 1968**
Benassi P, Bertolotti P, De Pietri L. no English title given [Flufenazina as alte dosi: esperienze clinico-terapeutiche]. *not known* not known; **not known**:1803–25.
- Berliner 1974**
Berliner J. No English title given [Eperimentation au niveau du centre de guidance d'lxelles d'un neuroleptique majeur: l'Anatensol decanoate]. *Acta Psychiatria Belgique* 1974;**74**(3):305–16.
- Bilone 1988**
Bilone F, Carcereri G, Lamonaca D. Fluphenazine decanoate and haloperidol decanoate - 2 neuroleptics compared in nonacute psychiatric pathology. Long-term crossover trial. II. Tolerability and side effects [Flufenazina decanoato e aloperidolo decanoato: due neurolettici a confronto nella patologia psichiatrica non acuta studio cross-over a lungo termine. II. Tollerrabilita ed effetti collaterali]. *Neurologia Psichiatria Scienze Umane* 1988;**8**(Suppl 3):49–59.
- Boyer 1987**
Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools. *Psychiatrie and Psychobiologie* 1987;**2**(4):296–305.
- Brankovic 1998**
Brankovic S, Milovanovic S, Damjanovic A, Paunovic VR. No difference between the effects of clozapine and fluphenazine on probabilistic reasoning in paranoid schizophrenia. 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12–16; Glasgow, Scotland. 1998. [MedLine: 94212428.]
- Breier 1987**
Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. *American Journal of Psychiatry* 1987;**144**:1549–55. 88074868.
- Caranza 1973**
Caranza J, Vargas L, Gomez J. A double-blind evaluation of sulpiride, a new antipsychotic compound. *American Social Clinical Pharmacological Therapeutics* 1973;**14**:132–2.
- Carpenter 1992**
Carpenter WT, Buchanan RW, Breier A, Kirkpatrick B, Hanlon T, Levine J, Waltrip RW. Novel neuroleptic dosage reduction strategies. *Schizophrenia Research* 1992;**6**(2):107. 75116033.
- Carpenter 1999**
Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. *American Journal of Psychiatry* 1999;**156**(3):412–8. 99178642.
- Casacchia 1989**
Casacchia M, Michele DIV, Volonte MV, Rossi A. Bromperidol decanoate vs fluphenazine decanoate in schizophrenia. Psychiatry Today: Accomplishments and Promises. Proceedings of the 8th World Congress of Psychiatry; 1989 Oct 13–19; Athens, Greece. 1989. [MedLine: 94212428.]
- Castellani**
Castellini A, Lorini M. Flufenazina decanoato e aloperidolo decanoato: due neurolettici a confronto nella patologia psichiatrica non acuta studio crossover a lunga termine. *not known*. not known, not known:33–48.

- Chacon 1972**
Chacon Carlos, Harper P, Harvey GF. Work study in the assessment of the effects of phenothiazines in schizophrenia. *Comprehensive Psychiatry* 1972;**13**(6):549–54. 73051431.
- Chacon 1973**
Chacon C, Harper P. Clinical and work performance variables in phenothiazine therapy of schizophrenia. *Acta Psychiatrica Scandinavica* 1973;**49**:65–76.
- Charalampous 1977**
Charalampous K, Thornby J, Ford BK, Freemesser GF. Penfluridol versus oral fluphenazine in the maintenance treatment of chronic schizophrenics. *Current Therapeutic Research* 1977;**21**(2):215–23.
- Chien 1974**
Chien CP, Dimascio A, Cole JO. Antiparkinsonian agents and depot phenothiazine. *American Journal of Psychiatry* 1974;**131**(1):86–90.
- Childers 1964**
Childers RT. Comparison of four regimens in newly admitted female schizophrenics. *American Journal of Psychiatry* 1964;**120**:1010–1. 72165461.
- Chouinard 1970**
Chouinard G, Lehmann HE, Ban TA. Pimozide in the treatment of chronic schizophrenic patients. *Current Therapeutic Research Clinical and Experimental* 1970;**12**(9):598–603. 70285984.
- Chowdhury 1980**
Chowdhury MEH, Chacon C. Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. *Comprehensive Psychiatry* 1980;**21**(2):135–9.
- Clark 1971**
Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. *Archives of General Psychiatry* 1971;**25**(5):404–9. 72081786.
- Cohen 1985**
Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B. Plasma levels of neuroleptic in patients receiving depot fluphenazine. *Journal of Clinical Psychopharmacology* 1985;**5**(6):328–32.
- Cole 1967**
Cole JO, Schooler NR National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Differences in clinical effects of three phenothiazines in “acute” schizophrenia. *Diseases of the Nervous System* 1967;**44**(6):369–83. 67248496.
- Cookson 1991**
Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. *Clinical Neuropharmacology* 1991;**14**(Suppl 2):S24–32. 92089872.
- Coufal 1981**
Coufal J, Novotny M. Fluphenazine and flupenthixol decanoate in psychiatric outpatients practice. *Acta Nervosa Superior (Praha)* 1981;**23**(4):269–71.
- Curry 1979**
Curry SH, Altamura AC, Montgomery S. Unwanted effects of fluphenazine enanthate and decanoate (letter). *Lancet* 1979;**1**(8111):331–2. 79133726.
- Curson 1985**
Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long term depot maintenance of chronic schizophrenic outpatients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial. *British Journal of Psychiatry* 1985;**146**:464–80.
- Curson 1986**
Curson DA, Hirsch SR, Platt SD, Bamber RW, Barnes TR. Does short term placebo treatment of chronic schizophrenia produce long term harm?. *British Medical Journal Clinical Research Edition* 1986;**293**(6549):726–8. 87027218.
- De Alarcon 1969**
De Alarcon R, Carney MWP. Severe depressive mood changes following slow-release intramuscular fluphenazine injection. *British Medical Journal* 1969;**3**(6 September):564–7.
- De Buck 1973**
De Buck RP. *Psychopharmacology sexual disorders and drug abuse*. North Holland, 1973.
- Del Giudice 1975**
Del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. *Psychosomatics* 1976;**16**:32–6.
- Dencker 1978**
Dencker SJ, Johansson R, Lundin L, Malm U. High doses of fluphenazine enanthate in schizophrenia. *Acta Psychiatrica Scandinavica* 1978;**57**:405–14.
- Dencker 1981**
Dencker SJ, Johansson R, Lundin L. Pharmacokinetics of fluphenazine depot in megadose: Comparison between the enanthate and the decanoate form. *Nordic Psykiatria Tidsskrift* 1981;**Not known**:365–9.
- Dengler 1969**
Dengler K. Contribution to the infusion therapy with fluphenazine in schizophrenics with regard to the control of the neuroleptic threshold [Beitrag zur Infusionstherapie mit Fluphenazin bei schizophrenen im Hinblick auf die Steuerbarkeit der neuroleptischen Schwelle]. *Medizinische Welt* 1969;**16**:977–81. 69204321.
- DeWolfe 1971**
DeWolfe AS, Barrell RP, London L, Spaner FE. Prolixin enanthate and thiorazine-stelazine regimens in the treatment of schizophrenic patients: An experimental evaluation. *Psychosomatics* 1971;**12**:186–90.
- Donlon 1976 1**
Donlon PT, Rada RT, Arora KK. Depression and the reintegration phase of acute schizophrenia. *American Journal of Psychiatry* 1976;**133**:1265–8. 77042351.
- Donlon 1977**
Donlon PT, Swaback DO, Osborne ML. Pimozide versus fluphenazine in ambulatory schizophrenics: a 12-month comparison study. *Diseases of the Nervous System* 1977;**38**(2):119–23. 77115433.
- Donlon 1978**
Donlon PT, Meadow A, Tupin JP, Wahba M. High vs standard dosage fluphenazine HCL in acute schizophrenia. *Journal of Clinical Psychiatry* 1978;**39**(11):800–4. 79067694.

Doongaji 1988

Doongaji DR, Sheth AS, Apte JS, Desai AB, Gupta L. Penfluridol vs fluphenazine decanoate: A double-blind clinical study in chronic and subchronic schizophrenia. *Current Therapeutic Research* 1988;**43**(3):416–22.

Dossenbach 1997

* Dossenbach M, Friedel P, Jakovljevic M, Hotujac L, Folnegovic V, Uglesic B, Dodig G. Olanzapine versus fluphenazine - six weeks' treatment of acute schizophrenia. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [MedLine: 21196608.

Dossenbach M, Jakovljevic M, Folnegovic F, Uglesic B, Dodig G, Friedel P, Hotujac L. Olanzapine versus fluphenazine - 6 weeks treatment of anxiety symptoms during acute schizophrenia. *Schizophrenia Research* 1998;**29**(1,2):203.

Downing 1963

Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. *Perceptual and Motor Skills* 1963;**17**(2):511–20.

Emsley 1999

Emsley R, Jones AM, Bailey P, Raniwalla J. 'Seroquel' In partially responsive schizophrenics. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:287.

Engelhardt 1973

Engelhardt DM, Polizos P, Waizer J, Hoffman SP. A double blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. *Journal of Autism and Childhood Schizophrenia* 1973;**3**(2):128–37.

Faltus 1974

Faltus F. The depot compounds moditen (fluphenazine) and IMAP (flusipirilene) in clinical practice. *Active Nervosa Superior* 1974;**16**(3):167–8.

Faretra 1970

Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. *American Journal of Psychiatry* 1970;**126**:1670–3. 70181755.

Ferenc 2000

Ferenc M, Dossenbach M, Jakovljevic M, Metcalfe S. Predictive value of early anti anxiety effect on the acute antipsychotic outcome: a comparison of fluphenazine and olanzapine. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.

Filip 1985

Filip V, Faltus F, Hanakova S, Janeckova E, Raboch J, Dobiasova A, Karen P, Posmurova M. Oxyprothepin decanoate in maintenance therapy of schizophrenia - a double-blind, standardized controlled study [Oxyprothepin dekanolat v udrzovaci lecbe schizofrenie--dvojite slepa, standardem kontrolovana studie]. *Ceskoslovenska Psychiatrie* 1985;**81**(1):6–14. 85152093.

Floru 1975

Floru L, Heinrich K, Wittek F. The problem of post-psychotic schizophrenic depressions and pharmacological induction. *International Pharmacopsychiatria* 1975;**10**(4):230–9.

Gianelli 1990

Gianelli A, Rabboni M, Zarattini F. Clinical profiles of the effects, indications, preferential therapeutic effect and contraindication of

three depot neuroleptics compared in a multicentre trial [Profili clinici di azione, indicazioni preferenziali, effetti terapeutici e controindicazioni di tre neurolettici depot in trial multicentrico di confronto]. *Revista di Psichiatria* 1994;**25**:7–23.

Giannelli 1990

Giannelli A, Rabboni M, Zarattini F. Clinical profiles of the effects, indications, preferential therapeutic effect and contraindication of three depot neuroleptics compared in a multicentre trial [Profili clinici di azione, indicazioni preferenziali, effetti terapeutici e controindicazioni di tre neurolettici depot in trial multicentrico di confronto]. *Rivista di Psichiatria* 1990;**25**(1):7–24.

Gillis 1981

Gillis JS, Parkison S. The effects of fluphenazine decanoate injection and chlorpromazine on symptom severity and learning in outpatient schizophrenics. *Current Therapeutic Research Clinical and Experimental* 1981;**29**:551–66.

Gitlin 1988

Gitlin MJ, Midha KK, Fogelson D, Nuechterlein K. Persistence of fluphenazine in plasma after decanoate withdrawal. *Journal of Clinical Psychopharmacology* 1988;**8**(1):53–6.

Goldberg 1967

Goldberg SC, Mattsson N, Cole JO, Klerman GI. Prediction of improvement in schizophrenia under four phenothiazines. *Archives General Psychiatry* 1967;**16**:107–17.

Goldberg 1968

Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. *Diseases of the Nervous System* 1968;**29**(5):153–8. 68399894.

Goldberg 1970

Goldberg Harold L, DiMascio Alberto, Chaudhary Basudeo. A clinical evaluation of prolixin enanthate. *Psychosomatics* 1970;**11**(3):173–7. 70229686.

Goldberg 1981

Goldberg SC, Shenoy RS, Sadler A, Hamer R, Ross B. The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. *Psychopharmacology Bulletin* 1981;**17**(1):116–7. 81200009.

Grosser 1970

Grosser HH. Experience of psychiatric management of schizophrenia with fluphenazine decanoate. *Diseases of the Nervous System* 1970;**31**(Supp):32–6.

Haider 1968

Haider I. A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics. *British Journal of Psychiatry* 1968;**114**:837–41.

Hall 1968

Hall WB, Vestre ND, Schiele BC, Zimmermann R. A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics. *Diseases of the Nervous System* 1968;**29**(6):405–8. 68409364.

Hamilton 1979

Hamilton M, Card IR, Wallis GG, Mahmoud MR. A comparative trial of the decanoates of flupenthixol and fluphenazine. *Psychopharmacology* 1979;**64**:225–9.

Hanlon 1965

Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative effectiveness of eight phenothiazines. *Psychopharmacologia* 1965;7(2):89–106. 66010572.

Harper 1976

Harper P, Chacon C. Work performance versus clinical assessment in the evaluation of phenothiazine therapy. *British Journal of Clinical Pharmacology* 1976;3:50–55.

Haslam 1975

Haslam MT, Bromham BM, Schiff AA. A comparative trial of fluphenazine decanoate and flupenthixol decanoate. *Acta Psychiatrica Scandinavica* 1975;51:92–100.

Held 1970

Held JM, Cromwell RL, Frank ET Jr, Fann WE. Effect of phenothiazines on reaction time in schizophrenics. *Journal of Psychiatric Research* 1970;7(3):209–13. 70166858.

Hirsch 1973

* Hirsch SR, Gained R, Rohde PD, Stevens BC, Wing J. Outpatients maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. *British Medical Journal* 1973;1:633–7.

Hirsch SR, Leff JP, Wing JK. Outpatient maintenance of chronic schizophrenics with long acting fluphenazine. *British Medical Journal* 1973;17:715–6.

Stevens B. The social value of fluphenazine decanoate. *Acta Psychiatrica Belgica* 1976;76:792–803.

Hirsch 1978

Hirsch SR, Knights A, Okasha MS, Salih MA. Maintenance therapy in out-patient schizophrenics: a report of a double-blind trial comparison of fluphenazine decanoate and flupenthixol decanoate. *British Journal of Psychiatry* 1978;133:371.

Hirsch 1989

Hirsch SR, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapse. *British Journal of Psychiatry* 1989;155(5):46–50.

Hogarty 1995

Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J. Pharmacotherapy of impaired affect in recovering schizophrenic patients. *Archives of General Psychiatry* 1995;52:29–41.

Holden 1970

Holden JM, Itil TM, Keskiner A. Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy. *Biological Psychiatry* 1970;2(2):173–82. 70291696.

Holt 1984

Holt RJ. Neuroleptic drug-induced changes in platelet levels. *Journal of Clinical Psychopharmacology* 1984;4(3):130–2. 84240338.

Hsu 1967

Hsu JJ, Nol E, Martinez ML, Lessien B, Paragas PG, Puhac M, Braun RA. One year study of fluphenazine enanthate. *Diseases of the Nervous System* 1967;28:807–11.

Inderbitzen 1994

Inderbitzen LB, Lewine RRR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, Vidanagama BP, Waternaux C. A double-blind

dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. *American Journal of Psychiatry* 1994;151:1753–59.

Ionescu 1983

Ionescu R, Tiberiu C, Miklos R, Angelescu C, Persiceanu AM. Penfluridol in the maintenance therapy of schizophrenia. *Neurologie et Psychiatrie* 1983;21(1):33–41. 83197141.

Iqbal 1978

Iqbal MJ, Young MA, Charles J, Elgart B, Von Greiff H, Simpson GM. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients. *Journal of Clinical Psychiatry* 1978;39(4):375–7.

Irwin 1986

Irwin M, Fuentenebro F, Marder SR, Yuwiler A. L-5-Hydroxytryptophan-induced delirium. *Biological Psychiatry* 1986;21(7):673–6. 86216405.

Itil 1970a

Itil T, Keskiner A. Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis. *Diseases of the Nervous System* 1970;31(5-9):37–42.

Itil 1970b

Itil T, Keskiner A, Heinemann L, Han T, Gannon P, Hsu W. Treatment of resistant schizophrenics with extreme high dosage fluphenazine hydrochloride. *Psychosomatics* 1970;11(5):456–63. 71007605.

Itil 1971

Itil TM, Saletu B, Hsu W, Kiremitci N, Keskiner A. Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment. *Acta Psychiatrica Scandinavica* 1971;47(4):440–51. 72165461.

Itil 1978

Itil TM, Reisberg B, Patterson C, Amin A, Wadud A, Herrman WM. Pipothiazine palmitate, A long-acting neuroleptic: Clinical and computerized EEG effects. *Current Therapeutic Research* 1978;24(6):689–707.

Jakovljevic 1999

Jakovljevic M, Dossenbach MRK. Olanzapine versus fluphenazine in the acute (six-week) treatment of schizophrenia. *Psychiatria Danubina* 1999;11(1-2):3–11. 77103340.

James 1977

James NM. Penfluridol: a double blind trial in chronic schizophrenia. *New Zealand Medical Journal* 1977;85(580):53–4. 77147536.

Johnson 1975

Johnson DA, Malik NA. A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. *Acta Psychiatrica Scandinavica* 1975;51:257–67.

Kabes 1980a

Kabes J, Balon R, Papezova H. Maintenance therapy with fluphenazine decanoate and oxyprothepine decanoate in schizophrenic patients - a DOUBLE blind cross-over comparative study. *Activitas Nervosa Superior* 1980;22(3):160–2. 90076019.

Kabes 1980b

Kabes J, Balon R, Hanzlicek L, Skovajsova M, Kozakova H. Clinical trial of oxyprothepin decanoate [Klinicke zkouseni

- oxyprothepin dekanatu]. *Ceskoslovenska Psychiatrie* 1980;**76**(1):16–25. 80200044.
- Kabes 1981**
Kabes J. Oxypromethazine decanoate in the maintenance treatment of schizophrenia: multiclinical controlled comparison with fluphenazine decanoate. *Activitas Nervosa Superior* 1981;**23**(3):241–3.
- Kane 1979**
Kane JM, Rifkin A, Quitkin F, Nayak D, Saraf K, Ramos-Lorenzi JR, Klein DF, Sachar EJ. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. *Psychiatry Research* 1979;**1**:341–8.
- Kane 1982**
Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. *Archives of General Psychiatry* 1982;**39**:70–3.
- Kane 1983 b**
Kane JM. Low dose medication in the treatment of schizophrenia. *Schizophrenia Bulletin* 1983;**9**(4):528–31.
- Kelly 1999**
Kelly D Conley RR. Sexual side effects of quetiapine and risperidone compared with fluphenazine. Stanley Foundation Research Awards - 1999 Research Award Recipients (<http://www.stanleyresearch.org/> accessed February 2001) 1999. [MedLine: 98271218.
- Kenway 1971**
Kenway AK, Masheter HC. Pimozide compared with fluphenazine in schizophrenia. *British Journal of Clinical Practice* 1971;**25**(2):69–72. 71157161.
- Keskiner 1968a**
Keskiner A, Simeon J, Fink M, Itil TM. Long acting phenothiazine (fluphenazine decanoate) treatment of psychosis. *Archives of General Psychiatry* 1968;**18**:477–81.
- Keskiner 1968b**
Keskiner A, Holden JMC, Itil TM. Maintenance treatment of schizophrenic outpatients with a depot phenothiazine. *Psychosomatics* 1968;**9**:166–71.
- King 1979**
King CE Goldstein MJ. Therapists rating of achievement of objectives in psychotherapy with acute schizophrenics. *Schizophrenia Bulletin* 1979;**5**(1):118–29.
- Kinon 1993**
Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koren A, Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. *Psychopharmacology Bulletin* 1993;**29**(2):309–14. 94120060.
- Kinross-Wright 1963**
Kinross-Wright J, Vogt AH, Charalampous KD. A new method of drug therapy. *American Journal of Psychiatry* 1963;**119**:779–80.
- Knights 1979**
Knights A, Okasha MS, Salih MA, Hirsch SR. Depressive and extrapyramidal symptoms and clinical effects: A trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. *British Journal of Psychiatry* 1979;**135**:515–23.
- Kong 1989**
Kong DSG, Yeo SH. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. *Pharmatherapeutica* 1989;**5**:371–9.
- Landmark 1994**
Landmark J, Merskey H, Cernovsky ZZ. Fluphenazine treatment of DSM-III-R Male Schizophrenic Patients Among the Xhosa. *Canadian Journal of Psychiatry* 1994;**39**:219–22.
- Lapierre 1975**
Lapierre YD, Lavallee J. Pimozide and the social behavior of schizophrenics. *Current Therapeutic Research* 1975;**18**(1):181–8.
- Lapierre 1976**
Lapierre Y, Lavallee J. A controlled pimozide, fluphenazine and group psychotherapy study of chronic schizophrenics. *Psychiatric Journal of the University of Ottawa* 1976;**1**(1-2):8–13.
- Lapierre 1978**
Lapierre YD. A controlled study of penfluridol in the treatment of chronic schizophrenia. *American Journal of Psychiatry* 1978;**135**:956–9. 78208642.
- Lapierre 1983**
Lapierre YD, von Frenckell R. AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics. *Modern Problems of Pharmacopsychiatry* 1983;**2**:193–203. 84013802.
- Lasky 1962**
Lasky JJ, Klett CJ, Caffey EM, Bennett JL, Rosenblum MP, Hollister LE. Drug treatment of schizophrenic patients. A comparative evaluation of chlorpromazine, chlorpromazine, fluphenazine, reserpine, thioridazine and trifluromazine. *Diseases of the Nervous System* 1962;**23**(12):698–706.
- Leff 1971**
Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. *British Medical Journal* 1971;**11**(12):599–604.
- Leff 1973**
Leff JP, Hirsch SR, Gajnd R, Rohde PD, Stevens BC. Life events and maintenance therapy in schizophrenic therapy. *British Journal of Psychiatry* 1973;**123**:659–69.
- Levinson 1990**
Levinson DF, Simpson GM, Lo ES, Cooper TB, Singh H, Yadalam K, Stephanos MJ. Fluphenazine plasma levels, dosage, efficacy, and side effects. *American Journal of Psychiatry* 1995;**152**(5):765–71. 95243387.
- * Levinson DF, Simpson GM, Singh H, Yadalam K. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. *Archives of General Psychiatry* 1990;**47**(8):761–8. 90334499.
- Levinson DF, Singh H, Simpson GM. Timing of acute clinical response to fluphenazine. *British Journal of Psychiatry* 1992;**160**:365–71. 92223990.
- Litman 1994**
Litman RE, Hommer DW, Radant A, Clem T, Pickar D. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. *Schizophrenia research* 1994;**12**(2):107–20.
- Ljubin 2000**
Ljubin T, Milas DZ, Mimica N, Folnegovic Smalc V, Makaric G. A preliminary study of the comparative effects of olanzapine and

- fluphenazine on cognition in schizophrenic patients. *Human Psychopharmacology* 2000;**15**(7):513–9.
- Marder 1986**
Marder SR, Hawes EM, van Putten T, Hubbard JW. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. *Psychopharmacology* 1986;**88**(4):480–3.
- Marder 1989**
Marder SR, Van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, Midha KK. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. *Psychopharmacology Bulletin* 1989;**25**(3):479–82.
- Marder 1990**
Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK. Fluphenazine plasma levels and clinical response. *Psychopharmacology Bulletin* 1990;**26**(2):256–9.
- Marder 1991a**
Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. *British Journal of Psychiatry* 1991;**158**:658–65.
- Marder 1991b**
Marder SR, Mintz J, Van Putten T, Lebell M, Wirshing WC, Johnston-Cronk K. Early prediction of relapse in schizophrenia: An application of receiver operating characteristic (ROC) methods. *Psychopharmacological Bulletin* 1991;**27**(1):79–82.
- Marder 1996**
Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. *American Journal of Psychiatry* 1996;**153**:1585–92.
- Martenyi 2000**
Martenyi F, Dossenbach M, Jakovljevic M, Metcalfe S. Predictive value of early anti anxiety effect on the acute antipsychotic outcome: a comparison of fluphenazine and olanzapine. *Schizophrenia Research* 2000;**41**(1):191. 70166858.
- Martin 1972**
Martin A, Masson JM, Quentin JC, Verrier JP, Jusseume P. Comparative study of the action of fluphenazine oenanthate and decanoate in chronic psychoses (73 cases) [Etude comparative de l'action de l'oenanthate de fluphenazine et du decanoate dans les psychoses chroniques (73 cas)]. *Annales Medico Psychologiques* 1972;**2**(5):705–8. 73200093.
- Mattes 1984**
Mattes Jeffrey A, Nayak Devi. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. *Biological Psychiatry* 1984;**19**(3):445–9. 84203817.
- McCreadie 1983**
McCreadie RG, McKane JP, Mackie M. Weekly pimoziide versus fluphenazine decanoate in schizophrenic out and day patients. *British Journal of Psychiatry* 1983;**143**:97–8.
- McCreadie 1986**
McCreadie RG, McKane JP, Robinson ADT, Wiles DH, Stirling GS. Depot neuroleptics as maintenance therapy in chronic schizophrenic in-patients. *International Clinical Psychopharmacology* 1986;**1**(Suppl 1):13–4. 83284029.
- Meco 1987**
Meco G, Aniello R, Lestingi L, Petrini P, Castellano A, Casacchia M. *In: Schizophrenia: an integrative view*. Milan: John Libbey, 1987.
- Mimica 1998**
Mimica N, Dossenbach M, Friedel P, Folnegovic-Smalc V, Makaric G, Jakovljevic M, Uglesic B. Olanzapine compared to fluphenazine in the treatment of schizophrenia. *Schizophrenia Research* 1998;**29**(1, 2):150. 84013802.
- Morris 1970**
Morris PA, MacKenzie DH, Masheter HC. A comparative double blind trial of pimoziide and fluphenazine in chronic schizophrenia. *British Journal of Psychiatry* 1970;**117**:683–4. 71077810.
- National 1964**
National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. *Archives of General Psychiatry* 1964;**10**:246–61. 68399894.
- Nestoros 1978**
Nestoros JN, Lehmann HE, Ban TA. Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial. *International Pharmacopsychiatry* 1978;**13**(3):138–50. 78241394.
- Owen 1993**
Owen RR, Gutierrez ER, Hsiao J, Hadd K. Effects of clozapine and fluphenazine treatment on responses to m chlorophenylpiperazine infusions in schizophrenia. *Archives of General Psychiatry* 1993;**50**(8): 636–44. 93343730.
- Palma 1997**
Palma Wenzel MI, Parada R, Osorio C, Dorr A, Bauer S. Flupentixol decanoate versus other neuroleptics in chronic schizophrenia [Decanoato de flupentixol versus otros neurolepticos en esquizofrenicos cronicos]. *Revista Chilena de Neuropsiquiatria* 1997;**35**(1):29–35. 97353440.
- Pichot 1988**
Pichot P, Boyer P. A double blind, controlled, multicenter trial of low dose amisulpride (Solian(R) 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia [Essai multicentrique controle, en double insu, amisulpride (solian(r) 50) contre fluphenazine a faibles doses dans le traitement du syndrome deficitaire des schizoprenies chroniques]. *Annales de Psychiatrie* 1988;**3**(3):312–20.
- Pickar 1987**
Pickar D, Breier A, Wolkowitz OM, Pato C. Profiles of the pharmacologic response of positive and negative symptoms in schizophrenia. *Psychiatrie and Psychobiologie* 1987;**2**(4):277–87.
- Pickar 1992**
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. *Archives of General Psychiatry* 1992;**49**(5):345–53. 92264872.
- Pickar 1994**
Pickar D, Litman RE, Hong WW, Su TP, Weissman EM. Clinical response to clozapine in patients with schizophrenia. *Archives of General Psychiatry* 1994;**51**:159–60.

Pollack 1964

Pollack SL, Tourlentes TT, Zocchi AF. Clinical trial of fluphenazine enanthate- A long-acting injectable tranquilizer. *American Journal of Psychiatry* 1964;**121**:73-4.

Preussler 1995

Preussler B, Bohle C, Jeschke G, Volz H P, Sauer H. Psychometric performance of clozapine and fluphenazine treated schizophrenics. *Pharmacopsychiatry* 1995;**28**:204. 20326685.

Preussler 1997

Preussler B, Hubner G, Rossgger G, Jeschke G, Lorenz S, Volz H P, Sauer H. Psychometric performance of chronic schizophrenics treated with a typical neuroleptic (fluphenazine) or an atypical neuroleptic drug (clozapine) - a double-blind controlled clinical trial. *Pharmacopsychiatry* 1997;**30**:207. 20326685.

Quitkin 1975

Quitkin F, Rifkin A, Klein DF. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients. *Archives of General Psychiatry* 1975;**32**(10):1276-81. 76038904.

Quitkin 1977

Quitkin F, Rifkin A, Klein DF. A one year double-blind comparison of long-acting oral (penfluridol) versus long-acting injectable (fluphenazine decanoate) antipsychotic drugs in multiple episode schizophrenics. *Psychopharmacological Bulletin* 1977;**12**:27-9.

Ravaris 1965

Ravaris CL, Weaver LA, Brooks GW. A controlled study of fluphenazine enanthate in chronic schizophrenic patients. *Diseases of the Nervous System* 1965;**25**:33-9.

Ravaris 1967

Ravaris CL, Weaver LA, Brooks GW. Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication. *American Journal of Psychology* 1967;**124**:248-9.

Rifkin 1976

Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics. *Psychopharmacology Bulletin* 1976;**12**:24-6.

Roose 1982

Roose K. Haloperidol decanoate as a replacement therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses. *Acta Psychiatrica Belgica* 1982;**82**:216-23.

Rossgger 1997

Rossgger G, Preussler B, Rauch J, Kunze M, Lorenz S, Harting J, Volz H P, Sauer H. Neuropsychological test performance of chronic schizophrenics treated with clozapine or fluphenazine - a double-blind, controlled clinical trial. *Pharmacopsychiatry* 1997;**30**:212. 20326685.

Saxena 1996

Saxena B. The value of depot neuroleptic injections in the treatment of chronic schizophrenia. Conference: schizophrenia 1996: Breaking down the barriers, 4th International Conference, Vancouver, B.C. Breaking down the barriers, 4th International Conference, Vancouver, B.C., Canada October 6-9, 1996. 1996.

Schausberger 1999

Schausberger B, Dossenbach M, Hotujac L, Folnegovic-Smalc V, Uglesic B, Jakovljevic M. Impact of olanzapine versus fluphenazine on patient's drug acceptance during acute treatment of schizophrenia. *Journal of the European College of Neuropsychopharmacology* 1999;**9**: S292.

* Schausberger B, Folnegovic-Smalc V, Hotujac L, Uglesic B, Jakovljevic M, Dossenbach M. Impact of olanzapine vs. Fluphenazine on patient's drug acceptance during acute treatment of schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999.

Schipper 1971

Schipper JA. Depot neuroleptics in the treatment of schizophrenia [Depot-neuroleptica bij de behandeling van schizofrenie]. *Nederlands Tijdschrift Voor Geneeskunde* 1971;**115**(16):707-9. 71156843.

Schooler 1971

Schooler NR, Boothe H, Goldberg SC. Life history and symptoms in schizophrenia. Severity at hospitalization and response to phenothiazines. *Archives of General Psychiatry* 1971;**25**(2):138-47. 71286095.

Schooler 1977

Schooler NR, Levine J. Dosage and side effect comparisons between oral and depot fluphenazine. *Psychopharmacology Bulletin* 1977;**13**: 29-31.

Schubert 1988

Schubert H, Zangerl K, Wibmer M. *Schizophrene Erkrankungen. Therapie Therapieresistenz eine Standortbestimmung*. Vieweg, 1988.

Simpson 1970

Simpson GM, Krakov L, Matke D, St Phard G. A controlled comparison of the treatment of schizophrenic patients when treated according to the neurologic threshold or by clinical judgment. *Acta Psychiatrica Scandinavica Supplementum* 1970;**212**:38-43. 70291112.

Steingard 1994

Steingard S, Allen M, Schooler NR. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. *Journal of Clinical Psychiatry* 1994;**55**(11):470-2. 95081045.

Stevens 1973

Stevens BC. Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. *Psychological Medicine* 1973;**3**:141-58.

Tegeler 1985

Tegeler J. A comparative trial of CIS(Z)-clopenthixol decanoate and fluphenazine decanoate. *Pharmacopsychiatria* 1985;**18**:78-9.

Tetreault 1969

Tetreault L, Bordeleau JM, Albert JM, Rajotte P. None given [Etude comparative de l'enantate de fluphenazine du bichlorhydrate de fluphenazine et du placebo chez le schizophrène chronique]. *Canadian Psychiatric Association Journal* 1969;**14**:191-8.

Tran 1998

Tran PV, Jakovljevic M, Tollefson GD, Crawford AM, Dossenbach M, Friedel P, Hotujac L, Folnegovic V, Uglesic B, Dodig G. Olanzapine versus fluphenazine: treatment of acute schizophrenic symptomatology and anxiety. *Biological Psychiatry* 1998;**43**:109S. 77103340.

Tran PV, Tollefson GD, Crawford AM, Dossenbach M, Friedel P, Folnegovic V, Jakovljevic M. Olanzapine versus fluphenazine in

- schizophrenia. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Canada. 1998.
- Turner 1966**
Turner P. A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. *Journal of Pharmacy and Pharmacology* 1966;**18**:836. 67163670.
- Ushakov 1990**
Ushakov IuV, Kravchenko NE, Kopeiko GI, Kalugina LI, Mirzozian MG. Neurophysiological dynamics in the treatment of endogenous depression using reflexotherapy [[data not available]]. *Zhurnal Nevropatologii i Psikiatrii imeni S.S. Korsakova* 1990;**90**(7):99–104. 91075905.
- van Putten 1986**
van Putten T, Marder SR. Low-dose treatment strategies. *Journal of Clinical Psychiatry* 1986;**47**(Suppl):12–6. 86195892.
- van Putten 1991**
van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. *Psychopharmacology Bulletin* 1991;**27**(2):91–6. 92021361.
- Verster 1998**
Verster GC, Joubert G, Stevens M, van-der-Merwe H. Generic substitution: comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product. *South African Medical Journal* 1998;**88**(3):260–2. 98271218.
- Vestre 1962**
Vestre ND, Hall WB, Schiele BC. A comparison of fluphenazine, trifluromazine, and phenobarbital in the treatment of chronic schizophrenic patients: a double-blind controlled study. *Journal of Clinical and Experimental Psychopathology* 1962;**23**:149–59. 77103340.
- Viala 1988**
Viala A, Durand A, Gouezo F, Hou N, Jorgensen A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. *Psychopharmacology* 1988;**94**:293–7.
- Villeneuve 1970**
Villeneuve A, Dogan K, Lachance R, Proulx C. A controlled study of fluspirilene in chronic schizophrenia. *Current Therapeutic Research Clinical and Experimental* 1970;**12**(12):819–27. 71159104.
- Vinar 1970**
Vinar O, Taussigova D, Bastecky J, Boleloucky Z. Long acting peroral fluphenazine and its dosage in psychoses. *Activitas Nervosa Superior* 1970;**12**(3):248–9. 70287097.
- Weiden 1993**
Weiden P, Schooler NR, Severe JB, Lee HJ, Schulz SC. Stabilization and depot neuroleptic dosages. *Psychopharmacology Bulletin* 1993;**29**:269–75.
- Wiles 1990**
Wiles DM, McCreadie RG, Whitehead A. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. *Psychopharmacology* 1990;**101**:274–81.
- Winter 1973**
Winter K, Fullerton AG, Hussain K, Tarlo L. A comparative double-blind trial of fluspirilene and fluphenazine decanoate in the treatment of chronic schizophrenia. *The British Journal of Clinical Practice* 1973;**27**(10):377–80.
- Wistedt 1981**
* Wistedt B. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. *Acta Psychiatrica Scandinavica* 1981;**64**:65–84.
- Wistedt B, Jorgensen A, Wiles D. A depot withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. *Psychopharmacology* 1982;**78**:301–4.
- Wistedt 1983a**
Wistedt B, Palmstierna T. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. *Journal of Clinical Psychiatry* 1983;**44**:369–71.
- Wistedt 1983b**
Wistedt B, Wiles D, Jorgensen A. A depot neuroleptic withdrawal study neuroleptical effects. *Psychopharmacology* 1983;**80**(2):101–5. 93126518.
- Zapletal 1981**
Zapletal M, Zbytovsky J, Preiningerova O, Kindernayova H, et al. Maintenance treatment of schizophrenia with oxyprothepine decanoate: double-blind comparison with standard. *Actavis Nervosa Superior (Praha)* 1981;**23**(3):243–4.

References to studies awaiting assessment

Del Giudice 1970

del Giudice J, Okun R, Clark WG. Recidivism with long acting fluphenazine. VII meeting of the International College of Neuropsychopharmacology. 1970. [MedLine: 21196608.

Engstrand 1969

Engstrand E. Fluphenazine enanthate in long term treatment of psychoses [Flufenazin-enantat i langtidsbehandling av psykoser]. *Nordisk Psykiatrisk Tidskrift* 1969;**23**:401–3. 77103340.

Jue 1996

Jue FY, Wang CZ, Yue XC, Fang YR, Xue HD, Chen SX. Flupenthixol vs fluphenazine in schizophrenia patients: a randomized controlled trial. *New Drugs and Clinical Remedies* 1996;**15**(1):19–22.

Kabes 1984

Kabes J, Filip V, Sikora J. A multiclinical study of the effectiveness of meclopin in maintenance therapy of schizophrenic patients - A DOUBLE-blind crossover comparative study with flufenazine decanoate. *Farmakoterapeutické Zpravy* 1984;**30**(2):159–81.

Ravanic 1996

Ravanic DB, Djukic-Dejanovic SM, Stojiljkovic M, Jankovic S, Paunovic VR, Bankovic D. Antipsychotic efficacy of clozapine vs fluphenazine in positive and negative schizophrenia syndrome. *Journal of Neural Transmission* 1996;**103**:XLVI. 20445745.

Additional references

Aaes-Jorgenson 1985

Aaes-Jorgenson A. Pharmacokinetics of oral and depot neuroleptics - Clinical relevance. Symposium Espo, 1985 Feb 1

Alderson 2004

Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. In: *The Cochrane Library*, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.

Altman 1996

Altman DG, Bland JM. Statistics Notes: Detecting skewness from summary information. *British Medical Journal* 1996;**313**:1200.

Asberg 1978

Asberg M, Montgomery SA, Perris C, Schalling D, Sedavll GA. A comprehensive psychopathological rating scale. *Acta Psychiatrica Scandinavica* 1978;**Supp 271**:5–27.

Barnes 1994

Barnes TRE, Curson DA. Long term depot antipsychotics. A risk benefit assessment. *Drug Safety* 1994;**10**(6):464–79.

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**:600.

Chouinard 1980

Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. *Canadian Journal of Neurological Science* 1980;**7**:233.

David 1994

David AS, Cutting JC (Eds). *The neuropsychology of schizophrenia*. Hove, E. Sussck: Lawrence Erlbaum Assoc, 1994.

Davis 1986

Davis JM, Andriukatis S. The natural course of schizophrenia and effective maintenance drug therapy. *Journal of Clinical Psychopharmacology* 1986;**6**(1Suppl):2S–10S.

De Alarcon 1969a

De Alarcon R, Carney MW. Severe depressive mood changes following slow-release intramuscular fluphenazine injection. *British Medical Journal* 1969;**3**(670):564–7.

Dencker 1980

Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. *Acta Psychiatrica Scandinavica* 1980;**61**(suppl 279):64–76.

Derogatis 1977

Derogatis LR. SCL-90-R: Administration, procedures and scoring manual, for the revised version. Clinical Psychometrics Research Unit, John Hopkins University, Baltimore 1977.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623–9.

DoH 1996

Department of Health. Burdens of Disease: a Discussion Document. Department of Health. NHS Executive 1996.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**:2971–80.

Feighner 1972

Feighner JP, Robins E, Guze S, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. *Archives of General Psychiatry* 1972;**26**:57–62.

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**:876–83 876–83.

Guy 1976

Guy W. *Clinical Global Impression (CGI)*. In: *Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology*. Washington DC: National Institute of Mental Health, 1976.

Guy 1976a

Guy, Waalwijk Doorn ESC. *ECDEU Assessment manual for psychopharmacology*. In: *DHEW publication No (ADM)*. Rockville MD: National Institute of Mental Health, 1976.

Haynes 1979

Haynes RB, Taylor WD, Sackett DL (eds). *Compliance in health care*. Baltimore: John Hopkins University Press, 1979.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60.

Hirsch 1973b

Hirsch SR, Gaid R, Rohde PD. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial. *British Medical Journal* 1973;**1**:633–7.

Honigfeld 1962

Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: A treatment sensitive ward behavior scale. *Psychological Reports* 1962;**10**:799–812.

Jablensky 1992

Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper J, E, Day R, Bertelsen ASO -A World Health Organization ten-country study. Schizophrenia: manifestations, incidence and course indifferent cultures. *Psychological Medicine Monograph Supplement* 1992;**20**:1–97.

Kane 1986

Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: A comparison review of standard, intermediate and low-dose regimens. *Journal of Clinical Psychiatry* 1986;**47**(suppl 5):30–3.

Kane 1998

Kane JM, Aguglia E, Carlo Altamura A, Guitierrez JLA, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapiere YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. *European Neuropsychopharmacology* 1998;**8**:55–66.

Krawiecka 1977

Krawiecka M, Goldberg D, Vaughan M. A standardised psychiatric assessment scale for rating psychotic patients. *Acta Psychiatrica Scandinavica* 1977;**55**:299–308.

Kurland 1970

Kurland AA, Dim BM, Olssen JE. The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics. *Diseases of the Nervous System* 1970;**31**(Supp9):18–23.

Lingjaerde 1987

Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psy-

chotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatr Scand Suppl* 1987;**334**:1–100.

Marder 1990

Marder SR, Van Putten T, Aravagiri M. Fluphenazine plasma levels and clinical response. *Psychopharmacology Bulletin* 1990;**26**:256–8.

Marshall 1998

Marshall. (personel communication). (personel communication) 1998.

Moher 2001

Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA* 2001;**285**:1987–91.

Overall 1962

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychological Reports* 1962;**10**:799–812.

Simpson 1970b

Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. *Acta Psychiatrica Scandinavica* 1970;**212**:s11–9.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):1–75.

* Indicates the major publication for the study

TABLES

Characteristics of included studies

Study	Adamson 1973
Methods	Allocation: randomised. Blindness: double. Duration: 28 days. Design: crossover x2.
Participants	Diagnosis: schizophrenia. N=37 (in phase II). Age: 24-65 years. Sex: 22M, 15F. History: all in hospital for > 1 year. Setting: hospital.
Interventions	1. Fluphenazine decanoate: dose 12.5mg/IM day one, 25mg/IM day 7. N=19. 2. Chlorpromazine: dose 50-100mg/bid. N=18.
Outcomes	Behaviour: leaving the study early. Adverse effects: various side effects. Unable to use - Mental state: BPRS (no data). Behaviour: WWBRS (no data).

Characteristics of included studies (Continued)

Notes No usable continuous data.

Allocation concealment B

Study **Albert 1980**

Methods Allocation: randomised.
Blindness: double.
Duration: 39 weeks.
Design: drug stabilisation period 2 months, treatment 3 months.

Participants Diagnosis: schizophrenia.
N=33.
Age: approximate age mid 40s.
Sex: all male.
History: average duration spent in hospital 16-20 years.
Setting: hospital.

Interventions 1. Fluphenazine enanthate: dose mean 50mg/IM/biweekly. N=11.
2. Pipothiazine palmitate: dose mean 100mg/IM or 150 mg/IM*/monthly. N=11.

Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: Evaluation Scale.

Unable to use -
Global state: CGI (no SD).
Mental state: BPRS (no SD).
Adverse effects: NOSIE (no SD).

Notes * 2 different dosage groups for PP.
Authors contacted.

Allocation concealment B

Study **Altamura 1985**

Methods Allocation: randomised.
Blindness: double.
Duration: 2-3 week (2 periods).
Design: parallel group.

Participants Diagnosis: schizophrenia (PSE- DSM III).
N=11.
Age: 35-60 years.
Sex: 2M, 9F.
History: duration illness <2yrs.
Setting: community.

Interventions 1. Fluphenazine decanoate: dose 25mg/IM every 3-4 weeks. N=6.
2. Fluphenazine enanthate: dose 25mg/IM every 3-4 weeks. N=5.

Outcomes Behaviour: leaving the study early.
Adverse effects: various side effects.

Unable to use -
Mental state: CPRS (no data).
Physiological: (various measures, blood tests - non-clinical outcomes, data unusable).
Cognitive: handwriting (non-clinical outcomes, data unusable).

Notes No usable continuous data.
Authors contacted.

Characteristics of included studies (Continued)

Allocation concealment B

Study	Asarnow 1988
Methods	Allocation: randomised. Blindness: double. Duration: 2 years. Design: dosage study.
Participants	Diagnosis: schizophrenia. N=36. Age: 34-41 years. Sex: all male. History: stabilised for <2 months, informed consent given. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 25mg/IM (standard) biweekly. N=14. 2. Fluphenazine decanoate: dose 5mg/IM (low) biweekly. N=22.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: BPRS (no SD). Cognitive: information-processing skills (non-clinical outcomes, data unusable).
Notes	Very little usable data
Allocation concealment	B

Study	Barnes 1983
Methods	Allocation: assigned to two groups by independent statistician. Blindness: double. Duration: 1 year. Design: parallel group.
Participants	Diagnosis: schizophrenia (PSE). N=36. Age: mean ~ 49 years. Sex: 18M, 18F. History: no stated. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 25mg/IM biweekly. N=19. 2. Pimozide: dose 8mg biweekly. N=17.
Outcomes	Behaviour: leaving the study early. Unable to use - Behaviour: SBAS (non-clinical outcomes, data unusable).
Notes	Analysis: last observation carried forward. No continuous outcomes measured.
Allocation concealment	B

Study	Chien 1973
Methods	Allocation: randomised. Blindness: single. Duration: 30 days. Design: parallel group.

Characteristics of included studies (Continued)

Participants	Diagnosis: psychosis. N=31. Age: 17-62 years, mean ~ 37 years. Sex: 24M, 22F. History: acutely psychotic, recently admitted. Setting: hospital.
Interventions	1. Fluphenazine enanthate: dose 12.5 -75mg/IM, mean 28.5 mg/IM every 12 days. N=16. 2. Chlorpromazine: dose mean 388mg/day. N=15.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Adverse effects: TESH. Unable to use - Behaviour: NOSIE (no data).
Notes	
Allocation concealment	B

Study	Chouinard 1978
Methods	Allocation: randomised. Blindness: double. Duration: 9 months. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=32. Age: 20-60 years. Sex: 16M, 16F. History: informed consent given. Setting: community.
Interventions	1. Fluphenazine enanthate: dose 6.25-100mg/IM biweekly. N=16. 2. Pipothiazine palmitate: dose 25-100mg/IM monthly. N=16. Dose adjusted to therapeutic response.
Outcomes	Global state: CGI, need for additional medication. Mental state: BPRS. Behaviour: leaving the study early. Adverse effects: HRSD, EPS, TESH. Unable to use - Adverse effects: various effects (no SD). Physiological: various measures (non-clinical outcomes, data unusable).
Notes	Analysis: last observation carried forward.
Allocation concealment	B

Study	Chouinard 1982
Methods	Allocation: randomised. Blindness: double. Duration: 7 months, preceded by 1 month stabilisation period. Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM II). N=50*

Characteristics of included studies (Continued)

	Age: 24-65 years, median ~ 41 years. Sex: 27M, 21F. History: on FE for 1 month, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 2.5-250mg/IM, mean 27mg/IM monthly. N=24. 2. Fluphenazine enanthate: dose 2.5-325 mg/IM, mean ~ 35 mg/IM biweekly. N=24. Dose adjusted to therapeutic response.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Additional medication. Unable to use - Mental state: BPRS (no SD). Adverse effects: TESF (no data); ESRS (authors own scale**).
Notes	Authors contacted. Results for FE & FD pooled. * 2 dropped out after randomisation/ moved & suicide. ** see Marshall et al 1998
Allocation concealment	B

Study	Chouinard 1984
Methods	Allocation: randomised, stratified by sex & past frequency of depot administration. Blindness: double. Duration: 8 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM III). N=72. Age: 18-66 years, mean ~ 44 years. Sex: 36M, 36F. History: on depot >3 months; duration illness 3-38 years, mean 16 years, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 2.5-300mg/IM, mean 75mg/IM every 2-4 weeks. N=36. 2. Haloperidol decanoate: dose 15-900mg/IM, mean 225mg/IM every 2-4 weeks. N=36.
Outcomes	Global state: CGI, need for additional medication. Mental state: BPRS. Behaviour: leaving the study early. Unable to use - Adverse effects: ESRS (authors own scale*), TESF (no data). Physiological: various measures (non clinical outcomes, data unusable).
Notes	Statistics: last observation brought forward. *see Marshall et al 1998.
Allocation concealment	B

Study	Cookson 1986
Methods	Allocation: randomised, separate randomisation sequences for males and females. Blindness: double.

Characteristics of included studies (Continued)

	Duration: 8 months. Design: parallel group.
Participants	Diagnosis: schizophrenia implied. N=19. Age: 26-60 years. Sex: 9M, 10F. History: 1yr treatment with fluphenazine decanoate, overweight BMI 25+, physically fit, stable during previous year Setting: community.
Interventions	Fluphenazine decanoate: dose 26.4mg/IM, every 2-6 weeks, average 3.6 months. N=9. 2. Haloperidol decanoate: dose 22.2mg/IM every 2-5 weeks, average 3.6 months. N=10.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: CPRS, KGS (no data). Adverse effects: SAS, AIMS (no data). Physiological: various measures (non clinical outcomes, data unusable).
Notes	Analysis: last observation carried forward.
Allocation concealment	B

Study Crawford 1974

Methods	Allocation: randomised. Blindness: double. Duration: 40 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia (Forest & Hay 1971/72 criteria). N=31. Age: 20-65 years. Sex: 9M, 22F. History: mean duration illness 1-27 years, mean - 14 years. Setting: community.
Interventions	1. Fluphenazine decanoate: (dosage not stated). N=14. 2. Trifluoperazine hydrochloride (oral): (dosage not stated). N=17.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: BPRS (no data).
Notes	
Allocation concealment	B

Study Curry 1972

Methods	Allocation: randomised. Blindness: double. Duration: 28 days. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=37. Age: not stated. Sex: male and female.

Characteristics of included studies (Continued)

	History: chronically ill. Setting: hospital.
Interventions	1. Fluphenazine decanoate: (dosage not stated). N=19. 2. Chlorpromazine (oral): (dosage not stated). N=18.
Outcomes	Behaviour: WWBRS. Leaving the study early. Unable to use - Mental state: BPRS (no SD).
Notes	Authors contacted.
Allocation concealment	B

Study Dencker 1973

Methods	Allocations: randomised. Blindness: double. Duration: 3 years. Design: 3 months adjustment, 1-3 months maintenance, 2-6 months maintenance, 2 year follow up.
Participants	Diagnosis: schizophrenia. N=67. Age: 18-65 years, mean ~ 41 years. Sex: 51M, 14F. History: duration illness > 5 years. Setting: 1 year in hospital, 2 years in community.
Interventions	1. Fluphenazine decanoate: dose 3.1-50mg/IM, mean 6.25mg/IM monthly (mean monthly dose for 2 year continuation phase 27.8 mg/IM). N=35. 2. Pipothiazine palmitate: dose 25-400mg/IM, mean 50mg/IM monthly (mean monthly dose for 2 year continuation phase 152.3mg/IM). N=32.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Adverse effects: EPS, HRSD. Unable to use - Mental state: BPRS, S-Scale, HRSD (no SD). Cognitive: Handwriting test (non-clinical outcomes, data not usable). Social ability: ADL, work performance, SRE (non-clinical outcomes, data not usable). Adverse effects: EPS (no data).
Notes	Authors contacted.
Allocation concealment	B

Study Donlon 1976

Methods	Allocation: randomised. Blindness: double. Duration: 2 months. Design: parallel group.
Participants	Diagnosis: schizophrenia. N= 40/41*. Age: 18-57 years, mean ~ 29 years. Sex: 12M, 18F. History: able to give informed consent.

Characteristics of included studies (Continued)

	Setting: hospital & community.
Interventions	1. Fluphenazine decanoate: dose 75-500mg/IM, mean 296.4mg/IM 2-3x week. N=14. 2. Fluphenazine enanthate: dose 50-550 mg/IM, mean 387.5 mg/IM 2-3x week. N=16.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Adverse effects: EPS Rating Scale. Unable to use - Global state: CGI (no data). Mental state: BPRS (no data).
Notes	Data put in depot vs depot category in both FE & FD treatment groups. *2 different N values in the paper.
Allocation concealment	B

Study Dotti 1979

Methods	Allocation: randomised. Blindness: double. Duration: 9 months. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=20. Age: 19-32 years. Sex: all male. History: previous episodes of psychosis. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 25-50mg (frequency not stated). N=10. 2. Placebo: (frequency not stated). N=10.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: BPRS (data unusable).
Notes	
Allocation concealment	B

Study Falloon 1978

Methods	Allocation: randomised. Blindness: double. Duration: 20 months. Design: 2 trials - I & II.
Participants	Diagnosis: schizophrenia (Schneider). N=44. Age: 17-60 years, mean ~ 39 years. Sex: 20M, 24F. History: stabilised prior to study entry. Setting: community.
Interventions	1. Fluphenazine decanoate: dose mean 25mg/IM/weekly, maximum 50mg/ biweekly. N=20. 2. Pimozide: dose mean 8mg/IM/day, maximum 16 mg/day. N=24. Flexible dosage.

Characteristics of included studies (Continued)

Outcomes Global state: need for additional medication.
 Behaviour: leaving the study early.
 Adverse effects: checklist for SE's.

Unable to use -
 Mental state: PSE (no data).
 Social ability: SPS (non-clinical outcome, data unusable).

Notes

Allocation concealment B

Study Feng 1990

Methods Allocation: randomised.
 Blindness: double.
 Duration: 12 weeks.
 Design: parallel group.

Participants Diagnosis: schizophrenia (Huangshan council schizophrenia standard 1984).
 N=30.
 Age: 27-54 years, mean ~ 41 years.
 Sex: 24M, 64F.
 History: all chronically ill > 5 years.
 Setting: not stated.

Interventions 1. Fluphenazine decanoate: dose 25mg/ml fortnightly injections. N=15.
 2. Haloperidol decanoate: dose 25mg/ml monthly injections. N=15.

Outcomes Behaviour: leaving the study early.
 Adverse effects.

Unable to use -
 Mental state: MIE (data unusable).
 Adverse effects: SAS (data unusable).

Notes

Allocation concealment B

Study Frangos 1978

Methods Allocation: randomised (randomisation code).
 Blindness: double.
 Duration: 16 weeks.
 Design: parallel group.

Participants Diagnosis: schizophrenia.
 N=50.
 Age: 21-62 years, mean ~ 44 years.
 Sex: 25 M, 25 F.
 History: hospitalised for at least 2 years.
 Setting: hospital.

Interventions 1. Fluphenazine decanoate: dose 25-150mg/IM, mean 76mg/IM biweekly. N=25.
 2. Fluspirilene decanoate: dose 4-20mg/IM, mean 12mg/IM weekly. N=25.

Outcomes Adverse effects: SE Rating Scale.

Unable to use -
 Global state: CGI (no data).
 Mental state: BPRS (no SD).

Characteristics of included studies (Continued)

	Behaviour: NOSIE (no SD).
Notes	Authors contacted.
Allocation concealment	B

Study	Goldstein 1978
Methods	Allocation: randomised. Blindness: single. Duration: 6 weeks. Design: 6 month follow-up (not controlled).
Participants	Diagnosis: schizophrenia. N=104. Age: mean ~ 23 years. Sex: 45M, 37F. History: acutely ill, 1st or 2nd admission, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine enanthate: dose (high) 1ml/IM biweekly. N=53. 2. Fluphenazine enanthate: dose (low) 0.25ml/IM biweekly. N=51.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: BPRS (no data). Family therapy: non-clinical outcome (data unusable).
Notes	last observation carried forward.
Allocation concealment	B

Study	Hirsch 1975
Methods	Allocation: randomised. Blindness: double. Duration: 7 months. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=81. Age: under 67 years. Sex: male & female. History: chronically ill. Setting: community.
Interventions	1. Fluphenazine decanoate: dose monthly average 25mg/IM. N=40. 2. Placebo. N=41.
Outcomes	Global state: relapse. Behaviour: leaving the study early. Unable to use - Mental state: PSE (data unusable). Behaviour: SPS (data unusable).
Notes	
Allocation concealment	B

Study	Hogarty 1979
Methods	Allocation: randomised.

Characteristics of included studies (Continued)

	Blindness: double. Duration: 2 years. Design: parallel study.
Participants	Diagnosis: schizophrenia. N=105. Age: 18-55 years, mean ~ 34 years. Sex: 46M, 54F. History: received no other psychotropic medication, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 12.5-125mg/IM, mean 25 mg/IM biweekly. N=27. 2. Fluphenazine hydrochloride (oral): dose 2.5-40mg/IM, mean 2.5 mg/IM daily. N=25.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: BPRS (no SD). Behaviour: KAS (no data). Adverse effects: SSI, SEC, HSC, TESS (no data).
Notes	last observation carried forward
Allocation concealment	B

Study Hogarty 1988

Methods	Allocation: randomised, stratification by dose & household EE. Blindness: double. Duration: 2 years. Design: dosage study.
Participants	Diagnosis: schizophrenia, schizoaffective (RDC). N=70. Age: mean 28 yrs, range 17-55 yrs. Sex: 40 M, 30 F. History: living at home, mean duration illness ~ 7 years, stabilised 6 months after discharge, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: standard dose mean 25mg/IM biweekly. N=33. 2. Fluphenazine decanoate: minimal dose mean 3.8mg/IM biweekly. N=37. Prescribed dose - no upper or lower limit.
Outcomes	Behaviour: leaving the study early. Unable to use - Mental state: BPRS, SCL-90 (no data). Adverse effects: MRQ (no data).
Notes	
Allocation concealment	B

Study Hranov 1998

Methods	Allocation: randomised. Blindness: not described. Duration: 6 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (ICD-10).

Characteristics of included studies (Continued)

	N=41. Age: 21-55. mean ~ 41 years. Sex: 17M, 24F. History: not stated. Setting: not stated.
Interventions	1 Fluphenazine decanoate: dose 99.3mg/IM/month. N=21. 2. Haloperidol decanoate: dose 47.3mg/month. N=20.
Outcomes	Behaviour: leaving the study early. Unable to use - Global state: CGI (data unusable). Mental state: PANSS (data unusable). Adverse effects: UKU (data unusable).
Notes	
Allocation concealment	B

Study	Jain 1975
Methods	Allocation: randomised. Blindness: double. Duration: 20 weeks, preceeded by 2 week washout. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=30. Age: 24-61 years, mean ~ 49 years. Sex: 14F, 16M. History: hospitalised for under 1year. Setting: hospital.
Interventions	1. Fluphenazine enanthate: dose 125mg/IM biweekly. N=15. 2. Pipothiazine palmitate: dose 250mg/IM biweekly. N=15.
Outcomes	Global state: CGI. Behaviour: leaving the study early. Adverse effects: TESS. Unable to use - Mental state: BPRS (no data).
Notes	73% drop-out rate in the PP group, data not usable.
Allocation concealment	B

Study	Javed 1991
Methods	Allocation: randomised. Blindness: double. Duration: 12 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM III). N=45. Age: mean ~ 50 years. Sex: 33M, 5F. History: stabilised for 6 months on neuroleptics, involved in rehabilitation, duration illness 13 years. Setting: not stated.

Characteristics of included studies (Continued)

Interventions	1. Fluphenazine decanoate: dose 25mg/IM biweekly. N=20. 2. Flupenthixol decanoate: dose 40mg/IM biweekly. N=18.
Outcomes	:Behaviour: leaving the study early. Mental state: HRS Adverse effects: EPSE, SE checklist. Unable to use - Global state: CGI (no SD). Mental state: BPRS (no SD).
Notes	Authors contacted.
Allocation concealment	B

Study Jolley 1990

Methods	Allocation: randomised. Blindness: double. Duration: 2 years. Design: 2 year follow up.
Participants	Diagnosis: schizophrenia (DSM III). N=54. Age: not stated. Sex: not stated. History: stable patients in remission, who has been free of florid symptoms (delusions, hallucinations, bizarre behaviour and thought disorders) for at least 6 months. Setting: community.
Interventions	1. Fluphenazine decanoate: (dosage not reported). N=27. 2. Placebo. (dosage not reported). N=27.
Outcomes	Death. Behaviour: leaving the study early. Adverse effects: AIMS. Unable to use - Adverse effects: SAS (data unusable). Social ability: SAS (non clinical outcomes, data unusable).
Notes	
Allocation concealment	B

Study Kane 1983

Methods	Allocation: randomised. Blindness: double. Duration: 1 year. Design: dosage study.
Participants	Diagnosis: schizophrenia (RDC). N=126. Age: 17-60 years, mean ~ 29 years. Sex: 63M, 37F. History: in state of remission, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate (low dose): dose 1.25-5.0mg/IM biweekly. N=62. 2. Fluphenazine decanoate (standard dose): dose 12.5-50 mg/IM biweekly. N=64.

Characteristics of included studies (Continued)

Outcomes Behaviour: leaving the study early.
Adverse effects: SDS, SAS.

Unable to use -
Global State: CGI (no data).
Mental State: BPRS (no data).
Behaviour: SAS-R (data unusable).

Notes

Allocation concealment B

Study Kaneno 1991

Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: parallel group.

Participants Diagnosis: schizophrenia.
N=259.
Age: 20 - 65 years.
Sex: 168M, 91F.
History: not stated.
Setting: hospital and community.

Interventions 1. Fluphenazine decanoate: dose 12-50mg/ml/IM administered 6 times at 4-week intervals. N=127.
2. Haloperidol: dose 3.0-12.1mg administered 6 times. N=132.

Outcomes Suicide.
Behaviour: leaving the study early.

Unable to use -
Mental state: BPRS, KORS (no SD).
Adverse effects: ORS (no SD).

Notes

Allocation concealment B

Study Kelly 1977

Methods Allocation: randomised.
Blindness: single.
Duration: 9 months.
Design: parallel group.

Participants Diagnosis: schizophrenia (Schneider 1st Rank).
N=60.
Age: 18 - 65 years, mean ~ 42 years.
Sex: 18M, 35F.
History: not stated.
Setting: community.
Excluded: epilepsy, ECT, brain damage, pregnancy, marked mental retardation or parkinsonism.

Interventions 1. Fluphenazine decanoate: dose 1ml/IM every 3 weeks. N=30.
2. Flupenthixol decanoate: dose 1ml/IM every 3 weeks. N=30.

Medication adjusted weeks 1-9, stable thereafter.

Outcomes Leaving the study early.
Global state: relapse.

Characteristics of included studies (Continued)

Unable to use -
 Mental state: BPRS (no SD).
 Adverse effects: EPS (no data).

Notes

Allocation concealment B

Study Keskiner 1971

Methods Allocation: randomised.
 Blindness: double.
 Duration: 8 weeks (4 weeks before cross over).
 Design: cross-over.

Participants Diagnosis: schizophrenia.
 N=12.
 Age: 25 - 51 years, mean ~ 38 years.
 Sex: 3M, 9F.
 History: duration of illness 5-25 years (mean 14 years).
 Setting: hospital.

Interventions 1. Fluphenazine enanthate: dose 1 mg/kg body weight/IM single dose. N=6.
 2. Fluphenazine decanoate: dose 1 mg/kg body weight IM single dose. N=6.

Outcomes Behaviour: leaving the study early.
 Unable to use -
 Global state: GES (data unusable).
 Mental state: BPRS (data unusable).
 Adverse effects: TESS (data unusable).

Notes

Allocation concealment B

Study Kissling 1985

Methods Allocation: randomised (coin throwing).
 Blindness: double.
 Duration: 6 months.
 Design: parallel group.

Participants Diagnosis: schizophrenia, schizoaffective psychosis (DSM III).
 N=54.
 Age: FD - mean age 28 years, HD - mean age 35 years.
 Sex: 24M, 7F.
 History: on oral medication, required depot treatment for >6 months, able to give informed consent.
 Setting: not stated.

Interventions 1. Fluphenazine decanoate: dose mean 25mg/IM biweekly. N=22.
 2. Haloperidol decanoate: dose mean 50 mg/IMmonthly. N=32.

Outcomes Behaviour: leaving the study early.
 Unable to use -
 Global state: need for additional anticholinergic medication (data unusable).
 Mental state: BPRS (data unusable).
 Adverse effects: EPMS, DOTES, STESS (data unusable).
 Physiological: serum levels (non clinical outcomes).

Notes The drop out rate after 6 months was FD-60%, HD- 30%.

Characteristics of included studies (Continued)

Allocation concealment B

Study	Kreisman 1988
Methods	Allocation: randomised. Blindness: double. Duration: 1 year. Design: dosage study.
Participants	Diagnosis: schizophrenia (Research Diagnostic Criteria - Spitzer 1977). N=132. Age: 17- 60 years. Sex: 91 M, 41 F. History: 'were in remission, at a stable clinical plateau'. Setting: community. Excluded: presumptive tardive dyskinesia, neurological disorders, serious substance abuse, mental retardation, physical illnesses, or requiring adjunctive medication except for antiparkinsonian agents and minor tranquilizers.
Interventions	1. Fluphenazine decanoate (low dose): dose 1.25-5mg/cc biweekly. N=66. 2. Fluphenazine decanoate (high dose): dose 12.5-50mg/cc biweekly. N=66.
Outcomes	Global state: relapse. Unable to use - Global state: GAS (data unusable). Mental state: BPRS (no SD). Behaviour: SAS II, PRS (no usable data).

Notes

Allocation concealment B

Study	Kurland 1966
Methods	Allocation: randomised. Blindness: double. Duration: 24 weeks (first arm 12 weeks). Design: cross-over.
Participants	Diagnosis: schizophrenia. N=19. Age: 23 - 53 years. Sex: all male. History: chronically ill. Setting: hospital.
Interventions	1. Fluphenazine decanoate: dose mean 25mg/IM monthly. N=9. 2. Fluphenazine enanthate: dose mean 22.8 mg/IM monthly. N=10.
Outcomes	Adverse effects. Unable to use - Physiological: weight measures, BP (non-clinical outcomes, data unusable).
Notes	No continuous outcomes measured. Data put in depot vs depot category in both FE & FD treatment groups.

Allocation concealment B

Study	Lehmann 1980
Methods	Allocation: randomised.

Characteristics of included studies (Continued)

	Blindness: double. Duration: 24 weeks. Design: dosage study.
Participants	Diagnosis: schizophrenia (ICD 2951). N=40. Age: 35 -38 years. Sex: 27M,13F. History: all patients chronically ill and resistant to standard doses of neuroleptics. Setting: not stated.
Interventions	1. Fluphenazine decanoate: dose 225 mg/day. N=20. 2. Fluphenazine decanoate: dose 25 mg/day. N=20.
Outcomes	Global state: GRS. Behaviour: leaving the study early. Unable to use - Mental state: EWL-K (no usable data).
Notes	
Allocation concealment	B

Study Leong 1989

Methods	Allocation: randomised. Blindness: partial. Duration: 28 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia (ICD-295). N=60. Age: 18 - 65 years, mean ~ 38 years. Sex: 27M, 33F. History: able to give informed consent, patients in remission. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 12.5-50mg/IM monthly. N=30. 2. Pipothiazine palmitate: dose 25-50mg/IM monthly. N=30. Flexible dose.
Outcomes	Global state: CGI, need for additional medication. Mental state: BPRS. Behaviour: leaving the study early. Adverse effects: various measures, EPS.
Notes	
Allocation concealment	B

Study Levenson 1976

Methods	Allocation: randomised. Blindness: double. Duration: 21 days. Design: 3 treatment groups.
Participants	Diagnosis: schizophrenia (Spitzerian criteria). N=12. Age: 18 - 53 years, mean ~ 30 years. Sex: 4M, 8F.

Characteristics of included studies (Continued)

	History: able to give informed consent. Setting: hospital.
Interventions	1. Fluphenazine decanoate: dose 2.5-7.5mg/day. N=5. 2. Thiothixine: dose 5 -15mg/day. N=3. 3. Haloperidol: dose 2.5 -7.5mg/day. N=4.
Outcomes	Behaviour: leaving the study early. Adverse effects. Unable to use - Mental state: BPRS (no usable data).
Notes	
Allocation concealment	B

Study **Lundin 1990**

Methods	Allocation: randomised. Blindness: double. Duration: 1 year (preceded by 6 month 'run-in' period). Design: parallel group.
Participants	Diagnosis: schizophrenia (NIMH Collaborative Study/ DSM III). N=58. Age: 18 -65 years. Sex: 46M, 12F. History: >3 months satisfactory response on depot, duration illness 6 -<24 months, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose mean 34.8 mg/IM monthly. N=30. 2. Flupenthixol decanoate: dose mean 54.7 mg/IM monthly. N=28.
Outcomes	Behaviour: leaving the study early. Unable to use - Global state: TES (no data). Mental state: BPRS, CPRS (no data). Adverse effects: EPS, HRSD, CSE (no data). Social ability: KAS (non clinical outcome, data unusable).
Notes	Authors contacted.
Allocation concealment	B

Study **MacCrimmon 1978**

Methods	Allocation: randomised. Blindness: double. Duration: 1 year. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=49. Age: 28-54 years, mean ~ 40 years. Sex: 16M, 23F. History: duration illness 1-21 years, mean ~ 12 years. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 25-37.5/IM every 28 days. N=24.

Characteristics of included studies (Continued)

	2. Fluphenazine enanthate: dose 25-37.5 mg/IM every 25 days. N=25.
Outcomes	Global state: need for additional medication. Mental state: BPRS. Behaviour: leaving the study early. Side effects: Bordeleau Scale.
Notes	
Allocation concealment	B

Study	Magnus 1979
Methods	Allocation: randomised, prearranged prescribing list. Blindness: open. Duration: 6 months. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=50. Age: 'approximately equal in both groups'. Sex: male and female 'approximately equal in both groups'. History: newly admitted to hospital (either first episode or relapse). Setting: community and hospital.
Interventions	1. Fluphenazine decanoate: every 2-3 weeks, dose range 50-100 mg/IM. N=26. 2. Fluspirilene: weekly, dose range 6-12 mg/IM. N=24. Individually adjusted doses.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Adverse effects. Unable to use - Mental state: BPRS (no SD) self and nurse's assessment (no data). Social ability: WWBRS (non-clinical outcomes, data unusable).
Notes	Authors contacted.
Allocation concealment	B

Study	Malm 1974
Methods	Allocation: randomised. Blindness: double. Duration: 8 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=62. Age: 18-65 years. Sex: 21M, 36F. History: duration illness 2-39 years, mean ~15 years. Setting: hospital.
Interventions	1. Fluphenazine enanthate: dose 7.5-50mg/IM, mean 28.5 mg/IM biweekly. N=26. 2. Fluspirilene: dose 1-14 mg/IM, mean 5.7mg/IMweekly. N=31.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Unable to use -

Characteristics of included studies (Continued)

Mental state: S-Scale (no data).
Behaviour: ADL (no data).
Adverse effects: SE scale (no SD).
Physiological: various measures (non-clinical outcomes, data unusable).

Notes

Allocation concealment B

Study **Marder 1984**

Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: dosage study.

Participants Diagnosis: schizophrenia.
N=50.
Age: mean ~ 36 years.
Sex: all male.
History: duration illness mean ~ 10 years, able to give informed consent , stabilised on FD <2 months.
Setting: community.

Interventions 1. Fluphenazine decanoate (low dose): dose 5-10mg/IM, mean 5mg/IM biweekly. N=28.
2. Fluphenazine decanoate (standard): dose 25-50mg/IM, mean 25mg/IM biweekly. N=22.

Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.

Unable to use -
Mental state: BPRS (no data).
Adverse effects: SCL-90, SE Scale, IMEPS, Subjective EPS Rating Scale (no data).

Notes

Allocation concealment B

Study **Marder 1987**

Methods Allocation: randomised.
Blindness: double.
Duration: 2 years.
Design: dosage study.

Participants Diagnosis: schizophrenia (DSM III).
N=66.
Age: mean ~ 35 years.
Sex: all male.
History: drug free for a month, duration illness mean 24 months (5mg), 170 months (25mg).
Setting: community and hospital.

Interventions 1. Fluphenazine decanoate (low dose): dose mean 5mg/IM biweekly. N=35.
2. Fluphenazine decanoate (standard): dose mean 25 mg/IM biweekly. N=31.

Outcomes Behaviour: leaving the study early.

Unable to use -
Mental state: BPRS (no data).
Adverse effects: Hopkins SCL-90R, side effects scale (no data).

Notes

Allocation concealment B

Characteristics of included studies (Continued)

Study	McClelland 1976
Methods	Allocation: randomised. Blindness: double. Duration: 6 months (preceded by pretrial of 6 weeks). Design: dosage study.
Participants	Diagnosis: schizophrenia (Kraepelinian). N=50. Age: 18-60 years. Sex: 22M, 28F. History: disabled, able to give informed consent, minimum hospital stay >12 months. Setting: hospital.
Interventions	1. Fluphenazine decanoate (very high dose): dose mean 250 mg/IM weekly. N=25. 2. Fluphenazine decanoate (standard): dose mean 12.5 mg/IM weekly. N=25.
Outcomes	Global state: need for additional medication. Mental state: BPRS. Behaviour: leaving the study early. Adverse effects: EPS Scale. Unable to use - Behaviour: WWBRS (no data). Physiological measures: weight (non-clinical outcomes, data unusable).
Notes	
Allocation concealment	B

Study	McCreadie 1980
Methods	Allocation: randomised. Blindness: double. Duration: 9 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (Feighner's Criteria). N=35. Age: 19-70 years, mean 47-55 years. Sex: all male. History: on antipsychotics for mean 4 years, duration illness 18-26 years, able to give informed consent. Setting: hospital and community.
Interventions	1. Fluphenazine decanoate: dose mean 12.5mg/IM, maximum 50mg weekly. N=18. 2. Pimozide: dose mean 8mg/IM, maximum 32mg every 4 days/week. N=16.
Outcomes	Global state: relapse, need for additional medication. Adverse effects: Kraweicka scale. Unable to use - Mental state: Hamilton-Lorr scale (no data). Behaviour: Wing Ward Behaviour Scale (no data).
Notes	N differs in the paper and abstract.
Allocation concealment	B

Study	McCreadie 1982
Methods	Allocation: randomised. Blindness: double.

Characteristics of included studies (Continued)

	Duration: 9 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (Feighner's criteria). N=28. Age: 27-70 years, mean ~ 55 years. Sex: all male. History: duration illness >27 yrs. Setting: hospital.
Interventions	1. Fluphenazine decanoate: dose 2-25mg/IM, mean 14mg/IM biweekly. N=15. 2. Pimozide: dose 10-60mg/IM, mean 40mg/IM weekly. N=13.
Outcomes	Mental state: Krawiecka sub-scales. Behaviour: leaving the study early. Adverse effects: parkinsonism, tardive dyskinesia. Unable to use - Mental state: HLS (no data). Behaviour: WWBRS (no data).
Notes	Authors contacted.
Allocation concealment	B

Study McKane 1987

Methods	Allocation: randomised. Blindness: double. Duration: 48 weeks. (preceded by 12 weeks 'run in' period where additional medication allowed). Design: parallel group.
Participants	Diagnosis: schizophrenia (Feighner (1972)). N=38. Age: 31-71 years, mean ~ 56 years. Sex: 22M, 16F. History: previously on antipsychotics, consent given by next of kin. Setting: hospital.
Interventions	1. Fluphenazine decanoate: dose mean 106mg/IM/week, week 12 dose mean 105/IM monthly. N=19. 2. Haloperidol decanoate: dose mean 127mg/IM, week 12 dose mean 120 mg/IM monthly. N=19.
Outcomes	Global state: Global 5-point scale, need for additional medication. Behaviour: leaving the study early. Adverse effects: AIMS, SAS, Parkinsonism.
Notes	5 people unaccounted for in the FD group.
Allocation concealment	B

Study McLaren 1992

Methods	Allocation: randomised. Blindness: double. Duration: 1 year. Design: parallel group.
Participants	Diagnosis: schizophrenia (ICD-9). N=47. Age: 20-65 yrs. Sex: 27M, 20F.

Characteristics of included studies (Continued)

	History: good physical health, received antipsychotics for at least 1 year previously, duration illness 18 years, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 16-300 mg/IM/month, mean 103mg/IM/month. N=24. 2. Bromperidol decanoate: dose 67-400 mg/IM/month, mean 242mg/IM/month. N=23.
Outcomes	Global state: relapse, need for additional medication. Behaviour: leaving the study early. Symptoms: NSRS. Unable to use - Mental state: KWS, MARDRS (no data). Social ability: MRSS (non clinical outcome, data unusable). Adverse effects: AIMS (data unusable), SAS (no data). Physiological measures: weight, blood samples (non-clinical outcomes, data unusable).
Notes	
Allocation concealment	B

Study **Odejide 1982**

Methods	Allocation: randomised. Blindness: double. Duration: 12 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (ICD-9). N=70. Age: not stated. Sex: not stated. History: treated with FD <2years, <2 acute periods, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 25mg/IM every 4-8 weeks. N=35. 2. Placebo. N=35.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Adverse effects: AIMS. Unable to use - Mental state: BPRS, PSE (no data).
Notes	2 drop-outs unaccounted for in th FD group.
Allocation concealment	B

Study **Pinto 1979**

Methods	Allocation: randomised. Blindness: double. Duration: 18 months (preceeded by 3 months 'run-in' period - medication unchanged). Design: parallel group.
Participants	Diagnosis: schizophrenia. N=64. Age: not stated. Sex: not stated. History: receiving depot for at least 6 months, stable - no hospital admission for at least 3 months prior to trial.

Characteristics of included studies (Continued)

	Setting: community.
Interventions	1. Fluphenazine decanoate: dose mean 25mg/IM every 3 weeks (initial dose 12.5 mg). N=33. 2 Flupenthixol decanoate: dose mean 36.6mg/IM every 3 weeks (initial dose 20 mg). N=31.
Outcomes	Global state: need for additional medication. Adverse effects: EPSE. Leaving the study early. Unable to use - Mental state: BPRS (no SD).
Notes	Authors contacted.
Allocation concealment	B

Study	Quitkin 1978
Methods	Allocation: randomised. Blindness: double. Duration: 1 year (six weeks prior to study entry, participants were stabilised on fluphenazine decanoate 0.5-2 ml/ 2 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia (RDC). N=60. Age: 17-49 years. Sex: 41M,19F. History: <2 psychotic episodes, able to give informed consent. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 0.5-4 ml/IM biweekly. N=29. 2. Penfluridol (oral): dose 20-160 mg/IM weekly. N=27.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Unable to use - Global state: CGI (no data). Mental state: BPRS (no data). Adverse effects: KAS (no data). Social ability: SAS (non clinical outcome, data unusable).
Notes	Authors contacted.
Allocation concealment	B

Study	Rifkin 1977
Methods	Allocation: randomised. Blindness: double. Duration: 1 year (psychotherapy given every 2 weeks for first 6 months, monthly thereafter). Design: 3 treatment groups.
Participants	Diagnosis: schizophrenia (Kraepelinian). N=73. Age: 17-38 years, mean Sex: 50M, 23F. History: 16 participants acutely ill, stable while receiving FD/F HCL for 4 weeks, able to give informed consent. Setting: community.

Characteristics of included studies (Continued)

Interventions	1. Fluphenazine decanoate: dose 0.5-2.0ml/IM, mean 0.5ml/IM biweekly. N=23. 2. Fluphenazine hydrochloride (oral): dose 5-20mg/IM, mean 5mg/IM daily. N=28. 3. Placebo. N=22.
Outcomes	Behaviour: leaving the study early. Mental state: relapse. Adverse effects: toxicity. Unable to use - Global State: CGI (no data). Mental state: BPRS (patient evaluation, no data). Adverse effects: KAS (no data).
Notes	N differs in paper I for chronic patients compared to paper II. Continous data reported in paper II but not usable- not seperated into seperate groups.
Allocation concealment	B

Study Rossi 1990

Methods	Allocation: randomised. Blindness: double. Duration: 6 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM III-R). N=30. Age: 19-42 years, mean ~ 29 years. Sex: 18M, 13F. History: duration of illness (< 1 year n=6), (1-6 years n=20), (> 6 years n=4). Setting: community.
Interventions	1. Fluphenazine decanoate: dose 25-50mg/IM, mean 30mg/IM monthly. N=15. 2. Bromperidol decanoate: dose 50-100 mg/IM, mean 85mg/IM monthly. N=15.
Outcomes	Behaviour: leaving the study early. Unable to use - Global state: CGI (no SD). Mental state: BPRS (no SD). Behaviour: CBS (no SD). Side effects: DOTES, TESS, EPSE (data unusable).
Notes	
Allocation concealment	B

Study Russell 1982

Methods	Allocation: randomised. Blindness: double. Duration: 6 months. Design: parallel group.
Participants	Diagnosis: schizophrenia (ICD-9). N=33. Age: mean ~ 36 years. Sex: 12M, 16F. History: duration illness 9 years, able to give informed consent. Setting: unclear.
Interventions	1. Fluphenazine decanoate: dose mean 12.5 mg/IM, maximum dose 25.5 mg/IM every 2-3 weeks. N=13.

Characteristics of included studies (Continued)

	2. Fluspiriline decanoate: dose mean 3mg/IM, maximum dose 10.94 mg/IM weekly. N=20.
Outcomes	Global state: need for additional medication. Behaviour: leaving the study early. Adverse effects: EPRS. Unable to use - Global state: CGI (no SD). Mental state: BPRS (no SD). Adverse effects: SAS (no data). Behaviour: MACC-BAS (no data).
Notes	Authors contacted.
Allocation concealment	B

Study Schlosberg 1978

Methods	Allocation: randomised. Blindness: double. Duration: 9 months (depot), 3 months (placebo)*. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=75 (12 in placebo trial). Age: mean 42 years. Sex: not stated. History: duration illness mean ~ 17 years. Setting: not stated.
Interventions	1. Fluphenazine decanoate: dose 6.25-50mg/IM monthly. N=30. 2. Pipothiazine palmitate: dose 6.25-50mg/IM monthly. N=30.
Outcomes	Leaving the study. Global Impression. Side effects. Unable to use - Mental state: BPRS (no SD). Behaviour: NOSIE (no SD).
Notes	* Wash-out period 14 days.
Allocation concealment	B

Study Schneider 1981

Methods	Allocation: randomised. Blindness: double. Duration: 1 year (preceded by 2 weeks washout). Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM II). N=59. Age: 21-65 years, mean ~ 45 years. Sex: 51M, 8F. History: duration illness mean ~ 21 years, able to give informed consent. Setting: hospital.
Interventions	1. Fluphenazine decanoate: dose 12.5-400mg/IM every 2-5 weeks. N=27. 2. Pipothiazine palmitate: dose 50-400 mg/IM every 2-5 weeks. N=32.

Characteristics of included studies (Continued)

Outcomes	Leaving the study early. Unable to use - Global state: CGI (no data). Physiological measures: blood samples (non-clinical outcome, data unusable).
Notes	67% attrition rate in the treatment group, therefore the data are not usable.
Allocation concealment	B

Study	Schooler 1976
Methods	Allocation: randomised. Blindness: double. Duration: 1 year. Design: parallel group.
Participants	Diagnosis: schizophrenia (Schneiderian 1st rank). N=197. Age: 18-55 years, mean ~ 30 years. Sex: 58M, 42F. History: newly admitted from the community. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 12.5-100mg/IM, mean 34.7mg/IM every 3 weeks. N=102. 2. Fluphenazine (orally): dose max 60mg, mean 25.2 mg/IM daily. N=95.
Outcomes	Leaving the study early. Additional medication. Side effects: TESS.
Notes	No continuous outcomes measured.
Allocation concealment	B

Study	Schooler 1979
Methods	Allocation: randomised. Blindness: double. Duration: 1 year. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=214*. Age: mean ~ 29 years. Sex: not stated. History: not stated. Setting: community.
Interventions	1. Fluphenazine decanoate: (dose and frequency not stated). N=107. 2. Fluphenazine hydrochloride: (dose and frequency not stated). N=107.
Outcomes	Relapse. Unable to use - Mental state: BPRS (no SD). Side effects: SCL-9 (no SD).
Notes	*Maintenance phase
Allocation concealment	B

Characteristics of included studies (Continued)

Study	Schooler 1980
Methods	Allocation: randomised, stratified by sex. Blindness: double. Duration: 1 year. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=290*. Age: 18-55 years, mean ~ 29 years. Sex: 170M, 120F. History: able to give informed consent. Setting: initially in hospital for 7-9 weeks intensive treatment, followed by community.
Interventions	1. Fluphenazine decanoate: dose 12.5-100mg/IM, mean 34.2mg/IM every 3 weeks. N=143. 2. Fluphenazine hydrochloride (oral): dose 2.5-60mg, mean 24.8mg daily. N=147.
Outcomes	Leaving the study early. Side effects: DOTES, SCL-90. Unable to use - Global state: CGI, Community Nursing Assessment (no data). Mental state: BPRS, HRSD (no data). Social ability: SAS (non clinical outcomes, data unusable).
Notes	Results for both FD & FHCL groups together. Authors contacted * 214 entered maintenance phase.
Allocation concealment	B

Study	Schooler 1997
Methods	Allocation: randomised. Blindness: double. Duration: 16-24 weeks. Design: dosage study.
Participants	Diagnosis: schizophrenia (DSM III). N=313. Age: mean 29.6 years. Sex: 207M 106F. History: acutely ill. Setting: community and /or hospital.
Interventions	1. Fluphenazine decanoate (low dose): dose 2.5-10mg biweekly. N=106. 2. Fluphenazine decanoate (standard): dose 12.5-50 mg biweekly. N=107.
Outcomes	Rehospitalised. Unable to use - Global impression: CGI (no data). Mental state: BPRS, SANS (no data). Side effects: AIMS, EPS, Early Signs Questionnaire (no data). Family therapy strategies: (non-clinical outcomes, data unusable).
Notes	Authors contacted.
Allocation concealment	B

Study	Sharma 1991
Methods	Allocation: randomised.

Characteristics of included studies (Continued)

	Blindness: double. Duration: 48 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM III). N=59. Age: 30-81 years, mean ~ 52 years. Sex: 34M, 25F. History: duration illness 22 years, able to give informed consent. Setting: not stated.
Interventions	1. Fluphenazine decanoate: dose 100mg/IM/monthly. N=29. 2. Haloperidol decanoate: dose 100mg/IM/monthly. N=30.
Outcomes	Leaving the study early. Additional medication. Side effects: EPS Rating Scale, AIMS. Unable to to use - Mental state: CPRS (data unusable). Physiological measures: weight (non-clinical outcomes, data unusable).
Notes	N and drop-out numbers for each group changes.
Allocation concealment	B

Study Shu 1983

Methods	Allocation: randomised. Blindness: double. Duration: 6 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia. N=34. Age: 15-48 years. Sex: all male. History: not stated. Setting: hospital.
Interventions	1. Fluphenazine decanoate: (dose and frequency not stated). N=16. 2. Penfluridol + placebo: (dose and frequency not stated). N=18.
Outcomes	Global state: CGI. Leaving the study early. Side effects: SAS.
Notes	
Allocation concealment	B

Study Simon 1978

Methods	Allocation: randomised. Blindness: open. Duration: 18 months. Design: 3 treatment groups.
Participants	Diagnosis: schizophrenia (French classification of mental illness). N=181. Age: 21-45 years. Sex: 117M, 64F.

Characteristics of included studies (Continued)

	History: duration illness 3-10 years. Setting: community and/or hospital.
Interventions	1. Fluphenazine decanoate: dose mean 88mg/IM every 22 days. N=57. 2. Pipothiazine decanoate: dose mean 90mg/IM every 25 days. N=61. 3. Standard oral neuroleptics: no further details. N=63.
Outcomes	Leaving the study early. Global state: CGI. Mental state: BPRS, NOSIE. Additional medication. Side effects.
Notes	
Allocation concealment	B

Study Singh 1979

Methods	Allocation: randomised. Blindness: double. Duration: 44 weeks. Design: parallel group.
Participants	Diagnosis: schizophrenia (DSM-II). N=30. Age: 29-59 years, mean ~ 44 years. Sex: 24M, 6F. History: duration illness 3-32 years. Setting: community.
Interventions	1. Fluphenazine enanthate: dose 25-75mg/IM, mean 44.2mg/IM/monthly. N=15. 2. Pipothiazine palmitate: dose 100-150 mg/IM, mean 125 mg/IM/monthly. N=15.
Outcomes	Mental state: BPRS. Side effects. Unable to use - Physiological measures: (non-clinical outcomes, data unusable).
Notes	
Allocation concealment	B

Study Song 1993

Methods	Allocation: randomised. Blindness: double. Duration: 6 months. Design: 3 treatment groups.
Participants	Diagnosis: schizophrenia. N=154. Age: not stated. Sex: not stated. History: chronic. Setting: hospital.
Interventions	1. Fluphenazine decanoate: (dose and frequency not stated). N=50. 2. Pipothiazine palmitate (oral): (dose and frequency not stated). N=52. 3. Pipothiazine palmate (oral, non-blinded): (dose and frequency not stated). N=52.
Outcomes	Leaving the study early.

Characteristics of included studies (Continued)

Mental state: BPRS*.

Unable to use -

Side effects: TESS (data unusable).

Notes

Allocation concealment B

Study **Van Praag 1970**

Methods Allocation: randomised.
Blindness: double.
Duration: 8 weeks, follow up 4 weeks.
Design: parallel group.

Participants Diagnosis: psychotic*.
N=25.
Age: not stated.
Sex: not stated
History: chronic and acute.
Setting: hospital.

Interventions 1. Fluphenazine enanthate: dose mean 25 mg/IM + oral placebo every 3 weeks.
N=13.
2. Fluphenazine oral + depot placebo: dose and frequency not reported. N=12.

All received concomittant orphenadrine (Disipal) 50 mg tds.

Outcomes Additional medication.

Unable to use -
Side effects: EPS checklist (no data).
Behaviour: Wing Scale - Scale A (no data), Scale B: (authors own scale **).
Physiological measures: (non-clinical outcomes, data unusable).

Notes * Group 1 were acutely ill.
Group 2. were chronically ill.

**Marshall 1998.

Allocation concealment B

Study **Van Praag 1973**

Methods Allocation: randomised.
Blindness: double.
Duration: 4 weeks.
Design: parallel group.

Participants Diagnosis: acutely psychotic.
N=33.
Age: 19-70 years, mean ~ 42 years.
Sex: 19F, 11M.
History: not stated.
Setting: hospital.

Interventions 1. Fluphenazine decanoate: dose 25mg/IM every 3 weeks. N=15.
2. Fluphenazine enanthate: dose 25mg/IM every 3 weeks. N=18.

Outcomes Leaving the study early.
Additional medication.

Characteristics of included studies (Continued)

	Unable to use - Behaviour: Wing Scale - A & B (no data).
Notes	Data put in depot vs depot category in both FE & FD treatment groups.
Allocation concealment	B
Study	Walker 1983
Methods	Allocation: randomised. Blindness: double. Duration: 24 weeks (preceeded by 12 week open trial). Design: parallel group.
Participants	Diagnosis: schziophrenia. N=39. Age: 23-67 years, mean ~ 45 years. Sex: male and female. History: currently maintained on depot neuroleptics, at least one hospitalisation, duration illness 1-20 years. Setting: community.
Interventions	1. Fluphenazine decanoate: dose 12.5mg/weeks-37.5 mg/4 weeks, mean 24.8 mg/IM every 3-4 weeks. N=20. 2. Clopenthixol decanoate: dose 200mg/4 weeks - 600 mg/2 weeks, mean 220 mg/IM every 3-4 weeks. N=19.
Outcomes	Side effects: Side Effects Inventory. Unable to use - Global state: CGI, Krawiecka, Goldberg & Vaughan Rating Scale (no SD). Mental state: BPRS (no SD). Physiological measures: blood/liver tests, weight, BP (non-clinical outcomes, data unusable).
Notes	Authors contacted. Analysis: last oservation carried forward.
Allocation concealment	B
Study	Wistedt 1983
Methods	Allocation: randomised. Blindness: double. Duration: 2 years. Design: parallel group.
Participants	Diagnosis: schizophrenia (Bleuler's criteria). N=32. Age: 26-67 years, mean ~ 41years. Sex: 15M, 17F. History: stabalised on depots, relapse in connection with withdrawl; duration illness mean ~ 14 years. Setting: not stated.
Interventions	1. Fluphenazine decanoate: dose mean 27mg/IM every 3 weeks. N=15. 2. Flupenthixol decanoate: dose mean 31mg/IM every 3 weeks. N=17.
Outcomes	Leaving the study early. Side effects: SRSE, AIMS. Unable to use - Global state: CGI (no data). Mental state: CPRS (no data).

Characteristics of included studies (Continued)

Notes Authors contacted.

Allocation concealment B

Study **Wistedt 1984**

Methods Allocation: randomised.
Blindness: double.
Duration: 20 weeks.
Design: parallel group.

Participants Diagnosis: schizophrenia (RDC).
N=51.
Age range: 21-63 years.
Sex: 33M, 18F.
History: 6 months treatment foreseen, duration illness <12 years, able to give informed consent.
Setting: 4 weeks in hospital, thereafter in the community.

Interventions 1. Fluphenazine decanoate: dose mean 84mg/IM/monthly. N=26.
2. Haloperidol decanoate: dose mean 122mg/IM/monthly. N=25.

Depot (FD/HD) dose range: 25-100 mg/injection, initially adjusted at 2nd injection (max. 300mg).

Outcomes Global State: CGI.
Mental state: CPRS.
Leaving the study early.
Additional medication.
Side effects: EPS, AIMS.

Unable to use -
Physiological measures: drug plasma levels, weight changes (non clinical outcomes, data unusable).

Notes

Allocation concealment B

Study **Woggon 1977**

Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: parallel group.

Participants Diagnosis: schizophrenia (ICD Nr).
N=61.
Age: 21-79 years.
Sex: 36M, 25F.
History: 6 months treatment.
Setting: community.

Interventions 1. Fluphenazine decanoate: dose 25-37.5mg/IM every 3 weeks. N=30.
2. Pipothiazine palmitate: dose 100mg/IM every 4 weeks. N=31.

Outcomes Leaving the study early.

Unable to use -
Side effects: (data unusable).

Notes

Allocation concealment B

Diagnostic tools:
DSM III - Diagnostic Statistical Manual, version 3

Characteristics of included studies (Continued)

ICD-9 - International Classification of Diseases, version 9

RDC - Research Diagnostic Criteria

Rating scales -

Global state:

CGI - Clinical Global Impression

GAS - Global Assessment Scale

GRS - Global Rating Scale

GES - Global Evaluation Scale

KWS - Krawiecka-Goldberg Scale

PRS - Patient Rejection Scale

TES - Therapeutic Effects Scale

GVRG - Goldberg & Vaughan Rating Scale

Mental state:

BPRS - Brief Psychiatric Rating Scale

CPRS - Comprehensive Psychopathological Rating Scale

EWL-K - List of Attributes self rating scale.

HLS - Hamilton-Lorr Scale

HRSD - Hamilton Psychiatric Rating Scale for Depression

IMPS - Inpatient Multidimensional Psychiatric Scale

KORS - Keio University's Simplified Rating Scale for Psychiatric Symptoms

MIE - Mental Illness Evaluation

PSE - Wing Ward Present State Examination

SANS - Scale for Assessment of Negative Symptoms

S-Scale - The Symptom Scale

Behaviour:

CBS - Current Behaviour Schedule

MACC-BAS - MACC Behaviour Adjustment Scale

WWBRS - Wing Ward Behaviour Rating Scale

Symptom scales:

HSC - Hopkins Symptom Checklist

MRSS - Morningside Rehabilitation Rating Scale

NSRS - Negative Symptom Rating Scale

SSI - Springfield Symptom Index

SCL-90 - Symptom Checklist -90

Social behaviour:

ADL - Activities of Daily Living

KAS - Katz Adjustment Scale

SAS - Social Adjustment Scale

SRE - Schedule of Recent Events

SBAS - Social Behaviour Assessment Schedule

SPS - Social Performance Schedule

Side - effects

AIMS - Abnormal Involuntary Movement Side effects

Bordeleau Scale

CSE - Clinical Side Effects Scale

DOTES - Dosage Record & Treatment Emergent Symptom Scale

EPMS - Extrapyrmidal Motor Side-effects

EPSS - Extrapyrmidal Side-effects Symptoms

Characteristics of included studies (Continued)

EPS - Extrapyrimal symptom scale
IMEPS - Involuntary Movement and EPS Scale
MARDRS- Montgomery-Asberg Depression Rating Scale
MRQ - Medication Response Questionnaire
NOSIE - Nurses Observation Scale for Inpatient Evaluation
OSR - Overall Safety Rating
SAS - Simpson and Angus Scale
SDS - Simpson Dyskinesia Scale
SRSE - Simpson Rating Scale for EPS
SEC -Side Effects Checklist
SCL-9 Side effects Check List 9
STESS - Total Score of Side Effects Self Rating
TESF - Treatment Emergent Symptom Form
TESS - Treatment Emergent Symptoms Scale
UKU - Side Effects Rating Scale

Miscellaneous:

BP - Blood Pressure.
EE - Expressed Emotion
NIMH - National Institute of Mental Health
PER-C - Periodic Evaluation Record - Community Version
VHD - Very High Dose

Characteristics of excluded studies

Abuzzahab 1976a	Allocation: not randomised.
Abuzzahab 1976b	Allocation: double blind. Participants: people with schizophrenia. Interventions: oral fluphenazine versus pimozide.
Abuzzahab 1977	Allocation: not randomised.
Abuzzahab 1980	Allocation: double blind. Participants: people with psychopathology. Interventions: fluphenazine HCl versus pimozide.
Ahlfors 1971	Allocation: randomly selected. Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus pipotiazine undecylenic ester. Outcomes: no data presented.
Ahlfors 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus pipotiazine undecylenate. Outcomes: no usable data, authors contacted.
Altamura 1987	Allocation: not randomised.
Angst 1975	Allocation: double blind. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluspirilen versus penfluridol versus perphenazino enanthate versus pipothiazine palmitate. Outcomes: no usable data.
Arato 1979	Allocation: not randomised (retrospective study).
Astrup 1974	Allocation: not randomised.
Balon 1982	Allocation: double blind - cross over study.

Characteristics of excluded studies (Continued)

	Participants: people with schizophrenia. Interventions: depot fluphenazine decanoate versus hydroxyprotepine decanoate. Outcomes: no usable data.
Bankier 1968	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine versus placebo.
Bao 1991	Allocation: randomised. Participants: people with schizophrenia. Interventions: flupenthixol decanoate versus chlorpromazine.
Barsa 1965	Allocation: double blind. Participants: not specified.
Bastie 1974	Allocation: not randomised.
Benassi 1968	Allocation: not randomised.
Berliner 1974	Allocation: not randomised.
Bilone 1988	Allocation: not randomised.
Boyer 1987	Allocation: randomised. Participants: people with schizophrenia. Interventions: amisulpride versus fluphenazine. Outcomes: no usable data (no SDs).
Brankovic 1998	Allocation: not randomised.
Breier 1987	Allocation: double blind. Participants: people with schizophrenia. Interventions: fluphenazine - withdrawal study.
Caranza 1973	Allocation: not randomised.
Carpenter 1992	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine versus placebo versus diazepam. Outcomes: withdrawal study.
Carpenter 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate injection 2/52 versus 6/52 with oral fluphenazine prescribed as required.
Casacchia 1989	Allocation: randomised. Participants: people with schizophrenia. Interventions: bromperidol decanoate versus fluphenazine decanoate. Outcomes: no usable data.
Castellani	Allocation: open - cross over study.
Chacon 1972	Allocation: double blind - cross over study.
Chacon 1973	Allocation: double-blind. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus chlorpromazine. Outcomes: no usable data, authors contacted.
Charalampous 1977	Allocation: random double blind fashion. Participants: people with schizophrenia. Interventions: oral fluphenazine versus pentofluridol.
Chien 1974	Allocation: randomised. Participants: people with psychotic illnesses including schizophrenia. Interventions: fluphenazine enanthate versus different dosages of antiparkinson drugs (not antipsychotics).
Childers 1964	Allocation: randomised.

Characteristics of excluded studies (Continued)

	Participants: people with schizophrenia. Interventions: electro convulsive therapy versus oral fluphenazine versus chlorpromazine versus chlorpromazine with ECT.
Chouinard 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus pimozide.
Chowdhury 1980	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus flupenthixol decanoate. Outcomes: no usable data, authors contacted.
Clark 1971	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus chlorpromazine versus thioridazine versus placebo.
Cohen 1985	Allocation: not randomised.
Cole 1967	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus chlorpromazine versus acetophenazine.
Cookson 1991	Allocation: double blind. Participants: people with schizophrenia. Interventions: haloperidol decanoate versus fluphenazine decanoate. Outcomes: no usable data.
Coufal 1981	Allocation: not randomised.
Curry 1979	Allocation: double blind - cross over study.
Curson 1985	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate and flupenthixol decanoate versus placebo, the data for the two antipsychotics (depot and oral) were analysed as one group.
Curson 1986	Allocation: not randomised.
De Alarcon 1969	Allocation: not randomised - case reports.
De Buck 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine (dosage study).
DeWolfe 1971	Allocation: randomised Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus thiorazine-stelazine (orally). Outcomes: data not usable, drop-out rate 60% in 6wk trial.
Del Giudice 1975	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus fluphenazine hydrochloride (orally). Outcomes: no usable data, no continuous outcomes measured.
Dencker 1978	Allocation: randomised. Participants: people with schizophrenia. Intervention: high - low doses of fluphenazine enanthate. Outcomes: no usable data.
Dencker 1981	Allocation: not randomised.
Dengler 1969	Allocation: not randomised.
Donlon 1976 1	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluphenazine enanthate.

Characteristics of excluded studies (Continued)

	Outcomes: no usable data.
Donlon 1977	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus pimozide.
Donlon 1978	Allocation: quasi randomised.
Doongaji 1988	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus penfluridol. Outcomes: no usable data, authors contacted.
Dossenbach 1997	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus olanzapine.
Downing 1963	Allocation: randomised. Participants: people with schizophrenia. Interventions: chlorpromazine versus fluphenazine versus thioridazine versus placebo. Outcomes: no usable data.
Emsley 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: quetiapine versus haloperidol with fluphenazine prescribed (4-week run in phase).
Engelhardt 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus haloperidol versus placebo.
Faltus 1974	Allocation: not randomised.
Faretra 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus haloperidol.
Ferenc 2000	Allocation: double blind. Participants: people with schizophrenia. Interventions: oral fluphenazine versus olanzapine.
Filip 1985	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus oxyprothepin decanoate with cross over at 6 months. Outcomes: no usable data - results provided at 12 months without seperating the treatments.
Floru 1975	Allocation: not randomised.
Gianelli 1990	Allocation: not randomised.
Giannelli 1990	Allocation: not randomised.
Gillis 1981	Allocation: randomised. Participants: people with schizophrenia. Interventions: no usable data.
Gitlin 1988	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: no usable data (plasma study).
Goldberg 1967	Allocation: randomised. Participants: people with schizophrenia. Interventions: chlorpromazine versus fluphenazine versus thioridazine. Outcomes: no usable data.
Goldberg 1968	Allocation: randomised. Participants: people with schizophrenia.

Characteristics of excluded studies (Continued)

	Interventions: placebo versus thioridazine versus chlorpromazine versus fluphenazine. Outcomes: no usable data.
Goldberg 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: prolixin ethanate versus oral phenothiazines.
Goldberg 1981	Allocation: randomised - withdrawl study.
Grosser 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluphenazine enanthate. Outcomes: no usable data.
Haider 1968	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus fluphenazine (oral). Outcomes: no usable data.
Hall 1968	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus haloperidol.
Hamilton 1979	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus flupenthixol decanoate. Outcomes: no usable data, no outcomes measured.
Hanlon 1965	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus chlorpromazine, thioridazine, trifluoperazine, prochlorpromazine, perphenazine, thiopropazate and trifluperazine.
Harper 1976	Allocation: double blind - cross over study. Participants: people with schizophrenia. Interventions: chlorpromazine depot preparations versus fluphenazine. Outcomes: no usable data.
Haslam 1975	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus flupenthixol decanoate. Outcomes: no usable data, data difficult to interpret.
Held 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: phenothiazines and placebo. Outcomes: no usable data.
Hirsch 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate and placebo, withdrawl study.
Hirsch 1978	Allocation: double blind. Participants: people with schizophrenia. Interventions: fluphenazine versus flupenthixol. Outcomes: no usable data.
Hirsch 1989	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus active injections with haloperidol prescribed as required.
Hogarty 1995	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate - low dose versus standard dose.

Characteristics of excluded studies (Continued)

	Outcomes: fluphenazine decanoate measured against anxiolytics or antidepressants not antipsychotics.
Holden 1970	Allocation: double blind - cross over study.
Holt 1984	Allocation: not randomised.
Hsu 1967	Allocation: randomised. Participants: people suffering from psychotic disorders, including schizophrenia. Interventions: fluphenazine enanthate versus placebo. Outcomes: no usable data.
Inderbitzen 1994	Allocation: not randomised.
Ionescu 1983	Allocation: not randomised.
Iqbal 1978	Allocation: not randomised.
Irwin 1986	Allocation: double blind. Participants: people with schizophrenia. Interventions: 5-HT versus placebo.
Itil 1970a	Allocation: not randomised.
Itil 1970b	Allocation: double blind - cross over.
Itil 1971	Allocation: double blind. Participants: people with schizophrenia. Interventions: fluphenazine hydrochloride. Outcomes: no usable data.
Itil 1978	Allocation: not randomised.
Jakovljevic 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus olanzapine.
James 1977	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus penfluridol. Outcomes: no usable data (no SD).
Johnson 1975	Allocation: not randomised.
Kabes 1980a	Allocation: "divided randomly into 2 groups" - cross over study. Participants: people with schizophrenia. Interventions: depot preparations plus fluphenazine, oxyprothepine/oxyprotepin. Outcomes: no usable data.
Kabes 1980b	Allocation: randomised. Participants: people with schizophrenia. Interventions: oxyprothepin decanoate versus fluphenazine decanoate - medication crossed over at 6 months. Outcomes: no usable data - results presented at 12 months without differentiating each treatment arm.
Kabes 1981	Allocation: double blind - cross over study. Participants: people with schizophrenia. Interventions: oxyprothepin decanoate versus fluphenazine decanoate. Outcomes: no usable data.
Kane 1979	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate and placebo. Outcomes: withdrawal study.
Kane 1982	Allocation: randomised. Participants: people with acute first episode schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: no usable data, authors contacted.

Characteristics of excluded studies (Continued)

Kane 1983 b	Allocation: not randomised - review article.
Kelly 1999	Allocation: not randomised.
Kenway 1971	Allocation: randomised - cross over study.
Keskiner 1968a	Allocation: not randomised.
Keskiner 1968b	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: withdrawl study.
King 1979	Allocation: randomised. Participants: people with schizophrenia. Interventions: family therapy in conjunction with high and low dose phenothiazines.
Kinon 1993	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine high dose versus fluphenazine low dose versus haloperidol. Outcomes: no usable data.
Kinross-Wright 1963	Allocation: not randomised.
Knights 1979	Allocation: not randomised.
Kong 1989	Allocation: not randomised.
Landmark 1994	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluphenazine hydrochloride (oral). Outcomes: no usable data, no clinical outcomes reported.
Lapierre 1975	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine versus pimozide. Outcomes: no usable data.
Lapierre 1976	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine versus pimozide + half of each group received psychotherapy. Outcomes: no usable data.
Lapierre 1978	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus penfluridol.
Lapierre 1983	Allocation: randomised. Participants: people with schizophrenia. Interventions: pipothiazine palmitate versus fluphenazine decanoate. Outcomes: no usable data.
Lasky 1962	Allocation: randomised. Participants: people with schizophrenia. Interventions: chlorpromazine versus thioridazine versus chlorprothixene versus triflupromazine. Outcomes: no usable data - drop outs > 50%.
Leff 1971	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluperazine versus chlorpromazine.
Leff 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: maintenance therapy and life events.
Levinson 1990	Allocation: randomised.

Characteristics of excluded studies (Continued)

	Participants: people with schizophrenia. Interventions: fluphenazine 10, 20 mg/day for 24 days and fluphenazine 10, 20 and 30 mg/day for 28 days. Outcomes: no usable data.
Litman 1994	Allocation: double blind. Participants: people with schizophrenia. Interventions: fluphenazine versus benztropine (1st phase) and fluphenazine versus clozapine (2nd phase). Outcomes: no usable data.
Ljubin 2000	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus olanzapine.
Marder 1986	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate (dosage study). Outcomes: no usable data.
Marder 1989	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluphenazine (oral). Outcomes: no usable data, drug metabolism study - no clinical outcomes measured.
Marder 1990	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate (dosage study). Outcomes: no usable data, authors contacted.
Marder 1991a	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate (dosage study). Outcomes: no usable data, pharmacological study - no clinical outcomes reported.
Marder 1991b	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: no usable data, trial of different measuring procedures.
Marder 1996	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: no usable data.
Martenyi 2000	Allocation: double blind. Participants: people with schizophrenia. Interventions: olanzapine versus fluphenazine. Outcomes: no usable data.
Martin 1972	Allocation: not randomised.
Mattes 1984	Allocation: double blind. Participants: people with schizophrenia. Interventions: lithium versus fluphenazine (oral and decanoate) versus placebo. Outcomes: no usable data.
McCreadie 1983	Allocation: not randomised.
McCreadie 1986	Allocation: double blind. Participants: people with schizophrenia. Interventions: haloperidol versus fluphenazine. Outcomes: no usable data.
Meco 1987	Allocation: not randomised but double blinded.

Characteristics of excluded studies (Continued)

	Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus haloperidol decanoate. Outcomes: no usable data, authors contacted.
Mimica 1998	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus olanzapine.
Morris 1970	Allocation: randomised - cross over study.
National 1964	Allocation: "randomly assigned". Participants: people with schizophrenia. Interventions: oral fluphenazine versus chlorpromazine versus thioridazine versus placebo.
Nestoros 1978	Allocation: "randomly assigned" Participants: people with schizophrenia. Interventions: oral fluphenazine versus butaclamol.
Owen 1993	Allocation: admitted sequentially - cross over study.
Palma 1997	Allocation: randomised. Participants: people with schizophrenia. Interventions: flupenthixol decanoate versus other neuroleptics including fluphenazine decanoate. Outcomes: fluphenazine decanoate results not presented separately from the other neuroleptics.
Pichot 1988	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus amisulpride.
Pickar 1987	Allocation: review of studies.
Pickar 1992	Allocation: double blind - cross over study.
Pickar 1994	Allocation: double blind - cross over study.
Pollack 1964	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: no usable data.
Preussler 1995	Allocation: randomised. Participants: people with schizophrenia. Interventions: clozapine versus fluphenazine. Outcomes: no usable data.
Preussler 1997	Allocation: randomised. Participants: people with schizophrenia. Interventions: clozapine versus fluphenazine. Outcomes: no usable data.
Quitkin 1975	Allocation: "randomly assigned". Participants: people with schizophrenia. Interventions: oral fluphenazine (dosage study).
Quitkin 1977	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus penfluridol. Outcomes: no usable data, preliminary report.
Ravaris 1965	Allocation: not randomised.
Ravaris 1967	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus fluphenazine (oral). Outcomes: no usable data.

Characteristics of excluded studies (Continued)

Rifkin 1976	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluphenazine (oral) versus placebo. Outcomes: no usable data.
Roose 1982	Allocation: not randomised.
Rossger 1997	Allocation: randomised. Participants: people with schizophrenia. Interventions: clozapine versus fluphenazine. Outcomes: no usable data.
Saxena 1996	Allocation: non-specific - authors contacted (conference abstract).
Schausberger 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus olanzapine.
Schipper 1971	Allocation: not randomised.
Schooler 1971	Allocation: randomised. Participants: people with schizophrenia. Interventions: acetophenazine maleate versus chlorpromazine versus fluphenazine hydrochloride. Outcomes: no usable data.
Schooler 1977	Allocation: not randomised - double blinded.
Schubert 1988	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine versus haloperidol. Outcomes: no usable data.
Simpson 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine. Outcomes: no usable data.
Steingard 1994	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine versus placebo. Outcomes: no usable data.
Stevens 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus placebo. Outcomes: no usable data.
Tegeler 1985	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus clopenthixol decanoate. Outcomes: no usable data, authors contacted.
Tetreault 1969	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine enanthate versus oral fluphenazine bichloralhydrate.
Tran 1998	Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus fluphenazine. Outcomes: no usable data.
Turner 1966	Allocation: randomised. Participants: not described.
Ushakov 1990	Allocation: not randomised, case series.
Verster 1998	Allocation: randomised.

Characteristics of excluded studies (Continued)

	Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus generic substitute.
Vestre 1962	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral fluphenazine versus triflupromazine versus phenobarbital.
Viala 1988	Allocation: not randomised.
Villeneuve 1970	Allocation: not randomised.
Vinar 1970	Allocation: double blind. Participants: people with schizophrenia. Interventions: fluphenazine versus fluphenazine long acting form. Outcomes: no usable data.
Weiden 1993	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate (dosage study). Outcomes: No usable data, prescribing patterns study.
Wiles 1990	Allocation: double-blind. Participants: people with schizophrenia. Interventions: haloperidol decanoate versus fluphenazine decanoate. Outcomes: no usable data, authors contacted.
Winter 1973	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate versus fluspirilene decanoate. Outcomes: no usable data.
Wistedt 1981	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate & flupenthixol decanoate versus placebo. Outcomes: no usable data, the two drug treatments are grouped as one group.
Wistedt 1983a	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine decanoate & flupenthixol decanoate versus placebo. Outcomes: no usable data - both drugs placed in 1 group.
Wistedt 1983b	Allocation: randomised. Participants: people with schizophrenia. Interventions: discontinuation study.
Zapletalek 1981	Allocation: not randomised.
van Putten 1986	Allocation: randomised. Participants: people with schizophrenia. Interventions: 1st report - haloperidol (dosage study), 2nd report - fluphenazine (dosage study). Outcomes: no usable data.
van Putten 1991	Allocation: randomised. Participants: people with schizophrenia. Interventions: fluphenazine (dosage study). Outcomes: no usable data.

ANALYSES

Comparison 01. FLUPHENAZINE DECANOATE vs PLACEBO

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Death	1	54	Relative Risk (Fixed) 95% CI	5.00 [0.25, 99.52]
02 Global state: Relapse			Relative Risk (Random) 95% CI	Subtotals only
03 Behaviour: Leaving the study early			Relative Risk (Fixed) 95% CI	Subtotals only
04 Mental state: Depression (medium term - 6 months to 1 year)	1	70	Relative Risk (Fixed) 95% CI	1.00 [0.45, 2.22]
05 Adverse effects: 1. Movement disorders - tardive dyskinesia (longer term - more than 1 year)			Relative Risk (Fixed) 95% CI	Subtotals only
06 Adverse effects: 2. Toxicity	1	45	Relative Risk (Fixed) 95% CI	7.65 [1.04, 56.26]

Comparison 02. FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: 1. No clinically important global change			Relative Risk (Fixed) 95% CI	Subtotals only
02 Global state: 2. Relapse			Relative Risk (Random) 95% CI	Subtotals only
03 Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score=worse)	1	34	Weighted Mean Difference (Fixed) 95% CI	-0.10 [-2.79, 2.59]
04 Behaviour: 1. Leaving the study early			Relative Risk (Fixed) 95% CI	Subtotals only
05 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)	1	120	Weighted Mean Difference (Fixed) 95% CI	-0.56 [-6.92, 5.80]
06 Behaviour: 3. skewed data (endpoint scores)			Other data	No numeric data
07 Mental state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score=poor)	1	120	Weighted Mean Difference (Random) 95% CI	-0.75 [-5.75, 4.25]
08 Mental state: 2. Depression			Relative Risk (Fixed) 95% CI	Subtotals only
09 Adverse effects: 1a. Movement disorders - general			Relative Risk (Fixed) 95% CI	Subtotals only
10 Adverse effects: 1b. Movement disorders - akathisia	1	51	Relative Risk (Fixed) 95% CI	20.54 [1.25, 337.96]
11 Adverse effects: 1c. Movement disorders - needing anticholinergic drugs			Relative Risk (Random) 95% CI	Subtotals only
12 Adverse effects: 1d. Movement disorders - tardive dyskinesia			Relative Risk (Fixed) 95% CI	Subtotals only

13 Adverse effects: 1e. Movement disorders - tremor (longer term - more than 1 year)	1	44	Relative Risk (Fixed) 95% CI	0.80 [0.26, 2.45]
14 Adverse effects: 1f. Movement disorders - average score (Simpson & Angus, 0 to 5 weeks, high = poor)	1	32	Weighted Mean Difference (Fixed) 95% CI	1.30 [0.01, 2.59]
15 Adverse effects: 2. Blurred vision - medium term (6 months to 1 year)	1	197	Relative Risk (Fixed) 95% CI	1.34 [0.75, 2.38]
16 Adverse effects: 3. Toxicity - medium term (6 months to 1 year)	1	51	Relative Risk (Fixed) 95% CI	4.87 [1.14, 20.72]
17 Adverse effects: 4. General adverse effects			Relative Risk (Fixed) 95% CI	Subtotals only

Comparison 03. FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Death	1	38	Relative Risk (Fixed) 95% CI	3.00 [0.13, 69.32]
02 Global state: 1. No clinically important global change (medium term - 6 months to 1 year)	3	187	Relative Risk (Fixed) 95% CI	1.04 [0.97, 1.11]
03 Global state: 2. Relapse			Relative Risk (Fixed) 95% CI	Subtotals only
04 Global state: 3. Severly ill (medium term 6 months to 1 year)	1	60	Relative Risk (Fixed) 95% CI	1.07 [0.94, 1.23]
05 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year)	2	91	Relative Risk (Fixed) 95% CI	0.53 [0.14, 1.96]
06 Global state: 5. Clinical Global Impression. (short term - 6 weeks to 5 months) (skewed data)			Other data	No numeric data
07 Global state: 6. Clinical Global Impression. (medium term - 6 months to 1 year)	2	90	Weighted Mean Difference (Fixed) 95% CI	-0.10 [-0.41, 0.21]
08 Global state: 7. Clinical Global Impression - not improved (high score=poor)			Relative Risk (Fixed) 95% CI	Subtotals only
09 Behaviour: 1. Leaving the study early			Relative Risk (Fixed) 95% CI	Subtotals only
10 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)	1	118	Weighted Mean Difference (Fixed) 95% CI	-5.21 [-10.85, 0.43]
11 Mental state: 1. BPRS (endpoint scores - high score=poor)			Weighted Mean Difference (Fixed) 95% CI	Subtotals only

12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data)	1	67	Relative Risk (Fixed) 95% CI	0.91 [0.59, 1.43]
13 Mental state: 3. Depression (6 months to 1 year)	1	67	Relative Risk (Fixed) 95% CI	1.02 [0.81, 1.28]
14 Adverse effects: 1a. Movement disorders - general	7	308	Relative Risk (Fixed) 95% CI	1.11 [0.91, 1.35]
15 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs			Relative Risk (Random) 95% CI	Subtotals only
16 Adverse effects: 1c. Movement disorders - parkinsonism	3	190	Relative Risk (Fixed) 95% CI	1.12 [0.47, 2.69]
17 Adverse effects: 1d. Movement disorders - tardive dyskinesia: longer term (more than 1 year)	2	150	Relative Risk (Fixed) 95% CI	0.62 [0.32, 1.23]
18 Adverse effects: 1e. Movement disorders - tremor			Relative Risk (Fixed) 95% CI	Subtotals only
19 Adverse effects: 2. Blurred vision			Relative Risk (Fixed) 95% CI	Subtotals only
20 Adverse effects: 3. Dry mouth: longer term (more than 1 year)	1	32	Relative Risk (Fixed) 95% CI	0.72 [0.38, 1.37]
21 Adverse effects: 4. General adverse effects			Relative Risk (Fixed) 95% CI	Subtotals only

Comparison 04. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: 1. Relapse (medium term - 6 months to 1 year)	2	182	Relative Risk (Random) 95% CI	2.11 [0.30, 14.91]
02 Global state: 2. Needing additional antipsychotic treatment (medium term - 6 months to 1 year)	1	50	Relative Risk (Fixed) 95% CI	1.67 [0.45, 6.24]
03 Global state: 3. Not improved (medium term - 6 months to 1 year)			Relative Risk (Fixed) 95% CI	Subtotals only
04 Behaviour: Leaving the study early (medium term - 6 months to 1 year)	2	90	Relative Risk (Fixed) 95% CI	0.60 [0.15, 2.36]
05 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score=poor)	1	50	Weighted Mean Difference (Fixed) 95% CI	-0.03 [-5.79, 5.73]
06 Adverse effects: Movement disorders - needing anticholinergic drugs (medium term - 6 months to 1 year)	1	50	Relative Risk (Fixed) 95% CI	1.67 [0.45, 6.24]

Comparison 05. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: Relapse			Relative Risk (Random) 95% CI	Subtotals only
02 Behaviour: Leaving the study early			Relative Risk (Fixed) 95% CI	Subtotals only
03 Adverse effects: 1. Movement disorders (medium term - 6 months to 1 year)			Relative Risk (Fixed) 95% CI	Subtotals only
04 Adverse effects: 2. Continuous data - skewed data (endpoint scores, high = poor)			Other data	No numeric data

Comparison 06. FLUPHENAZINE ENANTHATE vs PLACEBO

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Adverse effects: Movement disorders - general			Relative Risk (Fixed) 95% CI	Subtotals only

Comparison 07. FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: No clinically important global change (immediate - 0 to 5 weeks)	1	31	Relative Risk (Fixed) 95% CI	0.67 [0.27, 1.66]
02 Adverse effects: Movement disorders - general			Relative Risk (Fixed) 95% CI	Subtotals only

Comparison 08. FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year)	2	65	Relative Risk (Fixed) 95% CI	0.50 [0.24, 1.05]
02 Global state: 2. Relapse			Relative Risk (Fixed) 95% CI	Subtotals only
03 Behaviour: Leaving the study early			Relative Risk (Fixed) 95% CI	Subtotals only
04 Mental state: 1. BPRS - endpoint scores (medium term - 6 months to 1 year) (high score = poor)	1	30	Weighted Mean Difference (Fixed) 95% CI	0.40 [0.34, 0.46]
05 Mental state: 2. Depression (medium term - 6 months to 1 year)	1	30	Relative Risk (Fixed) 95% CI	7.00 [0.39, 124.83]
06 Adverse effects: 1a. Movement disorders - general (medium term - 6 months to 1 year)	2	63	Relative Risk (Fixed) 95% CI	1.52 [0.75, 3.07]

07 Adverse effects: 1b. Movement disorders - needing additional anticholinergic drugs			Relative Risk (Fixed) 95% CI	Subtotals only
08 Adverse effects: 1c. Movement disorders - tardive dyskinesia: medium term (6 months to 1 year)	1	32	Relative Risk (Fixed) 95% CI	0.89 [0.46, 1.71]
09 Adverse effects: 1d. Movement disorders - tremor (medium term - 6 months to 1 year)	3	95	Relative Risk (Fixed) 95% CI	1.24 [0.82, 1.87]
10 Adverse effects: 2. Blurred vision (medium term - 6 months to 1 year)	1	30	Relative Risk (Fixed) 95% CI	3.00 [0.13, 68.26]
11 Adverse effects: 3. Dry mouth (medium term - 6 months to 1 year)	2	62	Relative Risk (Fixed) 95% CI	0.80 [0.36, 1.76]

Comparison 09. FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: Relapse (short term - 6 weeks to 5 months)	1	104	Relative Risk (Fixed) 95% CI	9.35 [2.28, 38.29]
02 Behavior: Leaving the study early (short term - 6 weeks to 5 months)	1	104	Relative Risk (Fixed) 95% CI	3.12 [0.66, 14.74]

Comparison 10. FLUPHENAZINE DECANOATE vs FLUPHENAZINE ENANTHATE

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Global state: 1. Needing additional antipsychotic treatment			Relative Risk (Fixed) 95% CI	Subtotals only
02 Global state: 2. Relapse			Relative Risk (Fixed) 95% CI	Subtotals only
03 Behaviour: Leaving the study early			Relative Risk (Fixed) 95% CI	Subtotals only
04 Mental State: BPRS medium term (6 months to 1 year - high score=poor)	1	39	Weighted Mean Difference (Fixed) 95% CI	0.00 [-3.93, 3.93]
05 Adverse effects: 1a. Movement disorders - general			Relative Risk (Fixed) 95% CI	Subtotals only
06 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs			Relative Risk (Fixed) 95% CI	Subtotals only
07 Adverse effects: 1c. Movement disorders - parkinsonism (short term - 6 weeks to 5 months)	1	19	Relative Risk (Fixed) 95% CI	0.37 [0.02, 8.01]
08 Adverse effects: 2. General adverse effects (immediate - 0 to 5 weeks)	1	11	Relative Risk (Fixed) 95% CI	0.08 [0.01, 1.14]

INDEX TERMS

Medical Subject Headings (MeSH)

Antipsychotic Agents [*therapeutic use]; Delayed-Action Preparations [therapeutic use]; Fluphenazine [*analogs & derivatives; therapeutic use]; Randomized Controlled Trials; Schizophrenia [*drug therapy]

MeSH check words

Humans

COVER SHEET

Title	Depot fluphenazine decanoate and enanthate for schizophrenia
Authors	David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J
Contribution of author(s)	Seema Quraishi - prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report. Maurice Eisenbruch - prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report. Anthony David - acquired funding, helped prepare protocol, select studies, extract data, and produce the report. Clive Adams - acquired funding, helped prepare protocol, undertook searches, selected and acquired studies, extracted and summated data, produce the report and prepared the updated review. John Rathbone - selected and acquired studies, extracted and summated data and prepared the updated review (2004).
Issue protocol first published	1996/2
Review first published	1997/4
Date of most recent amendment	10 December 2004
Date of most recent SUBSTANTIVE amendment	22 January 2004
What's New	This November 2004 update contains seventy trials and ten comparisons. The previous version contained only six studies relevant to one comparison.
Date new studies sought but none found	Information not supplied by author
Date new studies found but not yet included/excluded	Information not supplied by author
Date new studies found and included/excluded	10 June 2002
Date authors' conclusions section amended	Information not supplied by author
Contact address	Prof Anthony David Institute of Psychiatry and GKT School of Medicine King's College School of Medicine and Dentistry 103 Denmark Hill London SE5 8AF UK E-mail: a.david@iop.kcl.ac.uk

Tel: +44 171 919 3138

Fax: +44 171 740 5301

DOI

10.1002/14651858.CD000307

Cochrane Library number

CD000307

Editorial group

Cochrane Schizophrenia Group

Editorial group code

HM-SCHIZ


GRAPHS AND OTHER TABLES

Analysis 01.01. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 01 Death

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 01 FLUPHENAZINE DECANOATE vs PLACEBO

Outcome: 01 Death




Analysis 01.02. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 02 Global state: Relapse

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 01 FLUPHENAZINE DECANOATE vs PLACEBO

Outcome: 02 Global state: Relapse




Analysis 01.03. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 03 Behaviour: Leaving the study early

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 01 FLUPHENAZINE DECANOATE vs PLACEBO

Outcome: 03 Behaviour: Leaving the study early




Analysis 01.04. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 04 Mental state: Depression (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 01 FLUPHENAZINE DECANOATE vs PLACEBO

Outcome: 04 Mental state: Depression (medium term - 6 months to 1 year)




Analysis 01.05. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 05 Adverse effects: I. Movement disorders - tardive dyskinesia (longer term - more than 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 01 FLUPHENAZINE DECANOATE vs PLACEBO

Outcome: 05 Adverse effects: I. Movement disorders - tardive dyskinesia (longer term - more than 1 year)




Analysis 01.06. Comparison 01 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 06 Adverse effects: 2. Toxicity

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 01 FLUPHENAZINE DECANOATE vs PLACEBO

Outcome: 06 Adverse effects: 2. Toxicity



Analysis 02.01. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 01
Global state: 1. No clinically important global change

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 01 Global state: 1. No clinically important global change




Analysis 02.02. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 02
Global state: 2. Relapse

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 02 Global state: 2. Relapse




Analysis 02.03. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 03
Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score=worse)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 03 Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score=worse)




Analysis 02.04. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 04 Behaviour: I. Leaving the study early


Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 04 Behaviour: I. Leaving the study early




(... Continued)



Analysis 02.05. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 05 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 05 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)



Analysis 02.06. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 06 Behaviour: 3. skewed data (endpoint scores)

Behaviour: 3. skewed data (endpoint scores)


Study	Intervention	mean	SD	N
Barnes 1983	Fluphenazine decanoate	5.7	4.1	19
Barnes 1983	Pimozide	4.2	5.5	17

**Analysis 02.07. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 07
Mental state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score=poor)**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 07 Mental state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score=poor)




**Analysis 02.08. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 08
Mental state: 2. Depression**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 08 Mental state: 2. Depression




Analysis 02.09. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 09
Adverse effects: 1a. Movement disorders - general

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 09 Adverse effects: 1a. Movement disorders - general




Analysis 02.10. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 10
Adverse effects: 1b. Movement disorders - akathisia

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 10 Adverse effects: 1b. Movement disorders - akathisia



**Analysis 02.11. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 11
Adverse effects: 1c. Movement disorders - needing anticholinergic drugs**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 11 Adverse effects: 1c. Movement disorders - needing anticholinergic drugs




**Analysis 02.12. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 12
Adverse effects: Id. Movement disorders - tardive dyskinesia**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 12 Adverse effects: Id. Movement disorders - tardive dyskinesia




**Analysis 02.13. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 13
Adverse effects: Ie. Movement disorders - tremor (longer term - more than 1 year)**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 13 Adverse effects: Ie. Movement disorders - tremor (longer term - more than 1 year)




**Analysis 02.14. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 14
Adverse effects: 1f. Movement disorders - average score (Simpson & Angus, 0 to 5 weeks, high = poor)**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 14 Adverse effects: 1f. Movement disorders - average score (Simpson % Angus, 0 to 5 weeks, high = poor)




**Analysis 02.15. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 15
Adverse effects: 2. Blurred vision - medium term (6 months to 1 year)**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Outcome: 15 Adverse effects: 2. Blurred vision - medium term (6 months to 1 year)




**Analysis 02.16. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 16
Adverse effects: 3. Toxicity - medium term (6 months to 1 year)**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 16 Adverse effects: 3. Toxicity - medium term (6 months to 1 year)



**Analysis 02.17. Comparison 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 17
Adverse effects: 4. General adverse effects**

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 02 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
 Outcome: 17 Adverse effects: 4. General adverse effects




Analysis 03.01. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 01 Death

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 01 Death




Analysis 03.02. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 02 Global state: I. No clinically important global change (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 02 Global state: I. No clinically important global change (medium term - 6 months to 1 year)




Analysis 03.03. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 03 Global state: 2. Relapse

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 03 Global state: 2. Relapse




Analysis 03.04. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 04 Global state: 3. Severly ill (medium term 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 04 Global state: 3. Severly ill (medium term 6 months to 1 year)



Analysis 03.05. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 05 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 05 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year)



Analysis 03.06. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 06 Global state: 5. Clinical Global Impression. (short term - 6 weeks to 5 months) (skewed data)

Global state: 5. Clinical Global Impression. (short term - 6 weeks to 5 months) (skewed data)


Study	Intervention	mean	SD	N
Wistedt 1984	Fluphenazine decanoate	2.9	2	26
Wistedt 1984	Pipothiazine	2.9	1.5	25

Analysis 03.07. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 07 Global state: 6. Clinical Global Impression. (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 07 Global state: 6. Clinical Global Impression. (medium term - 6 months to 1 year)




Analysis 03.08. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 08 Global state: 7. Clinical Global Impression - not improved (high score=poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 08 Global state: 7. Clinical Global Impression - not improved (high score=poor)




Analysis 03.09. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 09 Behaviour: I. Leaving the study early


Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 09 Behaviour: I. Leaving the study early



(... Continued)




Analysis 03.10. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 10 Behaviour: 2. NOSIE-30 - endpoint scores (high score=poor)



Analysis 03.11. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Mental state: I. BPRS (endpoint scores - high score=poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 11 Mental state: I. BPRS (endpoint scores - high score=poor)




Analysis 03.12. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data)




Analysis 03.13. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 13 Mental state: 3. Depression (6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 13 Mental state: 3. Depression (6 months to 1 year)




Analysis 03.14. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 14 Adverse effects: 1a. Movement disorders - general

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 14 Adverse effects: 1a. Movement disorders - general




Analysis 03.15. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 15 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 15 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs



Analysis 03.16. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 16 Adverse effects: 1c. Movement disorders - parkinsonism

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 16 Adverse effects: 1c. Movement disorders - parkinsonism




Analysis 03.17. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 17 Adverse effects: Id. Movement disorders - tardive dyskinesia: longer term (more than 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 17 Adverse effects: Id. Movement disorders - tardive dyskinesia: longer term (more than 1 year)




Analysis 03.18. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 18 Adverse effects: I.e. Movement disorders - tremor

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 18 Adverse effects: I.e. Movement disorders - tremor




Analysis 03.19. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 19 Adverse effects: 2. Blurred vision

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 19 Adverse effects: 2. Blurred vision




Analysis 03.20. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 20 Adverse effects: 3. Dry mouth: longer term (more than 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 20 Adverse effects: 3. Dry mouth: longer term (more than 1 year)




Analysis 03.21. Comparison 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 21 Adverse effects: 4. General adverse effects

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 03 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 21 Adverse effects: 4. General adverse effects




Analysis 04.01. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 01 Global state: I. Relapse (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome: 01 Global state: I. Relapse (medium term - 6 months to 1 year)




Analysis 04.02. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 02 Global state: 2. Needing additional antipsychotic treatment (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome: 02 Global state: 2. Needing additional antipsychotic treatment (medium term - 6 months to 1 year)




Analysis 04.03. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 03 Global state: 3. Not improved (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome: 03 Global state: 3. Not improved (medium term - 6 months to 1 year)




Analysis 04.04. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 04 Behaviour: Leaving the study early (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome: 04 Behaviour: Leaving the study early (medium term - 6 months to 1 year)




Analysis 04.05. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 05 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score=poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome: 05 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score=poor)




Analysis 04.06. Comparison 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 06 Adverse effects: Movement disorders - needing anticholinergic drugs (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 04 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD

Outcome: 06 Adverse effects: Movement disorders - needing anticholinergic drugs (medium term - 6 months to 1 year)




Analysis 05.01. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 01 Global state: Relapse

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD

Outcome: 01 Global state: Relapse




Analysis 05.02. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 02 Behaviour: Leaving the study early

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD

Outcome: 02 Behaviour: Leaving the study early




Analysis 05.03. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 03 Adverse effects: 1. Movement disorders (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD

Outcome: 03 Adverse effects: 1. Movement disorders (medium term - 6 months to 1 year)



Analysis 05.04. Comparison 05 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD, Outcome 04 Adverse effects: 2. Continuous data - skewed data (endpoint scores, high = poor)

Adverse effects: 2. Continuous data - skewed data (endpoint scores, high = poor)


Study	Intervention	mean	SD	N
Kane 1983	Fluphenazine decanoate (low dose)	0.52	1.00	62
Kane 1983	Fluphenazine decanoate (standard dose)	1.04	2.42	64

Analysis 06.01. Comparison 06 FLUPHENAZINE ENANTHATE vs PLACEBO, Outcome 01 Adverse effects: Movement disorders - general

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 06 FLUPHENAZINE ENANTHATE vs PLACEBO

Outcome: 01 Adverse effects: Movement disorders - general




Analysis 07.01. Comparison 07 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 01 Global state: No clinically important global change (immediate - 0 to 5 weeks)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 07 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS

Outcome: 01 Global state: No clinically important global change (immediate - 0 to 5 weeks)




Analysis 07.02. Comparison 07 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 02 Adverse effects: Movement disorders - general

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 07 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS
 Outcome: 02 Adverse effects: Movement disorders - general




Analysis 08.01. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 01 Global state: I. Needing additional antipsychotic treatment (6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 01 Global state: I. Needing additional antipsychotic treatment (6 months to 1 year)




Analysis 08.02. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 02 Global state: 2. Relapse

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 02 Global state: 2. Relapse




Analysis 08.03. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 03 Behaviour: Leaving the study early

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 03 Behaviour: Leaving the study early



(... Continued)




Analysis 08.04. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 04 Mental state: I. BPRS - endpoint scores (medium term - 6 months to 1 year) (high score =poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 04 Mental state: I. BPRS - endpoint scores (medium term - 6 months to 1 year) (high score =poor)




Analysis 08.05. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 05 Mental state: 2. Depression (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 05 Mental state: 2. Depression (medium term - 6 months to 1 year)



Analysis 08.06. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 06 Adverse effects: 1a. Movement disorders - general (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 06 Adverse effects: 1a. Movement disorders - general (medium term - 6 months to 1 year)




Analysis 08.07. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 07 Adverse effects: 1b. Movement disorders - needing additional anticholinergic drugs

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 07 Adverse effects: 1b. Movement disorders - needing additional anticholinergic drugs




Analysis 08.08. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 08 Adverse effects: 1c. Movement disorders - tardive dyskinesia: medium term (6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 08 Adverse effects: 1c. Movement disorders - tardive dyskinesia: medium term (6 months to 1 year)




Analysis 08.09. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 09 Adverse effects: 1d. Movement disorders - tremor (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 09 Adverse effects: 1d. Movement disorders - tremor (medium term - 6 months to 1 year)




Analysis 08.10. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Adverse effects: 2. Blurred vision (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS

Outcome: 10 Adverse effects: 2. Blurred vision (medium term - 6 months to 1 year)




Analysis 08.11. Comparison 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Adverse effects: 3. Dry mouth (medium term - 6 months to 1 year)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 08 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
 Outcome: 11 Adverse effects: 3. Dry mouth (medium term - 6 months to 1 year)



Analysis 09.01. Comparison 09 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 01 Global state: Relapse (short term - 6 weeks to 5 months)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 09 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE
 Outcome: 01 Global state: Relapse (short term - 6 weeks to 5 months)




Analysis 09.02. Comparison 09 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 02 Behavior: Leaving the study early (short term - 6 weeks to 5 months)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 09 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE

Outcome: 02 Behavior: Leaving the study early (short term - 6 weeks to 5 months)




Analysis 10.01. Comparison 10 FLUPHENAZINE DECANAOATE vs FLUPHENAZINE ENANTHATE, Outcome 01 Global state: 1. Needing additional antipsychotic treatment

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 10 FLUPHENAZINE DECANAOATE vs FLUPHENAZINE ENANTHATE

Outcome: 01 Global state: 1. Needing additional antipsychotic treatment



Analysis 10.02. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 02 Global state: 2. Relapse

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
 Outcome: 02 Global state: 2. Relapse




Analysis 10.03. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 03 Behaviour: Leaving the study early

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE

Outcome: 03 Behaviour: Leaving the study early




Analysis 10.04. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 04 Mental State: BPRS medium term (6 months to 1 year - high score=poor)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia


Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE

Outcome: 04 Mental State: BPRS medium term (6 months to 1 year - high score=poor)




Analysis 10.05. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 05 Adverse effects: 1a. Movement disorders - general

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
 Outcome: 05 Adverse effects: 1a. Movement disorders - general




Analysis 10.06. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 06 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs

Review: Depot fluphenazine decanoate and enanthate for schizophrenia
 Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
 Outcome: 06 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs



(Continued . . .)

(... Continued)




Analysis 10.07. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 07 Adverse effects: 1c. Movement disorders - parkinsonism (short term - 6 weeks to 5 months)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE

Outcome: 07 Adverse effects: 1c. Movement disorders - parkinsonism (short term - 6 weeks to 5 months)



Analysis 10.08. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 08 Adverse effects: 2. General adverse effects (immediate - 0 to 5 weeks)

Review: Depot fluphenazine decanoate and enanthate for schizophrenia

Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE

Outcome: 08 Adverse effects: 2. General adverse effects (immediate - 0 to 5 weeks)

